PROLACTIN A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Prolactin: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84516-6 1. Prolactin-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on prolactin. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON PROLACTIN ............................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Prolactin........................................................................................ 7 E-Journals: PubMed Central ....................................................................................................... 64 The National Library of Medicine: PubMed ................................................................................ 75 CHAPTER 2. NUTRITION AND PROLACTIN ................................................................................... 121 Overview.................................................................................................................................... 121 Finding Nutrition Studies on Prolactin .................................................................................... 121 Federal Resources on Nutrition ................................................................................................. 126 Additional Web Resources ......................................................................................................... 127 CHAPTER 3. DISSERTATIONS ON PROLACTIN ............................................................................... 129 Overview.................................................................................................................................... 129 Dissertations on Prolactin ......................................................................................................... 129 Keeping Current ........................................................................................................................ 131 CHAPTER 4. PATENTS ON PROLACTIN .......................................................................................... 133 Overview.................................................................................................................................... 133 Patents on Prolactin................................................................................................................... 133 Patent Applications on Prolactin............................................................................................... 153 Keeping Current ........................................................................................................................ 166 CHAPTER 5. BOOKS ON PROLACTIN ............................................................................................. 169 Overview.................................................................................................................................... 169 Book Summaries: Online Booksellers......................................................................................... 169 Chapters on Prolactin ................................................................................................................ 171 CHAPTER 6. PERIODICALS AND NEWS ON PROLACTIN ................................................................ 173 Overview.................................................................................................................................... 173 News Services and Press Releases.............................................................................................. 173 Newsletter Articles .................................................................................................................... 175 Academic Periodicals covering Prolactin................................................................................... 175 CHAPTER 7. RESEARCHING MEDICATIONS .................................................................................. 177 Overview.................................................................................................................................... 177 U.S. Pharmacopeia..................................................................................................................... 177 Commercial Databases ............................................................................................................... 178 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 181 Overview.................................................................................................................................... 181 NIH Guidelines.......................................................................................................................... 181 NIH Databases........................................................................................................................... 183 Other Commercial Databases..................................................................................................... 185 The Genome Project and Prolactin ............................................................................................ 185 APPENDIX B. PATIENT RESOURCES ............................................................................................... 191 Overview.................................................................................................................................... 191 Patient Guideline Sources.......................................................................................................... 191 Finding Associations.................................................................................................................. 193 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 195 Overview.................................................................................................................................... 195 Preparation................................................................................................................................. 195 Finding a Local Medical Library................................................................................................ 195 Medical Libraries in the U.S. and Canada ................................................................................. 195 ONLINE GLOSSARIES................................................................................................................ 201
viii Contents
Online Dictionary Directories ................................................................................................... 203 PROLACTIN DICTIONARY....................................................................................................... 205 INDEX .............................................................................................................................................. 293
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with prolactin is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about prolactin, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to prolactin, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on prolactin. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to prolactin, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on prolactin. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON PROLACTIN Overview In this chapter, we will show you how to locate peer-reviewed references and studies on prolactin.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and prolactin, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “prolactin” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Improvement of Sexual Function in Male Patients after Parathyroidectomy for Secondary Hyperparathyroidism Source: Journal of the American College of Surgeons. 193(5): 486-492. November 2001. Contact: Available from Journal of the American College of Surgeons. P.O. Box 2127, Marion, OH 43306-8227. (800) 214-8489 or (740) 382-3322. Fax (740) 382-5866. Summary: Clinically, the severity of uremia is known to be inversely proportional to sexual desire and activity in patients with chronic renal (kidney) failure. This article reports on a study of sexual function and sex hormones in male patients with symptomatic hyperparathyroidism before and 3 months after parathyroidectomy. From October 1998 to December 2000, 20 male patients with symptomatic secondary hyperparathyroidism were enrolled in this study. They underwent total
4
Prolactin
parathyroidectomy and autotransplantation of 90 milligrams of tissue to the subcutaneous tissue of the forearm or thigh. The patients all had regular sexual partners and were sexually active. Results showed that hemoglobin, hematocrit, testosterone and LH (leutenizing hormone) were noted to have not significantly changed 3 months after surgery. Serum levels of calcium, phosphorus, alkaline phosphatase, FSH (follicle stimulation hormone), and iPTH (intact parathyroid hormone) were significantly reduced, as were the levels of prolactin. But preoperative and postoperative FSH levels were within normal limits, and 70 percent of the postoperative alkaline phosphatase levels were above normal. Sexual function increased significantly 3 months after parathyroidectomy, as did monthly frequency of attempted intercourse, satisfaction of attempted intercourse, and enjoyment of intercourse. The authors conclude that sexual function of male patients with symptomatic hyperparathyroidism can possibly be improved by parathyroidectomy and autotransplantation. An appendix reprints the individual items of the International Index of Erectile Function Questionnaire. 5 tables. 18 references. •
Reproductive Endocrinology and Pregnancy in Women on Hemodialysis Source: Seminars in Dialysis. 6(2): 105-116. March-April 1993. Summary: The prevalence and natural history of the clinical and hormonal aberrations caused by end-stage renal disease (ESRD) in women are largely unknown. In this article, the authors summarize what is known and theorized about the endocrine function of women undergoing dialysis. Topics include menstrual function, the role of gonadotropin production in the regulation of menstruation, hypothalamic and pituitary regulation of gonadotropin production, the clinical significance of menstrual irregularity, prolactin in women on dialysis, the etiology of elevated prolactin levels, the physiology of prolactin regulation, the clinical significance of hyperprolactinemia, sexual function, pregnancy in women with ESRD, infertility, the diagnosis of pregnancy and accurate pregnancy dating, pregnancy complications, pregnancy outcome in mild and moderate renal insufficiency, pregnancy outcome in hemodialysis, congenital anomalies in pregnancy in women on dialysis, dialysis in pregnant women, the use of erythropoietin (EPO) in pregnancy, therapeutic abortion, and obstetrical management.
•
Lactation in Insulin-Dependent Diabetes Source: Progress in Food and Nutrition Science. Volume 14. 1990. p. 333-370. Summary: This article investigates factors that influence successful breastfeeding in women with insulin-dependent diabetes mellitus (IDDM). Topics include lactation in women with diabetes; hormonal changes in pregnancy and lactation; the role of prolactin in initiating lactation; thyroid hormones; milk synthesis; prolactin and insulin interrelationship; the role of insulin deficiency in diabetic lactation, including mammary gland metabolism; glucose transport, and RNA/DNA syntheses; insulin deficiency and breast milk of women with diabetes, including milk macronutrient composition, milk yield, hypoglycemia, breast milk macronutrient composition of women with diabetes, breast milk volume, and effect of metabolic control; maternal plasma nutrient levels, including plasma glucose, milk glucose, milk lactose, plasma lipids, postpartum lipids, and postpartum amino acids; additional factors that may influence lactation in women with IDDM, notably weight gain during pregnancy, prior lactation experience, method of delivery and feeding frequency, hospital protocol, mastitis, gestational age, fetal condition, metabolic control and insulin needs, dehydration, and maternal dietary intake; and the lactation management of women with IDDM. 1 figure. 1 table. 139 references.
Studies
•
5
Diabetes and Erectile Dysfunction Source: Clinical Diabetes. 19(1): 45-48. February 2001. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article provides clinicians with information on the etiology, diagnosis, and treatment of erectile dysfunction (ED). Awareness of ED as a significant and common complication of diabetes has increased in recent years. Studies suggest that the prevalence of ED in men with diabetes ranges from 35 to 75 percent versus 26 percent in the general population. Although the causes of ED are numerous, they generally fall into the categories of organic and psychogenic. The organic causes can be subdivided into the categories of vascular, traumatic/postsurgical, neurological, endocrine induced, and drug induced. Examples of psychogenic causes include depression, performance anxiety, and relationship problems. The natural history of ED in men who have diabetes is normally gradual. Both vascular and neurological mechanisms are commonly involved. Autonomic neuropathy is a major contributor to the high incidence of ED in men who have diabetes. The first step in evaluating ED is a thorough sexual and medical history and physical examination. Although few simple laboratory tests can help identify obvious causes of organic ED, initial tests should include glycosylated hemoglobin, free testosterone, thyroid function tests, and prolactin levels. Preventive measures such as improving glycemic control and hypertension, quitting smoking, reducing excessive alcohol intake, and avoiding medications that may contribute to ED may help reduce the risk of developing ED. However, once ED has developed, oral agents such as sildenafil and yohimbine are considered first line therapy. Intracavernosal injections are an acceptable alternative for men who are not candidates for oral therapy. Mechanical therapy with vacuum assisted erection devices is also effective, and penile prosthesis is a viable option. The article is accompanied by a patient information sheet.
•
Clinical Efficacy of Sildenafil in Patients on Chronic Dialysis Source: Journal of Urology. 165(6): 819-821. March 2001. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-3030 or (301) 714-2334. Fax (301) 824-7290. Summary: This article reports on a study that evaluated the clinical efficacy of sildenafil citrate (Viagra) for patients who are on chronic dialysis and who have concomitant erectile dysfunction (ED, formerly called impotence). A total of 35 men (mean age 60.7 years) on dialysis and with ED of various etiologies (causes) were administered 25 to 100 mg sildenafil for at least 6 months. The International Index of Erectile Function (IIEF) questionnaire, a global assessment question and partner satisfaction question were used to evaluate sildenafil efficacy. Patients also reported any adverse events that occurred during treatment. Treatment was effective for 28 of the 35 men (80 percent), according to the results of the IIEF and global assessment questions. Partner satisfaction correlated with the IIEF overall response and global assessment question results. No correlation was found between sildenafil failure and patient age, the etiology of ED, duration of ED, prior treatments, testosterone and prolactin blood levels, and the duration and etiology of renal (kidney) failure. In 3 of the 35 patients, sildenafil was stopped due to intolerable headaches, and in 7 others for lack of efficacy. The authors conclude that sildenafil is an effective and safe treatment for erectile dysfunction in most patients on chronic dialysis. 1 table. 15 references.
6
•
Prolactin
Music Therapy Increases Serum Melatonin Levels in Patients With Alzheimer's Disease Source: Alternative Therapies. 5(6): 49-57. November 1999. Summary: This journal article describes a study of the effects of music therapy on neurotransmitters and neurohormones in patients with Alzheimer's disease (AD). Participants were 20 male patients at the Miami Veterans Administration Medical Center. The researchers took blood tests to determine the concentrations of melatonin, norepinephrine, epinephrine, serotonin, and prolactin in the patients before initiating the therapy, immediately at the end of four weeks of therapy, and at a six week followup after cessation of the therapy sessions. Melatonin concentration increased significantly after therapy and had increased further at the six week follow-up. Norepinephrine and epinephrine levels increased after four weeks of music therapy, but returned to pre-therapy levels at the follow-up. Prolactin and platelet serotonin levels were unchanged. The authors conclude that increased levels of melatonin following the therapy may have contributed to patients' relaxed and calm mood. 2 tables, 86 references.
•
Hirsutism in Women Source: Postgraduate Medicine. 107(7): 93-94,99-104. June 2000. Summary: This journal article provides health professionals with information on the clinical presentation, evaluation, and management of hirsutism in women. This disorder, which is defined as excessive male pattern hair growth, commonly affects the face, neck, extremities, trunk, breasts, linea alba, lower back, upper pubic triangle, and upper inner thighs. Many drugs can induce hirsutism, including those that have androgenic activity and those that have nonandrogenic activity. Excessive androgen can also induce hirsutism. The clinical presentation of androgen excess syndrome includes seborrhea, acne, hirsutism, alopecia, obesity, and acanthosis nigricans. When hirsutism is associated with obesity and menstrual abnormalities, the source of excessive androgen is often an ovarian androgen disorder such as polycystic ovary syndrome. Hirsutism associated with normal weight and normal menses may be caused by adrenal androgens. These androgens are elevated in late onset adrenal hyperplasia, congenital adrenal hyperplasia, Cushing's syndrome, pituitary adenomas that produce excess corticotropin or prolactin, and acromegaly. Less common causes of androgen excess hirsutism include 21-hydroxylase deficiency and 3B-,11-hydroxysteroid dehydrogenase deficiency. Patient evaluation involves obtaining an extensive clinical history, performing a physical examination, and conducting laboratory tests. Treatment options include camouflaging with heavy makeup, bleaching hair, and removing it by physical methods. Thermodestruction of the hair follicle is possible with electrolysis. A new hair removal method is photothermodestruction using a laser. Obese women who have polycystic ovary syndrome and hirsutism can benefit from weight loss. Agents that may be effective in antiandrogen therapy include oral contraceptive agents, hormone replacement, cyproterone acetate, glucocorticoid agents, GnRH agonist, spironolactone, flutamide, finasteride, ketoconazole, and cimetidine. 3 figures, 2 tables, and 40 references.
•
Neuroendocrine Mechanisms in Rheumatic Diseases Source: Rheumatic Disease Clinics of North America. 26(4): i-xv,693-1042. November 2000.
Studies
7
Summary: This journal provides health professionals with information on neuroendocrine mechanisms in rheumatic diseases. The journal begins with an article on the reciprocal interactions between the neuroendocrine and immune systems during inflammation. This is followed by an article that explores the roles of prolactin and gonadotropin releasing hormone in affecting the hypothalamic pituitary axis and immune responses and gender differences in autoimmunity. The next article focuses on the influence of minor and major stress factors on the onset and course of various rheumatic diseases. The fourth article examines the role of the vascular endothelial system in the pathogenesis of inflammation and systemic rheumatic diseases and the way in which the neuroendocrine system influences these mechanisms. This is followed by an article that proposes an integrative physiopathogenetic concept for understanding the development of rheumatoid arthritis (RA). The next article investigates the hypothesis that abnormalities in the production and action of gonadal and sympthoadrenal hormonal mediators occur in RA and may have a role in susceptibility, severity, and progression. The seventh article focuses on the roles of androgens and estrogens in the susceptibility to autoimmune rheumatic diseases. This is followed by an article that examines the interactions of autonomic nervous, neuroendocrine, and immune systems in RA. The next article discusses the advantages and disadvantages of glucocorticoid therapy in the continuous search to optimize glucocorticoid therapy in patients with RA. The tenth article focuses on the use of sex hormone adjuvant therapy in RA. The next article reviews the multifactorial mechanisms of bone loss in RA and the effects of androgens and estrogens on bone preservation. This is followed by an article that investigates the influence of the hormonal system on pediatric rheumatic diseases. Several articles examine neuroendocrine involvement in various rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus, ankylosing spondylitis, fibromyalgia, and chronic fatigue syndrome. The final article reviews neuroendocrine immune mechanisms in rheumatic diseases and considers promising research. 33 figures, 23 tables, and numerous references.
Federally Funded Research on Prolactin The U.S. Government supports a variety of research studies relating to prolactin. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to prolactin. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore prolactin. The following is typical of the type of information found when searching the CRISP database for prolactin:
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
8
•
Prolactin
Project Title: ACCESS TO PHYSICAL ACTIVITY AND ITS RELATION TO HEALTH Principal Investigator & Institution: Alessio, Helaine M.; Physical Education, Health and Sports Stud; Miami University Oxford 500 E High St Oxford, Oh 45056 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 31-MAY-2006 Summary: (provided by applicant): Animal studies on mechanisms of oxidative stress, aging, and disease often include an experimental group receiving a certain intervention and a sedentary control group to which the experimental group is compared. The common use of a control group having no access to physical activity outside the cage poses a potential intervening variable that may affect results of studies investigating health and stress, in particular, oxidative stress. Animals participating in no physical activity outside of their cage may have different endogenous prooxidant and antioxidant levels, which over time may negatively affect their health. In previous studies where differences in biomarkers of oxidative stress or health were reported between control and experimental groups, investigators may have overestimated the effects of the intervention due to the hypokinetic effects of housing on the sedentary control animals. If animal studies are intended to generalize to other primate populations, including humans, then housing conditions and access to physical activity need to be carefully considered. The purpose of this study is to compare biomarkers of oxidative stress, a variety of health parameters, age and cause of death in animals that are grouped in three distinct ways: a) living solely in a standard cage with no access to physical activity outside the cage, 2) living in a standard cage with twice weekly one hour periods of physical activity in a large box, and 3) living in a standard cage with regular access to exercise on a running wheel. Cardiovascular parameters (blood pressure, heart rate, body weight, blood lipids) will be monitored weekly over the life span of the animals. Blood samples from a tail vein will be collected biannually and analyzed for antioxidants, lipids, and prolactin. Immediately after death, various tissues will be harvested and analyzed using a hematoxin and eosin staining method, and standard autopsy procedures performed by a veterinarian. Brain, ganglia, neurotrophic growth factor, pituitary gland, tumors, and organs and tissues will be analyzed for signs of pathology and differences among the three groups. Results of this study will distinguish cardiovascular parameters, morbidity, mortality, and biomarkers of oxidative stress due to different access to physical activity over the life span. These results will provide insight about the importance of housing and physical activity when designing animal experiments to study aging, selective health parameters, and oxidative stress. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ALCOHOL AND HYPERPROLACTINEMIA Principal Investigator & Institution: Sarkar, Dipak K.; Professor Ii and Director; Animal Sciences; Rutgers the St Univ of Nj New Brunswick Asb Iii New Brunswick, Nj 08901 Timing: Fiscal Year 2003; Project Start 01-APR-1998; Project End 31-JAN-2008 Summary: (provided by applicant): There are several reports showing evidence for the existence of high levels of prolactin (PRL) in chronic alcoholic men and women. The study conducted by us during the past funded period provided data that suggest that chronic ethanol administration not only elevates plasma levels of PRL but also increases proliferation of pituitary lactotropes. We also found that ethanol affects the expression of estrogen-responsive hormones and polypeptides that promote growth and transformation of lactotropes. Hence, we hypothesized that, like estrogen, chronic
Studies
9
ethanol might promote tumor development in lactotropes.The present proposal will address this issue by studying ethanol's in vivo and in vitro effects on lactotropic cell secretion, growth and transformation using the rat as an animal model. The proposed research will test the hypothesis that ethanol may cross-talk with estrogen receptors, an estrogen-responsive signaling cascade or estrogen-regulated cell-cell communication to control prolactin secretion and lactotropic cell proliferation. Specific proposal objectives are: (1) to evaluate the mechanisms of ethanol action on PRL gene transcription by determining the role of G protein-coupled D2 receptors and cAMP-PKA-CREB signaling, and the role of TGF-beta, estrogen receptors and p42/p44 MAP kinase; and (2) to determine the cellular action of ethanol on lactotrope proliferation by testing the role of estrogen receptors, G proteins, cAMP, PKA, PKC and MAPK in the ethanol actions. To study the mechanisms of ethanol action on lactotropes, we will pharmacologically and genetically manipulate the signal transduction systems, and measure the intracellular level of these signal transducers by histological, biochemical and molecular techniques.These studies have the potential to elucidate important cellular mechanisms underlying the ethanol effect on prolactinomas. Such knowledge will improve the understanding and management of hyperprolactinemia in alcoholic patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ALCOHOL EFFECT ON HUMAN LACTATION AND INFANT BEHAVIOR Principal Investigator & Institution: Mennella, Julie A.; Member; Monell Chemical Senses Center 3500 Market St Philadelphia, Pa 19104 Timing: Fiscal Year 2004; Project Start 24-SEP-1998; Project End 31-JAN-2008 Summary: (provided by applicant): The overall goal of the proposed research is to investigate the effects of maternal ethanol consumption from the perspective of both the lactating mother and her child. Research conducted during the previous grant periods revealed that: 1) the pharmacokinetics of ethanol, like a wide variety of other drugs, may be altered during lactation; 2) maternal ethanol consumption reduces milk production, disrupts milk ejection and alters the hormonal profile of the mother; 3) maternal ethanol consumption decreases milk intake and disrupts sleep-wake patterning in the breast-fed infant; 4) the ethanol that lactating mothers consume distinctly flavors human milk and such flavor changes are detected by the infant; and 5) children's hedonic response to odors of alcoholic beverages are related to the emotional context in which their parents' experience alcohol and their frequency of drinking. The proposed studies are designed to investigate the mechanisms underlying these changes, with a practical aim of providing information on a much neglected area in scientific research. To meet these objectives, research will focus on the effects of ethanol on the physiology and behavior of the lactating mother (AIMS 1 and 2) as well as her developing infant and child (AIMS 2 and 3).AIM 1: To investigate the effects of lactational state on ethanol pharmacokinetics as well as the effects of ethanol consumption on the endocrine milieu of lactating women and how such alterations impact upon lactational performance.AIM 2: To assess how ethanol consumption by the mother impacts upon her behaviors, moods and interaction with her child.AIM 3: To explore the role of early experiences with ethanol in mothers' milk and the emotional context of such experiences, on the recognition of, and preference for, the sensory properties of ethanol Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
10
•
Prolactin
Project Title: BIOCHEMICAL MARKERS IN THE NURSES' HEALTH STUDY COHORT Principal Investigator & Institution: Hankinson, Susan E.; Associate Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 01-JUN-1989; Project End 31-MAR-2004 Summary: We propose to analyze blood samples in a nested case-control manner from the 32,826 participants in the Nurses' Health Study (NHS) who provided samples in 1989-90 and were 43 to 69 years of age at that time. The samples have been stored at greater than or equal to 130 C in liquid nitrogen freezers since collection. We will assay samples from women who were diagnosed after blood collection and matched controls who remained disease-free, thus efficiently utilizing these prospectively collected samples. We propose to build upon our recent positive findings for several plasma hormones and nutrients in relation to breast and colon cancer risk, and to address new hormonal hypotheses in relation to risk of breast, ovarian and colon cancers and myocardial infarction. Specifically, we will examine (1) plasma estrogens, androgens and prolactin levels in relation to breast cancer risk in postmenopausal women, (2) a polymorphism in the catechol-O- methyl transferase (COMT) gene and risk of breast cancer, (3) DHEA, DHEAS and 5-androstene-3beta,17beta-diol and risk of breast and ovarian cancers and myocardial infarction, (4) insulin-like growth factor I and its binding proteins 1 and 3, plasma vitamin D and polymorphisms in the vitamin D receptor, and plasma antioxidant levels - all in relation to risk of breast and colon cancers. The ongoing NHS (CA40356 and HL34594) will provide follow-up and documentation of disease outcomes in addition to providing information on important covariates (such as exogenous hormone use, diet, smoking status, among others) for the proposed study. Participation in the NHS has been high: among the 32,826 women who provided a blood sample, 98 percent continue to complete questionnaires, and vital status has been documented for 99 percent. Overall, the large size of the cohort, the prospective design, the high follow-up rate, the detailed exposure data, and the availability of archived blood specimens provide a unique opportunity to test several hypotheses of public health importance. We also propose to collect a second blood sample from about 18,000 of the women who provided a first blood sample in 1989-90. This will increase our statistical power in future analyses, and allow us to assess in detail the temporal relationships between biomarkers and disease risk and to reduce the attenuating effects of measurement error. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BRAIN SEROTONIN AND ANGIOTENSIN II SYSTEMS IN MIGRAINE Principal Investigator & Institution: Terron, Jose A.; Cinvestav-Ipn Av Ipn # 2508, Col Zacatenco Mexico City, Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-MAR-2008 Summary: (provided by applicant) Long-term objectives. The brain serotonin (5-HT) system plays an important role in cerebrovascular and neuroendocrine control. These systems have been implicated in migraine. Migraine is a low 5-HT syndrome and attacks may be triggered by a massive release of 5-HT acting on sensitized receptors. This proposal will elucidate the association between the phenomena of decreased 5-HT neurotransmission and altered cerebrovascular and neuroendocrine responsiveness. Focus will be on 5-HT receptors recently implicated in migraine pathogenesis and/or prophylactic treatment (5-HT1A, 5-HTT, 5-HT2s and 5-HT2c). As a key activator of the
Studies
11
hypothalamic-pituitary-adrenal (HPA) axis, the role of the brain angiotensin II (Ang II) system will be addressed. The proposal intends to shed light into the pathophysiological mechanisms of migraine, and the mechanism of action of migraine prophylactic 5-HT and Ang II drugs. Specific aims. The following hypotheses will be challenged: 1) A decreased 5-HT transmission in the brain will cause sensitization and/or up-regulation of 5-HT receptor subtypes in the cerebral vasculature and the HPA axis; treatment with a migraine prophylactic compound that target these receptors will restore 5-HT receptor function and/or expression. This may be a useful animal model for drug screening in migraine prophylaxis. 2) The response to stress, which involves sequential activation of the brain Ang II and the HPA systems, will lead to decreased brain 5-HT levels, upregulation of 5-HT receptors, and/or amplified neuroendocrine and cerebrovascular responses to 5-HT receptor activation; treatment with an inhibitor of Ang II synthesis will restore serotonergic function. Design. 1) Cerebrovascular and neuroendocrine responses to 5-HT agonists, and expression of 5-HT receptors in the cerebral vasculature and the HPA axis, will be determined in control and 5-HT-depleted Wistar rats. It will be determined whether chronic treatment with a migraine prophylactic 5-HT antagonist restore 5-HT receptor function and/or expression. 2) Brain 5-HT content, expression of 5-HT receptors in the HPA axis, and neuroendocrine and cerebrovascular responses will be determined in control and stressed (acute and chronic isolation and restraint) Wistar rats. Reversal of stress-induced changes in these variables will be attempted by chronic treatment with the angiotensin-converting enzyme inhibitor, lisinopril (i.e. a migraine prophylactic agent). In vivo cerebrovascular reactivity will be assessed by laser- Doppler flowmetry (cortical blood flow) and the 4-iodo-[N-methyl-14C]-antipyrine method (regional cerebral blood flow). In vitro cerebrovascular reactivity will be analyzed with an arteriographic chamber system. The hormonal response (ACTH, corticosterone and prolactin) will be measured by radioimmuno assay in blood samples and 5-HT receptor expression will be determined by quantitative receptor autoradiography in tissue sections. 5-HT content will be measured by HPLC in brain homogenates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BREAST DENSITY, IGF-I, & PROLACTIN, IN FOUR POPULATIONS Principal Investigator & Institution: Maskarinec, Gertraud; Clinical Sciences; University of Hawaii at Manoa Honolulu, Hi 96822 Timing: Fiscal Year 2003; Project Start 27-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): The reasons for differences in breast cancer incidence by ethnicity and geographic location are not well understood. The focus of this proposal is to identify hormonal characteristics that may explain these discrepancies. Insulin-like growth factor I (IGF-I) has been proposed as a link between nutritional factors and breast cancer, in particular among premenopausal women. Prolactin directly affects the growth of breast epithelium and has been associated with breast cancer risk among postmenopausal women. Mammographic densities, a strong predictor of breast cancer risk, appear to be associated with both hormones. The objectives of this project are to compare mammographic densities among four populations at different breast cancer risk, examine the relation of IGF-I, IGFBP-3, and prolactin with mammographic densities, and investigate the relation between these hormones and mammographic density separately by ethnicity and menopausal status. All samples and mammograms were collected as part of previous epidemiologic studies in four locations: Hawaii, Japan, Arizona, and Norway. Combining data from these diverse studies provides the opportunity to examine the consistency and strength of previously observed associations. This design will allow us to include women with a
12
Prolactin
variety of ethnic backgrounds who have experienced different life-styles and exposures. The final analysis will include 1,520 women of different ethnicities: Caucasian women residing in all four locations, Japanese women living in two locations, Hispanic women from Arizona, and Filipino, Chinese, and Native Hawaiian women from Hawaii. The age of the subjects ranges from 40 to 80 years and approximately 60% of the women are postmenopausal. All subjects were recruited as part of previous projects, were never diagnosed with cancer, have a mammogram free of suspicious lesions, and provided information on reproductive and anthropometric characteristics. Blood samples were taken after an overnight fast, for premenopausal women during the luteal phase, and stored at -70xC. Serum samples will be analyzed in the same laboratory for IGF-I, IGFBP-3, and prolactin using an ELISA assay. After scanning the mammographic images from the four locations into the same computer, one reader will perform computer-assisted quantitative mammographic density assessment. For quality control purposes, a sample of serum samples and mammograms will be analyzed in duplicate. Because serum and mammographic analyses were partially funded by the previous projects, we are only requesting funds for 900 serum analyses and 600 mammographic density assessments. The statistical analysis will include mixed models to explore the relation between hormone levels and breast density while controlling for confounders and for clustering by study location. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CAV-1 IN JAK/STAT SIGNALING, LACTATION, & BREAST CANCER Principal Investigator & Institution: Lisanti, Michael P.; Professor; Molecular Pharmacology; Yeshiva University 500 W 185Th St New York, Ny 10033 Timing: Fiscal Year 2003; Project Start 23-JAN-2003; Project End 31-DEC-2007 Summary: (provided by applicant): The long-term objective of this proposal is to understand the role of caveolin-1 in i) Jak/STAT signaling, ii) lactation, and iii) the pathogenesis of breast cancer. Caveolae function as "message centers" for regulating signal transduction. Caveolin-1 (Cav-1) is the principal structural protein of caveolae membranes that are found in most cells. We mapped human CAV-1 to a suspected tumor suppressor locus (7q31.1/D7S522). In addition, the Cav-1 gene is mutated (P132L) in up to 16% of human breast cancers. The aim of this proposal is to test the hypothesis that Cav-1 expression is important for regulating lactation via modulation of Jak/STAT signaling and that loss of Cav-1 contributes to the oncogenicity of breast cancer cells. To test this hypothesis, we will use a variety of complementary in vivo approaches, such as i) a Cav-1 null mouse model and ii) the development of transgenic mice that express dominant-negative Cav-1 (PI32L) found in human breast cancers. The three Specific Aims of the project are: 1) To determine the role of Cav-1 in negatively regulating Jak/STAT signaling. We will examine the effects of Cav-1 on the activation of Jak/STAT signaling in cultured mammary epithelial cells that are responsive to prolactin. Our preliminary results indicate that Cav-1 negatively regulates Jak/STAT5a signaling by inhibiting Jak-mediated phosphorylation of STAT5a; 2) To examine the role of Cav-1 in lactation and epithelial cell hyperplasia. Signaling from the hormone prolactin vial the Jak/STAT pathway controls normal mammary gland development. Thus, if Cav-1 were a negative regulator of Jak/STAT signaling, we would predict that a loss of Cav-1 expression leads to premature lactation. Indeed, our preliminary results show that Cav1 null mice exhibit premature lactation, as well as hyper-activation of the Jak/STAT5a signaling cascade; and 3) To determine if transgenic expression of Cav-1 (P132L) predisposes towards mammary tumor development. For this purpose, we will generate
Studies
13
Cav-1 (P132L) mice that transgenically express this form of Cav-1 in the mammary gland. Our preliminary results indicate that Cav-1 (P132L) acts in a dominant-negative fashion in cultured cells. In addition, our preliminary results with Cav-1 null mice show early development of wide-spread mammary epithelial hyperplasia. We predict that this phenotype will be accelerated Cav-1 (P132L) transgenic mice. We will cross Cav-1 (P132L) transgenic mice with other well-established models of mammary tumorigenesis, such as MMTVErbB2 and MMTV-polyoma middle T mice. It is expected that these studies will contribute fundamental knowledge towards understanding the role of Cav1 in Jak/STAT signaling and mammary tumorigenesis in vivo. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CENTER FOR WOMEN'S HEALTH AND REPRODUCTION Principal Investigator & Institution: Fazleabas, Asgerally T.; Professor; Obstetrics and Gynecology; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2002; Project Start 02-MAY-2002; Project End 31-MAR-2007 Summary: The objective of the Specialized Cooperate Centers Program in Reproductive Research (SCCPRR) at the University of Illinois is to conduct innovative basic and clinical research in the reproductive sciences. Four projects are proposed Projects I (Project by Fazleabas) and II (Project by Bulun) focus on the etiology and pathophysiology of endometriosis while Projects II (Project by Gibori) and IV (Project by Nowak) address important questions relating to decidualization and implantation in rodent models, however, will be directly applicable to understanding the physiology and pathobiology of human reproduction. Project I "Endometriosis in the Baboon"-will test the hypothesis that the development of endometriosis occurs in two distinct phases. The data generated will determine if ovarian steroids are necessary to first establish to first establish the disease and if local steroid biosynthesis will maintain it. This project will also establish a direct link between endometriosis and aberrations in uterine receptivity. Project II "Hormone Action in Endometriosis"will test the hypothesis that progesterone resistance in endometriotic tissue disrupts the induction of the key estradiol (E2) metabolizing enzyme 17beta- hydroxydehydrogenase (HSD) type 2. A major goal is to determine whether aberrations in nuclear receptor expression causing progesterone resistance and the absence of 17beta-HSD-2 giving rise to increased tissue 32 levels are responsible for altered cell fate in endometriosis. Project III "Cell Signaling and Gene Regulation in Decidual Development" will focus on the functional role of decidual- derived proteins. Using transgenic mice mod3els, the role and regulation of cell cycle inhibitors, activin A and prolactin in the development and maintenance of the decidua during pregnancy will be evaluated. Project IV "EMMPRIN Regulates Metalloproteinases in the Endometrium" tests the hypothesis that an inducer of metalloproteinases (EMMPRIN) that is secreted by uterine epithelial cells regulates metalloproteinase (MMP) production in the endometrium. These studies will focus on the importance of MMPs in implantation and determine if EMMPRIN expression is required for MMP production by endometriotic tissue. These projects will be supported by an administrative core and two research cores: A) Imaging and Microscopy and B) Tissue Procurement and Cell Culture. These research cores will operate in an open access formula and support 7 other NIH approved grants whose research objectives will contribute but will not infringe upon the goals of the U54 application. The U54 Center at the University of Illinois will be established within a strong interactive and collegial environment and in an institution that has a rich history in reproductive research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
14
•
Prolactin
Project Title: COLOSTRUM FROM MOTHERS TREATED WITH CYCLOSPORINE Principal Investigator & Institution: Thiagarajan, Kristina D.; None; University of Tennessee Knoxville Knoxville, Tn 37996 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): The candidate's long-term goal is to develop interventions that support women who require immunosuppressive therapy during their childbearing years to achieve optimal health. The immediate goal is to describe and compare the quantity of immune factors and prolactin present in colostrum from those mothers' treated with immunosuppresive agents and those mother's who are not. To achieve these goals, a focused research career development plan is proposed, including intensive study of: (1) lymphocytes, cytokines and immunoglobulins in relation to colostrum and breast milk, (2) immunsuppression in women during lactation, (3) and longiturdinal design. Increasingly, women after organ transplants and/or with autoimmune diseases who are treated with immunosuppressive drugs become pregnant and interested in breast-feeding. Over 50% of infants born to cyclosporine and tacrolimus treated mothers are low birth weight (LBW) and preterm compared to 5% in the general population. The benefits of administering colostrum to this high-risk infant population are substantial. However, since cyclosporine and tacrolimus is excreted in breast milk, breast-feeding is not recommended, despite current studies that report infants do not absorb detectable amounts of cyclosporine. No studies have described the effects of cyclosponne or tacrolimus on the immune factors of colostrum that are so valued for the infant. The purpose of the proposed study is to investigate the effects of cyclosporine and tacrolimus on specific immune factors found in breast milk (IL-1b, IL4, IL-10, IgA, IgE, IgG, and IgM) and prolactin that are known to have a direct relationship with cyclosporine and tacrolimus in the adult systemic immune system. Specific aims include measuring immune factors, prolactin and levels of cyclosporine and tacrolimus in colostrum on days 1 and 3, post partum. Mothers will be 18 to 45 yrs of age and approximately 20 treatment-subjects and 20 control-subjects will be recruited and matched according to post partum duration. We will measure immune factors and protactin by method of ELISA. Tacrolimus and cyclosporine will be quantified using HPLC method and lymphocytes utilizing flow cytometry. Data analysis will include descriptive statistics, Students' t-test to make comparisons and Pearson's Product moment for correlations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: COPPER TRANSPORT IN LACTATION Principal Investigator & Institution: Linder, Maria C.; Professor of Biochemistry; Chemistry and Biochemistry; California State University Fullerton 800 N State College Blvd Fullerton, Ca 926313599 Timing: Fiscal Year 2004; Project Start 10-FEB-2004; Project End 31-DEC-2008 Summary: (provided by applicant): Many aspects of the mechanisms by which Cu is taken up from the blood plasma by different kinds of cells (including the transporters and delivery proteins involved), and just how (after cell entry) Cu finds its way to specific secretions, remain to be defined. We have obtained evidence that lactation profoundly alters the tissue distribution of newly absorbed Cu, diverting most of it from the liver and kidney to the mammary gland, where it rapidly appears in the milk and in milk ceruloplasmin. Cu in milk ceruloplasmin may be more bio-available to the infant than the other forms of Cu in the milk, which have not been well defined. A polarized cell culture model responsive to lactational hormones has been developed for studying
Studies
15
milk production by mammary epithelial cells. Mutant rodent models lacking specific proteins that could be involved in the steps required for uptake of Cu by mammary gland and its delivery to developing milk are available. The long term objective is to understand how Cu distribution and transport are regulated under normal conditions and in gestation and lactation. The immediate objectives are to determine how Cu from the exchangeable plasma pool enters mammary (and hepatic) cells, under normal conditions and in lactation, to explain the marked changes in distribution observed in the latter condition (what potential membrane transporters are involved, and how their expression and/or disposition is changed by lactation). The objectives are also to determine how, after cell entry, copper is routed to the milk and milk cemloplasmin; the role(s) of ATOX1, WND and/or MNK in this process and in regulating the copper content of the milk; and to further define the copper components of mammalian milk. Expression of potential transporters will be measured at the mRNA and protein levels, by Real Time PCR and immunoassays, respectively; and localization will be followed with immunofluorescence and confocal microscopy. Alterations in expression will be induced in the cell culture model with lactational hormones, transfection, and antisense oligos. Effects of natural and knockout mutations of specific transporters in whole animal models on copper distribution and transport will be determined. Cu uptake and its emergence in milk and milk ceruloplasmin will be followed with 67Cu/64Cu and immunoprecipitation. Effects on Cu uptake of specific antibodies against membrane transporters will be measured. Cu binding components in milk secretions will be characterized. It is expected that the proposed studies will greatly advance our knowledge of how Cu is distributed to cells from the blood and particularly how mammary epithelial cells put Cu into components of the milk that may have specific effects on the infant. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DECIDUAL PROLACTIN IN NORMAL AND PATHOGENIC PREGNANCIES Principal Investigator & Institution: Handwerger, Stuart; Professor of Pediatrics; Children's Hospital Med Ctr (Cincinnati) 3333 Burnet Ave Cincinnati, Oh 45229 Timing: Fiscal Year 2003; Project Start 01-APR-1981; Project End 31-MAR-2008 Summary: (provided by applicant): Decidualization is critical for favorable uterine receptivity of the blastocyst during implantation and the survival of the embryo. Nevertheless, relatively little is known about the transcription factors and signaling molecules that regulate this vital process. We have demonstrated that human fibroblasts isolated from decidual tissue are precursors of decidual cells and that these cells are an excellent model system to study the regulation of decidualization. Using DNA microarray and RT-PCR analyses, we have identified and categorized many genes not previously known to be regulated during the decidualization process, including the transcription factors Ets-1, fork head in rhabdomyosarcoma (FKHR), Twist, and Id3. We subsequently showed that Ets-1 induces expression of the prolactin gene, which is a specific marker of decidualization; and others recently showed that FKHR induces prolactin gene expression. The overall goal of this proposal is to test the hypothesis that Ets-1, FKHR, Twist and Id3 are critical components of the genetic program that directs human decidualization. Our specific aims are to test the hypotheses that 1) Ets-I and FKHR, which are up regulated early during decidualization, induce a cascade of transcription factors and signaling molecules that are critical for hormone production and other biochemical processes essential for human decidualization and decidual cell function; 2) Twist and Id3, which are critical for the differentiation of several cell types,
16
Prolactin
are important for maintaining the differentiated state of decidual cells; and 3) the expression of Ets-1, FKHR, Twist and Id3 during decidualization is coordinately regulated by cAMP and Ets-1. The first and second specific aims will utilize experiments with adenoviruses that express the transcription factors as well as antisense oligonucleotides that block their translation. The third aim will utilize transient transfections, gel shift assays, and site-directed mutagenesis. Since abnormalities of decidualization are frequent causes of spontaneous human abortion, a better understanding of the genetic program involved in decidualization may lead to the development of new drugs that will be useful in the treatment of infertility. The studies should also provide new insight into the mechanisms involved in the induction of prolactin in other extra pituitary tissues (such as lymphocytes and brain) and the genetic programs used by other human progenitor cells during differentiation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DECIDUAL SIGNALS IN THE ESTABLISHMENT OF PREGNANCY Principal Investigator & Institution: Soares, Michael J.; Professor; University of Kansas Medical Center Msn 1039 Kansas City, Ks 66160 Timing: Fiscal Year 2002; Project Start 02-MAY-2002; Project End 31-MAR-2007 Summary: The establishment and maintenance of pregnancy require the appropriate development of a specialized maternal tissue, referred to as decidua. Decidual cells arise from uterine stroma via the actions of progesterone, form intimate relationships with placental structures, and facilitate the development of the embryo. Among the important functions of decidual cells are their hormone/cytokine producing capabilities. Hormone/cytokines related to prolactin (PRL) are prominent decidual cell secretory proteins and include, decidual/trophoblast prolactin-related protein (d/tPRP). The uteroplacental PRL family contributes to the regulation of uterine inflammatory cell responses accompanying pregnancy. D/tPRP has been shown to associate with heparin containing molecules in the extracellular matrix and specifically interact with eosinophils. Eosinophils are a part of the maternal inflammatory response and must be controlled in order to ensure the establishment of pregnancy. We hypothesize that the decidual cell product, d/tPRP, participate in the modulation of maternal adaptations to pregnancy, including mediation of the anti-inflammatory actions of progesterone. In this research project, we propose to investigate decidual cell signaling. In Aim 1 we propose to identify cellular responses to d/tPRP. Aim 2 focuses on determining mechanisms underlying the interactions of d/tPRP with heparin and eosinophils. Under Aim 3 we examine d/tPRP- eosinophil interaction in vivo. The planned research utilizes cellular and molecular and in vitro and in vivo strategies. Data derived from the proposed experimentation will improve our understanding of the nature of decidua cell signaling and the role of the decidual PRL family in the regulation of viviparity. These findings will provide considerable insight into the etiology of developmental disorders associated with pregnancy failure and will also have important ramification on our understanding of the control of eosinophil functions in aberrant processes such as immune disease and cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DOPAMINE AND IRON IN RESTLESS LEGS SYNDROME Principal Investigator & Institution: Earley, Christopher J.; Associate Professor; Neurology; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2007
Studies
17
Summary: (provided by applicant): Restless Legs Syndrome (RLS) is a common sensorymotor disorder whose symptoms predominans Legs Syndrome (RLS) is a common sensory-motor disorder whose symptoms predominant at night and often lead to significant sleep loss and changes in one's quality of life. Like Parkinson's disease, restless legs syndrome is exquisitely sensitive to dopamine agents and aggravated or precipitated by dopamine antagonists. Previous studies and our pilot data are consistent with an involvement of brain iron and dopamine in the pathogenesis of RLS. Based on that data we have proposed that RLS symptoms result from altered dopaminergic mechanisms, which are precipitated by a relative or absolute reduction of iron in the brain. Prior PET and SPECT studies found small decreases in D2R binding potentials and one study have reported abnormal prolactin release. These studies were all done during the day when subjects are asymptomatic and therefore the clinical relevance of the findings is in question. Prior studies have also suggested the presence of brain-ironinsufficiency state in restless legs syndrome. Although the obvious iron-dopamine relation is tyrosine hydroxylase's dependency on iron as a co-factor, animal studies suggest a more dynamic effect of CNS iron reduction on dopaminergic function. Of relevance to this Project is that iron-deficiency animals show similar CNS DA abnormalities to those observed in the limited PET studies of restless legs syndrome. This project is designed to assess abnormalities expected in the tuberoinfundibular (prolactin pulsatility), Nigrostriatal (Pet imaging of midbrain and striatum) and mesolimbic (PET imaging of nucleus accumbens) DA systems. Our general model leads to the following hypotheses to be tested in this project: (1) PET and pulsatile prolactin indices of the dopaminergic activity will be altered in RLS patients compared with controls; degree of abnormalities noted in these indices will correlate (2) with CSF and/or MRI indices of brain iron status and/or (3) with clinical symptom severity. A 4PET procedure will assess D2R binding potential and Bmax; DAT; and DA release (amphetamine challenge) in the N. Accumbens, Striatum, and Substantia Nigra of RLS and control subjects. Prolactin will be measured at 10-minute intervals to determine release and pulsatility values. Using CSF and MRI measurements of iron will assess the CNS iron status. RLS severity will be based on subjective (rating scale and diary) and objective (PSG) measurements. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFECT OF SSRI THERAPY ON SPERM FUNCTION AND QUALITY Principal Investigator & Institution: Ellington, Joanna E.; Health Research & Educ Ctr; Washington State University-Spokane 601 W 1St Ave Spokane, Wa 99201 Timing: Fiscal Year 2002; Project Start 01-SEP-2001; Project End 31-AUG-2004 Summary: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressant medications in the US. The majority of individuals (55%) receiving SSRIs for treatment of their depression are between the ages of 18 and 50. Thus, clinical depression commonly occurs and is treated concurrent with the reproductive years in an individual's life. Recent statistics suggest that at least 2.5 million men of reproductive age are exposed to SSRI therapy annually. In spite of the large number of individuals taking SSRIs, there is currently little information on their potential impact on sperm function, and specifically on sperm chromatin (DNA) integrity. A critical role of sperm chromatin integrity in normal reproduction has been recognized. Specifically; sperm with high levels of chromatin damage can lead to fertility disorders including: infertility, early embryonic losses spontaneous abortions, and even possible pathology in children. Recent preliminary data by the PI and others suggest a possible risk to sperm chromatin integrity for patients on SSRI therapy.
18
Prolactin
Therefore, we hypothesize that SSRI therapy deleteriously affects sperm chromatin integrity in reproductive age men. A pilot study is proposed which aims to evaluate sperm chromatin integrity before and during SSRI therapy in clinically depressed male patients (treated group) versus depressed male patients undergoing psychotherapy alone (control group). In addition, other aspects of sperm function such as cell numbers and motility, as well as levels of sexual dysfunction and hormone concentrations will also be compared for these two groups of men. This proposal offers a unique interdisciplinary approach, combining expertise in clinical psychopharmacology and reproductive physiology to evaluate the impact of a commonly prescribed SSRI on sperm chromatin quality, and to determine if a patient profile exists for those men most at risk of such sperm chromatin damage during SSRI therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ENDOCRINE REGULATION OF MATERNAL BEHAVIOR Principal Investigator & Institution: Bridges, Robert S.; Professor of Biomedical Sciences; Veterinary Biomedical Sciences; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2002; Project Start 01-SEP-1990; Project End 31-MAY-2005 Summary: The long-term goal of this project is to identify the neural and neurochemical mechanisms underlying the regulation of maternal behavior and to elucidate potentially novel mechanisms of neural plasticity associated with the expression of maternal behavior in the adult mammal. The specific hypothesis that will be tested is that the induction, maintenance, and retention of maternal care are under endocrine regulation by a neural lactogenic system, a system that displays significant plasticity as a function of reproductive experience. The first series of studies will examine the role of the neural prolactin (PRL) receptor in the initiation of maternal behavior. Using a rat model, we will determine whether placental lactogens, like PRL, act via the PRL receptor to stimulate the onset of behavior. A second study will use the novel PRL receptor antagonist, S 179D-PRL, which will be administered centrally to test the hypothesis that activation of the PRL receptor by lactogenic hormones around the time of birth is essential for the normal onset of maternal care. The third study using ISHH will measure how pregnancy concentrations of progesterone (P) and estradiol affect expression of mRNA for neural PRL receptors. Then, central sites of P action will be examined to see how P affects the onset of maternal care and to delineate a mechanism of P's action in the initiation of maternal behavior. A second series of experiments will determine the involvement of the endocrine system in ongoing maternal care. First, the effects of exposure to PRL-secreting ectopic pituitary grafts on pup-directed maternal care and maternal aggression will be measured. Then, the effects of central administration of the PRL receptor antagonist, S179D- PRL, will be examined in lactating rats. The third set of experiments will delineate the role of the endocrine system in the retention of maternal behavior: The involvement of PRL in the opioidmediated establishment of the retention of maternal behavior will be assessed. Finally, the effects of prior maternal experience on activation of the neural lactogenic system will be measured to see whether prior maternal experience up-regulates the brain PRL system and makes the female more sensitive to her own neural hormones. The results of these investigations will delineate common endocrine and neurochemical regulators of maternal care in mammals, present a new model for examining neuroplasticity in the adult female, and provide a basis for evaluating the effects of endocrine and neurochemical imbalances on mother-young interactions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
Project Title: ENDOMETRIUM DECIDUALIZATION
GENE
REGULATION
19
DURING
Principal Investigator & Institution: Tseng, Linda; Professor; Ob, Gyn, and Reproductive Med; State University New York Stony Brook Stony Brook, Ny 11794 Timing: Fiscal Year 2002; Project Start 30-SEP-1985; Project End 31-JAN-2004 Summary: The long-term goal of this study is to determine the function of transcription factors expressed during endometrial cell decidualization. We hypothesize that a handful of transcription factors regulate the downstream target gene activation to develop deciduoma receptive to the embryo and to maintain diversified biological functions during pregnancy. To pursue the proposed study, human endometrial cell culture which recapitulates the process of decidualization in vivo has been established. Using this system we have elucidated the progestin-induced production of insulin-like growth factor binding protein-1 (IGFBP-1), the major secretory protein of decidual cells. We have also identified the essential cis-elements in the promoter of the, IGFBP-1 gene. These cis-elements provide molecular tool to analyze the functions of decidual cell transcription factors. The proposed study has four specific aims: Aim 1 will identify and characterize the transcription factors that regulate the activation of the IGFBP-1 gene. The study will focus on the modes of action of the binding proteins of C/TCAAT, CRE , Sp1 and GATA motifs and progesterone receptor (PR) of PRE motif. Aim 2 will determine the functions of the transcription factors, described in aim 1, in the promoters of prolactin (PRL), PR, and fibronectin (FN) in stromal/decidual. Aim 3 will determine how these transcription factors act on the endogenous gene, IGFBP-1, PRL, PR and FN. Aim 4 will determine the effects of estrogen, progesterone and synthetic steroids, agonists/antagonists on the mRNA levels of the functional transcription factors. Results obtained from the proposed study will help us to understand how the transcription factors control the process of decidualization in the human endometrial stromal/decidual cells. This information can be applied to improving the fertility regulation, tissue-specific fertility control, treatment of implantation failure and pregnancy disorder. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COMPOUNDS
EPIDEMIOLOGIC
EVALUATION
OF
PERFLUOROOCTYL
Principal Investigator & Institution: Raymer, James H.; Research Triangle Institute Box 12194, 3040 Cornwallis Rd Research Triangle Park, Nc 27709 Timing: Fiscal Year 2002; Project Start 01-SEP-2001; Project End 31-AUG-2004 Summary: This epidemiologic study will evaluate the potential endocrine and reproductive ramifications in human males of exposures to environmental concentrations of perfluourinated chemicals, including perfluourooctylsulfonate (PFOS) and perfluoroocatanoate (PFOA). Products containing these chemicals were recently withdrawn from the market by a major manufacturer amid concerns of persistence, toxicity, and widespread population exposures to these chemicals. The proposed study will focus on the semen quality and endocrine status of a potentially susceptible subpopulation, i.e., men of couples who present at a fertility clinic. It will use a casecontrol design in that the study population will include a high prevalence of men experiencing reproductive problems ("cases") as well as men with a normal fertility status ("controls"). By using a case-control design (the approach of choice for investigating rare outcomes), the study will be able to efficiently detect any important exposure-related reproductive problems. If exposure levels are associated with male
20
Prolactin
reproductive problems, the study participants are expected to represent a range of exposure to PFOA and PFOS, which will be measured in samples of blood and semen; concentrations in these biological media will reflect the multi-route exposures to these chemicals experienced by virtually all people in our society. Semen quality will be assessed using both routine measures and a test designed to more accurately and reproducibly assess normal, motile, and fertile sperm. Measurements of Follicle Stimulating Hormone, Luteinizing Hormone, Prolactin, Estradiol and free and total Testosterone will reflect the hormonal status of the males and will provide evidence of perturbed endocrine function. If the exposure effect is limited to a sensitive subset of the general population, our study is more likely to detect an association compared to studies that sample on PFOA/PFOS exposure status in an occupational setting. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ESTOGENS, DIETARY ENERGY AND PITUITARY TUMORIGENESIS Principal Investigator & Institution: Shull, James D.; Professor; None; University of Nebraska Medical Center Omaha, Ne 681987835 Timing: Fiscal Year 2002; Project Start 15-AUG-1995; Project End 31-MAY-2004 Summary: Estrogens play a central role in the regulation of cell proliferation in numerous mammalian tissues and are inextricably implicated in the etiology of several major human cancers. The prolactin (PRL)-producing lactotroph of the rat anterior pituitary gland provides a valuable model for studying regulation of cell proliferation by estrogens. It is well established that estrogens stimulate lactotroph proliferation and induce development of PRL-producing pituitary tumors in several different inbred rat strains. Clinical observations indicate that estrogens act similarly in the human anterior pituitary gland. We have demonstrated that estrogens induce pituitary tumors in F344 and ACI rats by stimulating cell proliferation and inhibiting apoptosis. A 40 percent restriction of dietary energy consumption was demonstrated to virtually abolish estrogen induced pituitary tumorigenesis in the F344 rat, not by inhibiting estrogen induce cell proliferation, but by modulating the ability of estrogen to inhibit apoptosis. Interestingly, these effects of dietary energy restriction were not observed in the ACI rat strain, strongly suggesting that different molecular mechanisms regulate lactotroph proliferation and death in the F344 and ACI rat strains. Using a genetic approach, we demonstrated that the ACI alleles of at least 2 genes act in a dominant manner to confer the pituitary growth response of the ACI rat to estrogens. Herein we propose 4 specific aims to characterize further the genetic bases of estrogen induced pituitary tumor development in the ACI rat and to begin to elucidate the molecular mechanisms through which dietary energy restriction modulates, in a rat strain specific manner, the homeostatic equilibrium between proliferation and death in the lactotroph population. Specific Aim 1 is to define the genetic bases underlying estrogen induced pituitary tumor development in the ACI rat strain. Specific Aim 2 is to map quantitative trait loci (QTL)that confer the tumorigenic response of the ACI rat pituitary gland to estrogen. Specific Aim 3 is to generate congenic rat strains which carry, on the BN genetic background, ACI alleles of QTL that confer the tumorigenic response of the pituitary gland to estrogen. Specific Aim 4 is to compare the effects of dietary energy restriction on the ability of administered estrogen to induce pituitary tumor development in F344, ACI and F344/ACI FI progeny. The research proposed herein will ultimately lead to the identification of genes that are involved in the regulation of lactotroph proliferation and death by estrogens and will reveal how the actions of these genes are modulated by dietary energy consumption. We believe that this new knowledge may have broad implications for other estrogen regulated cell populations and will thereby contribute
Studies
21
significantly toward our efforts to prevent and treat cancers in which estrogens are etiologic factors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FETAL REGULATION
MEMBRANE
AQP
EXPRESSION/AMNIOTIC
FLUID
Principal Investigator & Institution: Ross, Michael G.; Professor and Chair; Harbor-Ucla Research & Educ Inst 1124 W Carson St Torrance, Ca 905022052 Timing: Fiscal Year 2003; Project Start 12-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): Amniotic fluid (AF) is an essential accompaniment of normal pregnancy, necessary for fetal movement, growth and development. Excess (polyhydramnios) or deficient (oligohydramnios) AF volume is associated with significant perinatal morbidity. Despite the critical importance of AF volume, there is a lack of understanding of mechanism(s), which result in AF volume abnormalities. The intramembranous pathway of AF fluid absorption (across the amniotic membrane) has recently been recognized as a critical regulatory path for AF resorption, contributing importantly to AF volume homeostasis. Yet the underlying molecular and cellular mechanisms for water absorption across the amniotic membranes remain unknown. Aquaporins (AQPs) are cell membrane water channel proteins that greatly enhance cell membrane water permeability. Of the 11 mammalian AQPs identified to date, our studies detected the expression of three AQPs (AQP 3, 8 and 9) in human and ovine chorioamniotic membranes and placenta. In situ hybridization reveals that AQP8 is expressed in epithelial cells of human amnion and chorion, as well as trophoblasts of placenta. In addition, the investigators have demonstrated that AQP8 gene expression is maintained in a human amnion epithelial cell line, and AQP8 gene expression in amnion cells is upregulated by second messenger cAMP. In view of preliminary studies, the investigators hypothesize that AF water absorption occurs via, and is regulated by, select AQP water channels in the chorioamniotic membranes. The investigators propose to: 1) Characterize the temporal and spatial expression of water channels (AQP 3, 8 and 9) in both human and ovine fetal membranes, and correlate its change to known changes in AF volume dynamics throughout pregnancy in sheep; 2) Investigate the endocrine (oxytocin, prolactin) and second messenger camp regulation of AQPs gene expression in human amnion cell line in vitro; and 3) Explore endocrine and cAMP regulation of epithelial AQPs gene expression in vivo and determine the effect on AF volume. Our objective is to determine the regulatory mechanisms of fetal membrane AQP expression and delineate the role of AQPs in AF homeostasis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTION OF THE DECIDUAL TISSUE Principal Investigator & Institution: Gibori, Geula; Professor; Physiology and Biophysics; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2003; Project Start 01-DEC-1978; Project End 31-JAN-2008 Summary: (provided by applicant): The establishment and maintenance of pregnancy requires the coordinate activity of a specialized maternal tissue, the decidua. Extensive investigation from our and other laboratories has established that decidual cells are able to produce hormones and cytokines, and to express steroidogenic enzymes. The overall objective of our research is to understand the involvement of these decidua-derived factors in the maintenance of the proper milieu for fetal development. Gene knockout strategies have revealed a crucial role for prolactin (PRL), Interleukin-11 (IL-11) and for
22
Prolactin
decidual steroidogenic enzymes, 5alpha-reductase type 1 (5alphaR1) and 20ahydroxysteroid dehydrogenase (20alphaHSD), in the normal progress of pregnancy in rodents. The focus of this grant application is to define the role, regulation and interaction of these decidua-derived factors. The first specific aim centers on the role of decidual-PRL in the inhibition of IL-6 and caspase-3, genes involved in inflammation and cell death respectively. Using both PRL and IL-6 knockouts as well as primary decidual cells and cell lines, we propose to examine whether it is indeed IL-6 expression that leads to fetal death in the PRL (-/-) mice, whether pregnancy can be salvaged by generating double knockout mice for PRL and IL-6, and by preventing IL-6 production in the PRL null mice. We will also determine the molecular mechanism by which PRL silences the decidual expression of the IL-6 gene. Another objective of this specific aim is based on our findings that dPRL acts as a survival factor preventing the expression and activation of the cell death inducer, caspase-3, in the decidua. We will examine the mechanism by which dPRL prevents the activity of this executioner caspase, and determine whether PRL inhibition of caspase 3 is at the transcriptional level and involves the Akt/forkhead pathway. The second aim will focus on the role of decidual IL-11 in the normal progress of pregnancy and more specifically on the reason why IL11Ralpha gene deletion leads to small decidua and to uncontrolled trophoblast invasion. Finally, in the third aim, we will examine the regulation and the role of decidual steroidogenic enzymes in the maintenance of pregnancy. We will examine the mechanism by which PRL prevents decidual 20alphaHSD expression and whether PGF2a stimulates its expression at the end of pregnancy. We will also examine whether 5alphaR1 is not expressed in the IL-11Ralpha null mice causing high levels of circulating estradiol and precipitating fetal death. We will also test the hypothesis that fetal death in 5alphaReductase type 1 null mice is due to the inhibition of IL-11 signaling in the decidua by high levels of estradiol. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTION OF THE PRL RECEPTOR COMPLEX IN BREAST CANCER Principal Investigator & Institution: Clevenger, Charles V.; Associate Professor; Pathology and Lab Medicine; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 16-APR-1996; Project End 31-MAR-2007 Summary: The neuroendocrine hormone prolactin (PRL) is an important growth and differentiation factor for the human breast. The mediation of these effects of PRL on breast issues occurs through the prolactin receptor (PRLr), a Type I transmembrane receptor and member of the cytokine receptor superfamily. Within the breast, four structurally and functionally distinct PRLr isoforms (the long, intermediate, deltaS1, and PRLBP) are expressed. The extracellular binding of ligand by the PRLr isoforms initially induces receptor dimerization and phosphorylation that activates intracellular PRLrassociated signaling proteins The triggering of these PRLr associated signaling networks results in the enhanced growth and motility of human breast cancer cells. Our laboratory has demonstrated that tyrosine phosphorylation of the PRLr is necessary for these actions. PRLr action is also modulated by stimulation with extracellular matrix, indicating the presence of signaling intermediaries between the integrins and the PRLr. We have recently demonstrated that the complex of the transmembrane protein SHPS1 and the protein tyrosine phosphatases (PTP) SHP1 and SHP associate with the deltaS1 PRLr and undergo tyrosine phosphorylation following PRL stimulation. Additional data have also revealed that the SHPS1/SHP1/SHP2 complex, in turn, can modulate the
Studies
23
signaling and function of associated receptors. Given these findings, it is the central hypotheses of this proposal that phosphorylation of the PRLr isoforms and their interaction with the SHPS1/SHP1/SHP2 complex contributes to the in vitro motility and in vivo progression of human breast cancer. This hypothesis will be tested by three specific aims using tissue culture and xenograft models of human breast cancer. First, the mechanism and functional significance of PRLr isoform phosphorylation will be examined through molecular approaches. Second, the phosphorylation, association, and role of the SHPS1/SHP1/SHP2 complex during the PRLr signaling will be assessed by over-expression of wild type and mutant forms of these proteins. Third, the role of the phosphorylated PRLr isoforms and the SHPS/SHP1/SHP2 complex to breast cancer motility and metastasis will be evaluated. These studies will provide insight into the function of the newly discovered PRLr isoform and the associated SHPS1 complex, further mapping the function of PRL within the breast. Such structure/function analysis of the PRLr isoforms may ultimately provide the basis for novel therapeutic strategies aimed at interrupting the function of the PRL/PRLr complex in human breast cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE SEQUENCES INVOLVED IN PROLACTIN ACTION Principal Investigator & Institution: Yu-Lee, Li-Yuan; Associate Professor; Medicine; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 15-MAR-1998; Project End 31-MAR-2004 Summary: The long term objective of this proposal is to understand how prolactin (PRL) regulates cell proliferation and differentiation. To study multiple components along the PRL-stimulated mitogenic pathway, we cloned and characterized the PRL receptor (PRL-R), a member of the hematopoietin/cytokine receptor superfamily, and a panel of early response genes (transcription factors, cytokines, cytokine receptors) and delayed early response genes, such as RNUDC. The structure and function of two of these genes will be analyzed: the PRL-R which mediates the mitogenic effects of PRL, and RNUDC, whose synthesis is a result of PRL-stimulated cellular proliferation. AIM number 1 analyzes PRL-R domains involved in interacting with signaling proteins. How the PRL-R intracellular domain tyrosine residues serve as docking sites for recruiting the transcription factors Stat1 and Stat5 will be examined by mutagenesis, transfection, gel sift and in vitro interaction assays. The significance of PRL-R interaction with the enzyme 2',5- oligoadenylate synthetase (OAS), which was identified as a PRL-R interacting protein by yeast two-hybrid genetics, will be addressed. PRL-R truncations will be used to determine the site of PRL-R/OAS interaction, and OAS sense and antisense constructs will be used to address potential OAS function in PRL-R signal transduction. AIM number 2 addresses RNUDC structure and function. Genetic complementation studies in Aspergillus nidulans have shown that rat RNUDC is a functional homologue of a nuclear movement protein in the fungus; however, its function in mammalian cells is unclear. Our localization of RNUDC staining to the centrosome/Golgi region suggests the exciting possibility that RNUDC may play a role in centrosome/Golgi structure and/or function. A series of biochemical, pharmacological, genetic and immunofluorescence microscopy studies are outlined to determine the cellular localization of RNUDC, and to address potential RNUDC function by sense and anti-sense strategies in mammalian cells. Finally, the identity of a 50 kDa RNUDC interacting protein will be determined by microsequencing. These combined studies should provide new insights into the signaling mechanisms, signaling molecules, and gene sequences involved in PRL regulation of cell proliferation. On a
24
Prolactin
broader scale, these studies may elucidate important steps in cellular growth controls and provide insights into neuroendocrine-immune system interactions. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETICS OF SUSCEPTIBILTY TO MMTV INDUCED MAMMARY TUMORS Principal Investigator & Institution: Ross, Susan R.; Professor; Microbiology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 15-MAY-1987; Project End 31-JAN-2003 Summary: All animals, including humans, show differential susceptibility to infection with viruses. Study of the genetics of susceptibility or resistance to specific pathogens is most easily studied in inbred mice. We have been using mouse mammary tumor virus (MMTV), a retrovirus that causes mammary tumors in mice, to study virus/host interactions. These studies have focused on understanding the mechanisms which determine genetic susceptibility to MMTV- induced mammary tumors and the regulation of virus gene expression in vivo. Genetic susceptibility may be determined by the ability of different mouse strains to regulate MMTV expression. Because MMTV infects both the immune system and mammary gland, it has acquired transcriptional regulatory regions that control its expression in these tissues. We will focus on 2 of these regions, the mammary gland enhancer and the STAT (Signal Transducers and Activators of Transcription) recognition element. To determine the role of the STAT family of transcription factors in mammary gland and lymphoid tissue expression of MMTV we will identify the factors that interact with the STAT consensus sequence and elucidate their in tissue-specific and cytokine-, lipopolysaccharide- or prolactinmediated regulation of MMTV transcription using transfection studies and transgenic mice. We will also identify, characterize and clone the transcription factor that controls mammary gland-specific expression. Finally, we have found a genetic locus in C3H/HeN mice that confers dominant susceptibility to MMTV infection. We will determine what step in the infection pathway is controlled by this locus, perform genetic linkage analysis using PCR-based microsatellite markers to determine its chromosomal location, establish a physical map of the region and use cloned large genomic fragments (YAC/BAC) to create transgenic mice as a functional means to test candidate loci and clone the susceptibility gene. The results obtained from these studies will greatly increase our understanding of the genetic mechanisms which viruses use to infect their hosts and how genetic resistance to such viruses in the hosts occurs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLYCOPROTEIN PROCESSING GLUCOSIDASES Principal Investigator & Institution: Vijay, Inder K.; Professor; Animal Science; University of Maryland College Pk Campus College Park, Md 20742 Timing: Fiscal Year 2002; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: The ultimate objective of our research is to understand the structure/function relationships of the components of the biochemical machinery for protein glycosylation and the molecular basis of their gene expression during animal growth and development. The focus of investigation is on the biosynthesis and regulation of Nlinked glycoproteins in the mammary gland during its ontogeny. The biosynthesis of the precursor carbohydrate unit of these proteins is initiated by a stepwise, dolichol-linked assembly of the tri-branched Glc3Man9GlcNAC2-P-P-dolichol followed by its transfer en bloc to the nascent polypeptide in the RER. Subsequently, an extensive re-modeling
Studies
25
of the oligosaccharide moiety occurs to give rise to completed glycoproteins. Glucosidases I and II are critically juxtapositioned in the post-translational maturation phase of N-linked glycoprotein synthesis since the sequential action of these two enzymes serves as a trigger for the oligosaccharide processing and polypeptide folding machinery for glycoprotein maturation in the secretory pathway of the cell. Inhibition of glucosidases I and II has been shown to interfere with normal folding, transport and egress of glycoproteins from the ER and cause accumulation and degradation of the malfolded glycoproteins. The impairment of oligosaccharide processing has been shown to affect the biological activity of many glycoproteins, transport of receptors of the cell surface, myoblast fusion, virus assembly and infectivity, reversal of the transformed phenotype of cells in vitro, and inhibition of tumor cell metastasis in vivo. Based on preliminary studies, we propose to pursue the following specific aims: 1 and 2. Identify the active site of amino acid residues and the catalytic nucleophile of glucosidases I and II by a combination of labeling with novel photoaffinity probes, conjugation with a suicide substrate and mutagenesis of selected evolutionary conserved nucleophiles and acidic residues in the enzymes; 3, Express catalytically active recombinant forms of Glucosidases I and II, and determine the crystal structure of the enzymes; 4. Investigate the significance of subunit interaction in the regulation of glucosidase II during the development and lactogenic differentiation of the mammary gland. N-linked glycoproteins, with diverse and versatile sugar moieties, represent the largest class of glycoproteins, participate in myriad biological phenomena, and are implicated in numerous pathologies, including malignancy, atherosclerosis, many genetic disorders and host-viral interaction leading to AIDS. Transgenic biotechnology can potentially provide the mammary gland as an excellent bioreactor for a 'molecular pharming' of glycoprotein pharmaceuticals. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GORDON RESEARCH CONFERENCE ON PROLACTIN Principal Investigator & Institution: Melmed, Shlomo R.; Professor and Director; Gordon Research Conferences Box 984, 512 Liberty Ln West Kingston, Ri 02892 Timing: Fiscal Year 2002; Project Start 27-JAN-2002; Project End 31-DEC-2006 Summary: (provided by applicant): We are requesting funding for three (3) Prolactin Gordon Research Conferences to be held in Ventura, California in the Winters of 2002, 2004 and 2006. These successful research meetings have been held biannually since 1982 and are dedicated to cutting-edge discussion on aspects of prolactin expression, secretion, action and pathophysiology. In recent years, the content has also included growth hormone action, especially in light of the common phylogenetic origin and signalling action of the two hormones. A program committee comprising recognized experts, is elected for each subsequent meeting by participants, as are a Chair and a Vice-Chair who assumes the Chair, thus ensuring continuity, and avoiding duplication of content. The meeting lasts from Sunday evening through Thursday evening and attracts about 130 scientists, trainees, graduate students and endocrinologists. The budget includes expenses to support speaker registration and travel, as well as trainee travel awards. Support includes Gordon Conference support, philanthropy and this NIH request. The foci of this year's meeting include pituitary development, new technologies, behaviour, pituitary regulation, novel analogs, PRL and GH physiology and signalling, and the role of PRL and GH in cancers. This request will ensure continuation of this highly regarded meeting which has contributed to the large body of new knowledge in the prolactin field that has been generated over the past 18 years. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
•
Prolactin
Project Title: GROWTH FACTOR INVOLVEMENT IN PITUITARY FUNCTION Principal Investigator & Institution: Kudlow, Jeffrey E.; Medicine; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-JUN-1991; Project End 31-MAY-2005 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HORMONAL AND DEVELOPMENTAL REGULATION OF GENE EXPRESSION Principal Investigator & Institution: Rosenfeld, Michael G.; Professor; Medicine; University of California San Diego 9500 Gilman Dr, Dept. 0934 La Jolla, Ca 920930934 Timing: Fiscal Year 2002; Project Start 01-JUN-1977; Project End 31-MAR-2006 Summary: Understanding the molecular mechanisms by which specific cell types develop from a common primordium in the anterior pituitary gland represents a basic question in molecular and developmental biology. Under this Grant, we analyzed the roles of Pit-1, cloned and characterized Prop-1 as the hypomorphic allele causing the Ames genetic dwarfism, and identified disease alleles in human pituitary combined hormone deficiency syndrome; identified the signaling molecules from ventral diencephalon and opposing signaling gradients that dictated the positional commitments of organ and cell-type determination events, and provided the initial evidence of the roles of induced transcription factors as the "molecular memory" of the transient signaling gradients. In this competitive renewal application, we propose to investigate the role of a series of transcription factors, including the members of the Six, Pax, GATA and Pitx families, and of specific co-activators, in nearly and late developmental events. The roles of specific protein-protein interactions, and coactivators and co-repressors, on their actions will be considered, and we propose to identify artificial target genes that mediate their biological actions. The role of signaling factors, including Shh, BMP, Wnt and retinoic acid, will be further explored using in vivo and in vitro approaches. The mechanism of Pit-1 lineage determination will be explored, with experiments directed at understanding the activation of the early Pit-1 gene enhancer, regulation of the Pit-1 lineage by Prop-1, and the mechanisms of control by Pit-1 of the terminal differentiation of three pituitary cell types. The allosteric effects of cognate Pit-1 DNA binding sites on these events will be explored structurally, and in vitro, and the role of co-repressor complex assembly will be investigated. This research proposal extends the approach used over the current grant period, which has been the most successful in our 22 years under this grant, combining biochemical and genetic approaches to investigate potentially important regulatory proteins, and systematically exploring the functional role of the novel proteins. We believe that these experimental approaches will provide insights into the intriguing problems of organ and cell-type differentiation, and cell-specific patterns of gene activation, with clear implications for human diseases that are caused by abnormalities of these developmental events. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HORMONAL CONTROLS OF PLACENTAL ANGIOGENESIS Principal Investigator & Institution: Linzer, Daniel I.; Professor; Biochem/Molecular & Cell Biol; Northwestern University 633 Clark Street Evanston, Il 60208 Timing: Fiscal Year 2002; Project Start 01-AUG-1988; Project End 31-MAY-2003
Studies
27
Summary: Rapid growth of a network of blood vessels in the uterus and placenta upon implantation of the mammalian embryo is required for the exchange of nutrients and waste products between the mother and the fetus. The formation of the vasculature at this site presents several critical regulatory problems, which will be explored in the mouse. Unlike other vessels, uterine vessels that reach the placenta do not reseal at the growing end, but instead release blood into pools called blood sinuses; placental cells directly contact the maternal blood in these sinuses, enabling an efficient exchange of metabolites and gasses and the rapid distribution of placental-hormones throughout the maternal bloodstream. Another unusual feature is that vessel growth is prevented through the outer layers of the placenta; if vessels from the mother and fetus did not cross these layers, two consequences would be the exposure of the fetus to maternal immune cells (which would attack the fetus as foreign) and extensive (possibly fatal) vessel rupture and hemorrhaging at birth. our recent results suggest that we have discovered two of the key regulators of uterine-placental neovascularization in the mouse, proliferin and proliferin-related protein, which are both members of the prolactin/growth hormone family of protein hormones and are, respectively, major positive and negative regulators of blood vessel growth (angiogenesis) secreted by the placenta. This discovery makes several predictions about how the unique aspects of angiogenesis at the implantation site are regulated. Proposed experiments, using transgenic and targeted gene disruption mouse models, will test the hypothesize physiological roles of proliferin- related protein in the temporal and spatial restriction of vessel growth. Other studies will investigate the signal transduction pathways through which proliferin induces, and proliferin-related protein inhibits, angiogenesis. This research has direct implications for the management and treatment of infertility and pregnancy-related disorders, but may also provide novel insights into the process of vascularization to human disease, for example in cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HORMONAL INDUCTION ANIMAL MODEL OF PROSTATE CANCER Principal Investigator & Institution: Bosland, Maarten C.; Professor; Environmental Medicine; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2002; Project Start 12-JAN-1999; Project End 31-DEC-2003 Summary: Combined treatment with testosterone (T) + estradiol-17beta (E2) induces prostate adenocarcinomas in 100 percent of NBL rats, and T alone a 40 percent incidence. This is the only model in which steroid hormones alone produce a high prostate cancer incidence; it offers opportunities to study the mechanisms whereby steroid hormones cause prostate cancer. We hypothesize that E2, either formed endogenously from T by the enzyme aromatase or exogenously administered, acts via a genotoxic mechanism that involves the generation of reactive oxygen species to produce prostate carcinomas in the presence of T, and that estrogen receptor (ER)-mediated mechanisms are not involved. To address the hypothesis and resolve some uncertainties about the model, the following specific aims are proposed. Aim 1: To establish whether E2 is an essential factor in the hormonal induction of prostate cancer by T, and whether it acts via a mechanism that is ER-independent; we will establish whether treatment with an aromatase inhibitor reduces or eliminates prostate cancer induction by T, and to demonstrate that antiestrogen treatment does not affect the tumor response. Aim 2: To determine whether induction of oxidative DNA damage and of prostate carcinomas by T and E2 are linked and, therefore, probably causally related; we will administer antioxidant vitamins (C and E) to T+E2-treated rats, which should reduce both prostate
28
Prolactin
cancer induction and prostatic oxidative DNA damage (measured by formation of 8hydroxydeoxyguanosine). Aim 3: To demonstrate that T+E2-induced carcinomas have the potential to metastasize and determine whether T+E2-induced peripheral prostate dysplasia can progress to cancer; we will determine whether lowering of the E2 dose or shortening of the E2 treatment duration, while continuing T administration, will sufficiently lower or delay pituitary tumor formation and prolong survival to allow progression of prostate carcinomas to the metastatic stage. Aim 4: To establish whether T+E2- induced prostate carcinomas are androgen-sensitive and their induction is androgen-dependent and prolactin-independent; we will test the response of prostate cancers transplanted into syngeneic rats to castration and determining the effect of castration of T+E2-treated rats at a time at which very small carcinomas have already formed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HORMONAL REGULATION OF BREAST CANCER Principal Investigator & Institution: Rosen, Jeffrey; Associate Professor; Molecular and Cellular Biology; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-AUG-1978; Project End 31-JAN-2007 Summary: (provided by applicant): The long-term objectives of these studies are to elucidate the mechanisms by which hormones regulate the normal development of the mammary gland and milk protein gene expression, and to determine how these regulatory mechanisms have deviated in breast cancer. This proposal addresses the question of why the same hormones, which promote growth and terminal differentiation during normal mammary gland development, result in aberrant growth in the majority of breast tumors. Specific emphasis has been placed upon studying the mechanisms by which the lactogenic hormones, prolactin and glucocorticoids, regulate the expression of milk protein genes. These studies have established that composite response elements containing multiple binding sites for several transcription factors, including CCAAT/enhancer binding protein (C/EBP) beta, nuclear factor (NF) I, signal transducers and activators of transcription (Stat)5, and the glucocorticoid receptor (GR) mediate the hormonal and developmental regulation of milk protein gene expression. Analysis of C/EBP beta knockout (KO) mice revealed alterations not only in functional differentiation, but also surprisingly in ductal morphogenesis and lobuloalveolar development. These studies led to the hypothesis that steroid hormone regulated mammary epithelial cell (MEC) proliferation occurs via paracrine/juxtacrine mechanisms mediated by local growth factors, and that a switch to an autocrine signaling mechanism is an early event in the progression to breast cancer. To test this hypothesis we propose to combine mouse genetics with the in situ analysis of signal transduction pathways. Transgenic, conditional KO and KO-transplant mouse models will be employed for these studies. The following specific aims are proposed: 1. To elucidate the mechanisms by which C/EBP beta regulates ductal morphogenesis and lobuloalveolar development. 2. To analyze steroid receptor distribution, cell proliferation and local growth factor expression in several KO mice known to affect lobuloalveolar development, including PrlR, Stat5 A & B and p27 KO mice. 3. To utilize a novel, ligand-independent, drug inducible fibroblast growth factor receptor transgenic mouse model to understand the role of local growth factors in cell proliferation and lobuloalveolar development. 4. To utilize novel transgenic and conditional mouse models to study the role of beta-catenin in mediating Wnt signaling during mammary gland development. 5. To understand the role of C/EBP beta, Stat5 and GR in hormonally regulated chromatin remodeling.
Studies
29
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HORMONE, CYTOKINE, AND GENETIC RISKS FOR RA IN WOMEN Principal Investigator & Institution: Karlson, Elizabeth W.; Assistant Professor; Brigham and Women's Hospital 75 Francis Street Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2008 Summary: (provided by applicant): Rheumatoid arthritis (RA) is a highly disabling autoimmune disease with reduced survival that disproportionately affects women 3 to 4 times more frequently than men. Clinical, epidemiological and animal studies suggest a role and potential interaction between genetic factors, sex steroid hormones, and inflammatory cytokines on risk of RA, but these interrelationships are poorly understood. The overall goal of this study is to define the contribution of serum hormones, inflammatory markers and genetic factors in the etiology of RA in women using a prospective nested case-control design. The proposed study uses 3 ongoing cohorts, the Nurses' Health Study (NHS), the Nurses' Health Study II (NHS II), and the Women's Health Study (WHS). Blood samples were collected and archived since 1989 from 90,572 cohort participants. The study will be almost three times larger than the next largest prospective study. We will use a validated method to ascertain RA cases; we expect to confirm 1200 incident cases overall and will have archived blood samples available for 500 cases. Specifically, we hypothesize that low plasma total and free testosterone, low DHEAS, and low levels of prolactin are positively associated with subsequent risk of RA among women and men. Similarly, elevated levels of C-reactive protein (CRP) and interleukin-6 (IL-6) are prospectively associated with increased risk. We will also examine the association of genetic polymorphisms in the progesterone, estrogen, and androgen and receptors, as well as the association of polymorphisms in corticotrophin releasing hormone, CYP19, and tumor necrosis factor genes with risk of RA. The large size (>500 RA cases) and prospective nature of the proposed study, along with the availability of archived blood samples and data on other RA risk factors, provides a unique opportunity to further our understanding of the etiology of RA in women. Ultimately, this study could lead to the identification of potential targets for therapeutic interventions to treat RA or to reduce the risk of this serious autoimmune disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HUMAN PROLACTIN ANTAGONIST AS A CHEMOPREVENTIVE AGENT Principal Investigator & Institution: Chen, Wen Y.; Assoiate Professor; Microbiol & Molec Medicine; Clemson University 300 Brackett Hall Clemson, Sc 296345702 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): The involvement of human prolactin (hPRL) in breast cancer has been recently established based upon its autocrine/paracrine proliferative effects in mammary tumor epithelial cells. More importantly, recent evidence suggests that hPRL may constitutively activate oncogene HER2/neu through activation of JAK2 kinase. Although the molecular events involved in this cross activation is not well understood, it is believed that constitutive phosphorylation of HER2/neu contributes to poor prognosis and unsatisfactory clinical response of HER2/neu positive breast cancer to anti-HER2/neu monoclonal antibody therapy. The purpose of this two-year pilot study is to identify the alteration of gene expression in the mammary gland resulted from the interaction between hPRL and HER2/neu, more
30
Prolactin
importantly between a hPRL antagonist (G129R) and HER2/neu, using bi-transgenic mouse models. We are especially interested to test the hypothesis that G129R can be used as a chemopreventive agent to prevent or delay the onset of HER2/neu initiated breast cancer and identify those genes involved in this process for future studies. Our specific aims are (1) to establish bi-transgenic mice by cross-breeding male mouse metallothionein I promoter (MT) hPRL transgenic mice (MT/hPRL) and MT/G129R transgenic mice with female MMTV/neu transgenic mouse to generate bi-transgenic lines (MT/PRL+MMTV/neu and MT/G129R+MMTV/neu), (2) to monitor the rate of breast tumor formation in bi-transgenic mice to determine the role of hPRL in HER2/neu induced breast tumor and the efficacy of potential chemopreventive effects of G129R, (3) to use commercial cDNA microaray services to identify alterations in gene expression in the mammary tissue of the bi-transgenic mice to identify genomic signatures of hPRL, G129R and HER/neu interaction. We hope that the results from this pilot study will not only contribute to a better understanding of the HER2/neu positive breast cancer but also lay a solid foundation for further studies to define therapeutic targets for HER2/neu positive breast cancer as well as to develop HER2/neu specific tumor inhibitors. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HYPOPITUITARISM: CHARACTERIZATION
CLINICAL
&
MOLECULAR
Principal Investigator & Institution: Radovick, Sally M.; Section Chief; Pediatrics; University of Chicago 5801 S Ellis Ave Chicago, Il 60637 Timing: Fiscal Year 2002; Project Start 01-JUN-2000; Project End 31-MAR-2005 Summary: Pituitary development and hormone expression in mammals is controlled by pituitary-specific transcription factors including: Rpx, Lhx3, Prop-1 and Pit-1. These factors initiate a cascade of development events resulting in mature pituitary cell-types and mutation or deletion of the genes encoding these factors have been shown to result in anterior pituitary hormone deficiency in mammals. A consistent feature of these animal models is GH deficiency associated with either TSH and/or prolactin deficiency. Many patients have been described with complete or partial deficiency of hormone secretion from these cell types. However, in many cases, the pituitary function has not been carefully evaluated and patients are frequently diagnosed as having 'idiopathic' GH deficiency. My laboratory and others have described a genetic basis for combined pituitary hormone deficiency (CPHD) in man due to point mutations in the Pit-1 and Prop-1 genes. We and others have also discovered Pit-1 and Prop-1 mutations in patients with presumed idiopathic GH deficiency. These observations demonstrate that mutations in these genes may be a frequent cause of not only CPHD, but also 'isolated' GH deficiency. In addition, mutation or deletion of other pituitary developmental factors (Rpx, also 'isolated' GH deficiency. In addition, mutation or deletion of other pituitary developmental factors (Rpx, Ptx2 and Lhx3) has been associated with pituitary hormone deficiencies. This proposal will clinically characterize patients with hypopituitarism and investigate the structure of candidate genes. Study of mutations in pituitary transcription factors and their diverse pathophysiological mechanisms should increase our understanding of anterior pituitary gland development and gene regulation in normal and disease states. The candidate is an Associate Professor of Pediatrics at Harvard Medical School and an Associate Physician at Children's Hospital, Boston, where she is the director of the reproductive endocrine unit and endocrine clinical laboratories. She has independent support to study GnRH gene expression (RO1-HD34551) and Pit-1 gene function (R01-DK53977) in mammals. She also directs a
Studies
31
CRC protocol to evaluate and categorize patients with hypopituitarism. She actively mentors four BE/BC pediatric endocrinologists, a BE obstetrician-gynecologist, two of whom are funded by the intramural Endocrine training grant (T32HD07277), one funded by a mentored grant (K11DK02329), one by a Janeway fellowship award from Children's Hospital mentoring success, in an environment rich with academic opportunities, this award will allow her to increase her mentoring activities and to enhance her own commitment to patient- oriented research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOLOGICAL ASPECTS OF HEMORRHAGE Principal Investigator & Institution: Chaudry, Irshad H.; Professor, Professor, Vice Chairman & Di; Surgery; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-APR-1988; Project End 31-MAR-2003 Summary: Our recent studies indicate that proestrus female mice [with cycle- increased levels of estrogen and prolactin (PRL)] have improved immune responses after traumahemorrhage as opposed to markedly depressed responses in males. Moreover, the survival rate of proestrus females following sepsis after trauma-hemorrhage was significantly higher than age-matched males. In contrast to young proestrus mice, aged females (defined by lowered estradiol levels) show marked immunosuppression after trauma. Our hypothesis, therefore, is that it is the high estradiol or a high estradiol: androgen ratio which directly (receptor- mediated) or indirectly (receptor-independent) enhance immune functions in proestrus females, and the loss of these estrogenic effects may contribute to the failure to maintain immune responses in aged females after trauma-hemorrhage. Studies are proposed to determine the mechanism of regulation of estradiol and estrone by hypothalamic/pituitary factors adrenals and aromatase activity and determine how differences in estradiol levels or the estradiol: androgen ratio due to the estrus cycle, ovariectomy (OVX, in middle aged mice to reduce estrogen), and age affect immune responses after trauma. Sex steroids (SS) receptor- mediated and receptor-independent gene activation mechanisms will be studied in T-cells and macrophages (Mphi). Since activation of AF-1 and AF-2 regions of estrogen receptor (ER) is critical for agonist and antagonist effects, activation of the ER agonist regions by estrogens in T-lymphocytes will be evaluated by transfection studies. Moreover, since SS non-ligand response also involve [Ca2+]i mobilization, T cells and Mphi will be examined for Ca2+ signal transduction and the expression and translocation of PKC isoforms. The release of TH1 and TH2 cytokines and IL-6 and the effects of PRL on their release in proestrus, OVX, aged, ER-, and PRL-knockout mice will also be evaluated. Additionally, the effect of SS on PRL and TH1 and TH2 cytokine-induced JAK-STAT expressions will be evaluated. Analysis of bone marrow for lymphoblastoid/myeloblastoid cell composition, and the effect of SS on the population of these cells will be determined. We will evaluate if administration of beta-estradiol, Raloxifene or PRL in vivo after trauma-hemorrhage improves the depressed immune responses in estrogen deficient mice. If a single dose is ineffective, multiple doses of these drugs with or without gonadotropin releasing hormone (GnRH) or flutamide (androgen receptor antagonist) will be administered to determine whether synergistic beneficial effects on immune responses are produced and whether the susceptibility to sepsis after trauma is decreased. Detailed mechanistic studies of T cell and Mphi functions using molecular biological techniques to determine why low estradiol fails to maintain immune functions in aged females after trauma and the use of estradiol, Raloxifene, PRL, GnRH or flutamide to restore immune functions should yield novel
32
Prolactin
information and provide an innovative approach for improving the immune responses and reducing mortality from sepsis following trauma-hemorrhage in postmenopausal as well as in surgically OVX patients with low estrogen activity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOSUPPRESSANT MODULATION OF DRUG METABOLISM Principal Investigator & Institution: Brunner, Lane J.; Pharmaceutics; University of Texas Austin 101 E. 27Th/Po Box 7726 Austin, Tx 78712 Timing: Fiscal Year 2002; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: (Verbatim from Investigator's Abstract): Immunosuppressants, such as cyclosporine, are widely administered to transplant patients to prevent organ rejection. The clinical use of cyclosporine is hampered by significant toxicity to the CNS, liver and kidney. While these toxicities are related to circulating cyclosporine concentrations, they are not always predictable. Although dosing regimens exist, large inter- and intrapatient variability in pharmacokinetic parameters may complicate predicting therapeutic cyclosporine blood concentrations. The toxicity may be related to changes in hepatic or intestinal drug metabolism. Cyclosporine is known to alter its own hepatic metabolism which may be responsible for the large variability in clinical responses. The objective of the proposal is to investigate possible mechansims of immunosuppressantinduced alterations in drug metabolism, using cyclosporine as the prototype drug. The hypothesis being tested is that chronic immunosuppressive therapy causes a modulation in pituitary function leading to altered circulating levels of growth hormone and prolactin which results in decreased drug metabolism. In addition, chronic immunosuppressive therapy causes an increase in circulating transforming growth factor Beta-1 or TGF Beta-1 which results in suppressed drug metabolism. These changes, alone or in concert with one another, may explain the changes in drug metabolism seen previously with immunosuppressive therapy. In order to investigate the role of growth hormone, rats will be administered cyclosporine along with growth hormone. These studies will determine the role of growth hormone and whether or not cyclosporine changes growth hormone levels. Next the proposed studies will examine the role of prolactin. Along with cyclosporine, rats will be administered exogenous prolactin or a prolactin antagonist to determine the effects of cyclosporine on the circulating levels of this pituitary hormone. Finally, rats will be given cyclosporine and TGF beta1 to determine whether or not this cytokine has a significant role in immunosuppressant-induced changes in drug metabolism. These studies will provide information how cyclosporin and other immunosuppressive drugs may regulate hepatic and intestinal drug metabolism. This information will have direct application to transplant patients and give clinicians needed information regarding the relationship between immunosuppressive therapy and the prediction of toxicity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMPACT OF A LITTERMATE ON PSYCHOLOGICAL STRESS IN RATS Principal Investigator & Institution: Wilson, Janie H.; Psychology; Georgia Southern University Statesboro, Ga 30460 Timing: Fiscal Year 2003; Project Start 01-JAN-2003; Project End 31-DEC-2004 Summary: (provided by applicant): Generally known for its reproductive role, the hormone prolactin is now known to be released in response to stress. Acute psychological stress reliably increases prolactin and affects behaviors in adult male rats;
Studies
33
however, responses of adult females and juvenile males and females remain to be explored. In the proposed experiments, four psychological stressors will be examined: novel open field, noise, the conditioned-emotional- response (CER) paradigm, and nonpainful exposure to a cat. As a second component, the present slate of experiments will examine the impact of a conspecific on responses to psychological stressors by testing animals in the presence of a same-sex littermate. A third component, pretreatment with 1 mg/kg i.p. injection of the oxytocin antagonist 1-deamino-2-D-Try(Oet)-4-Thr-8-Om-oxytocith will examine the possible role of oxytocin in social buffering as measured by prolactin levels. Prolactin and individual as well as social behaviors in the stressful environments will be recorded. It is hypothesized that adult male and female rats tested alone in the chamber will have lower levels of prolactin than those tested alone in the chamber with a stressor. Low levels of prolactin are also expected in females exposed to a stressor in the presence of a conspecific, and the oxytocin antagonist is expected to block oxytocin in the pre-treated conspecific females, resulting in high levels of prolactin comparable to those found in animals tested alone with a stressor. Conversely, adult males may not experience social buffering and are expected to have high levels of prolactin in the social condition; therefore, pre-treatment with an oxytocin antagonist will not cause higher levels of prolactin as compared with the nontreated social animal. Among juvenile males and females, no such sex X treatment condition interaction is expected. Juveniles are expected to respond to stress, social buffering, and the oxytocin antagonist in a pattern similar to adult females (above). Each animal model will serve as a foundation to build an understanding of responses to stress and social buffering, particularly in nonverbal populations such as children, the aged, and adults with brain injuries. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INFLUENCE OF LACTATION ON POSTPARTUM STRESS AND IMMUNITY Principal Investigator & Institution: Groer, Maureen W.; None; University of Tennessee Knoxville Knoxville, Tn 37996 Timing: Fiscal Year 2002; Project Start 01-AUG-2001; Project End 31-JUL-2004 Summary: (provided by applicant): The long-term objectives of the research are to understand the regulation of neuroendocrine and immunological responses to naturalistic stress in postpartum women, and to determine if lactational state is associated with significant differences in these variables. It is known from animal studies that lactation confers stress resistance, which may be accompanied by immunologic protection during stress. Clinical benefits of lactating may therefore include a maternal health-protecting effect. Most of the research studies on postpartum women do not distinguish lactational state, yet all animal studies naturally are of lactating organisms. Since many women do not lactate, it is essential that knowledge of the neuroendocrinology, stress responses, immune parameters, and health effects of lactating and non-lactating women be explored to determine if any differences of importance do exist. The study will analyze relationships between lactational state and stress, hormones, immune function, and symptoms of infection. The data will provide new information about whether a lactational stress resistance exists in the human species, and if lactation confers any immunological or health benefit to the mother. The specific aims of this study are to 1) To analyze perceived stress, stressful life events, mood states, levels of stress-associated hormones, and relationships among these variables in lactating compared to non-lactating women; 2) To analyze immune variables and occurrence and severity of symptoms of common infection in lactating
34
Prolactin
compared to non-lactating women; 3) To analyze relationships between stress, and mood, variables, immune variables, and incidences and severity of symptoms of common infection in lactating and non-lactating women. Maternal health, and immunity will be examined at 4-6 weeks postpartum. Stress will be measured as both life events stress and perceived stress. Mood states are determined by scores on the Profile of Mood States. Stress-associated hormones are analyzed in serum and include prolactin, oxytocin and cortisol, while immune function is assayed through cytokines, T-cell proliferation, immunoglobulin level, neopterin levels and CD markers. Symptoms of infection are measured by the Carr SCL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS AND PREVENTION OF SURGERY-INDUCED METASTASIS Principal Investigator & Institution: Ben-Eliyahu, Shamgar; Associate Professor; Tel Aviv University Ramat-Aviv Tel Aviv, Timing: Fiscal Year 2002; Project Start 01-AUG-1996; Project End 31-MAY-2006 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF DEVELOPMENTAL TOXICITY OF BISPHENOL-A Principal Investigator & Institution: Soto, Ana M.; Professor; Anatomy and Cellular Biology; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2002; Project Start 01-SEP-1996; Project End 31-AUG-2005 Summary: The increase of the incidence of malformation of the genital tract and hormone-related cancers is a main health problem in the industrialized world. Environmental estrogens are suspected to be the casual agent. The long- term goal of this proposal is to understand the mechanisms underlying the toxicity of the environmental estrogen Bisphenol-A (BPA) on the female reproductive system and mammary gland. During the first period of funding, we found evidence that perinatal exposure to low- environmentally relevant doses of BPA produces irreversible alterations in the structure and function of estrogen-target tissues in female rodents. Increased body weight, changes in morphology of the ovary, uterus and mammary gland, and alterations in pattern of estrus cyclicity suggested that perinatal exposure to BPA may decrease reproductive success, and increase the risk of mammary gland cancer. Given the similarity of toxic effects of the synthetic estrogen diethylstilbestrol in rodents and humans, our results raise concern the exposure to BPA may put human health at risk. The overall hypothesis to be tested is that perinatal exposure to BPA results in morphological and functional alterations of the hypothalamus and/or pituitary as well as estrogen sensitive peripheral organs (i.e. mammary gland) by an ERmediated process. These effects of BPA in development would in turn result in an altered response to ovarian and pituitary hormones in adulthood. The following complementary Specific Aims are proposed: Aim1: To assess the hypothesis that perinatal exposure to BPA alters a) sexual differential of the brain and b) the functionality of the circuitry involved in the luteinizing hormone and prolactin surges thus altering permanently the hormonal milieu of peripheral organs (i.e. mammary gland). Aim 2: To assess the hypothesis that in utero exposure to BPA directly affects the prenatal development of the mammary gland anlage by altering the expression of ER and downstream homeobox genes Msx2, Wnt10b). Aim 3: To assess the hypothesis that the morphological changes observed in the mammary glands are due to an altered
Studies
35
response to gonadal and pituitary hormones. The responsiveness to various sex hormones will be assessed in ovariectomized mice following in utero exposure to BPA. The following techniques will be used: immunocytochemistry, in sit hybridization, quantitative PCR, morphometry, radioimmunoassays. The information obtained from these studies will considerably advance our understanding of the mechanisms underlying the developmental and reproductive toxicity of BPA. These data are needed to develop biomarkers and research strategies to apply these data to assess the toxic impact of xenoestrogens on human development and reproduction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS OF ORDERED BINDING OF LACTOGENS AND RECEPTORS Principal Investigator & Institution: Brooks, Charles L.; Associate Professor; Veterinary Biosciences; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2002; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: Human lactogenic hormones, including growth hormone (hGH), placental lactogen (hPL) and prolactin (hPRL), all bind the human lactogen receptor. Current data suggests that lactogen and receptor bind with a 1:2 ratio and the two binding reactions have affinities that differ by at least an order of magnitude. Current information suggests lactogens may be similar to hGH and the somatotropin receptor where binding is an ordered process. The ordered hGH mechanism was demonstrated by mutagenic studies, where mutation of Site 1 eliminated binding at Site 2, but mutation of Site 2 had no effect of Site 1 binding. These results documented a uni-directional interaction between the two somatotrophic sites of hGH. Similar studies have been difficult to perform with lactogens because of the low affinity of Site 2. In fact, until examined by surface plasma resonance techniques, binding at Site 2 has been difficult to consistently document. No detailed structural mechanism has been described that will account for the interaction between Sites 1 and 2 in any lactogen. Using biological assays for lactogenic activity, we have recently described a series of contiguous hydrophobic residues in hGH that may be the motif by which Site 1 interacts with Site 2. Mutation of these residues, which span from Site toward Site 2, severely reduced the activity at Site 2. The main goal of this application is to determine if this motif is responsible for the interaction between Sites 1 and 2 in hGH, hPL and hPRL. Specific Objective 1 will characterize and compare the nature of lactogen/receptor binding; determining if the two binding sites interact and the nature and degree of interaction. Characterization of the binding mechanism of hGH, hPL and hPRL must be completed before studies probing the structural motif can be interpreted. Specific Objective 2 will determine the physical nature of the motif that apparently conducts the communication between Sites 1 and 2 of hGH. These studies will determine the size of the motif and characterize the role of each member residue in the communication between the two receptor binding sites. Specific Objective 3 will determine the same or a similar motif is conserved and operation in hPL and hPRL. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF ORPHANIN'S EFFECTS ON PROLACTIN RELEASE Principal Investigator & Institution: Janik, James M.; Zoology; Miami University Oxford 500 E High St Oxford, Oh 45056 Timing: Fiscal Year 2000; Project Start 01-SEP-2000; Project End 31-AUG-2004
36
Prolactin
Summary: The hypothesis to be tested is that Orphanin FQ (OFQ) is involved in the physiological regulation of prolactin secretion and that this peptide's mechanism of action is at the hypothalamic level. Specifically, OFQ inhibits the activity of the tuberoinfundibular and tuberohypophyseal dopaminergic (TIDA and THDA, respectively) neurons, which produces a stimulatory effect on prolactin secretion. Furthermore, OFQ plays a physiological role in prolactin regulation and is involved in the suckling-induced prolactin increase. The hypothesis will be tested using several approaches in male and females rats. First, the mechanism of action will be examined by determining the neurochemical response to OFQ administration. DOPA accumulation will be used as index of dopaminergic activity and 5-hydroxytryptophan as an index of serotonergic activity in specific regions of the brain involved in prolactin regulation. Second, pharmacological specificity of the stimulatory effects of OFQ on prolactin release will be demonstrated by blocking this response with Acetyl-RYYRIK-NH2, an OFQ antagonist that has been shown to have antagonist activity in rat brain. Third, double-label immunocyto-chemical studies will determine the specific dopaminergic neurons in the arcuate nucleus that are inhibited by OFQ. Simultaneous expression of tyrosine hydroxylase and c-fos will be examined. Finally, the role of OFQ in mediating the suckling-induced prolactin increase will be determined by pretreated post-partum, lactating female rats with Acetyl-RYYRIK-NH2 prior to a suckling bout. The sucklinginduced prolactin increase, as well as the suckling-induced inhibition of TIDA and THDA neurons and activation of serotonergic neurons, will be quantified. The long term objectives of this research are to understand the neural regulation of prolactin release and the interaction between the prolactin releasing and inhibiting factors in different physiological states, such as lactation, as well as gender differences in the regulation of this hormone. Prolactin has many important physiological roles. It can affect reproductive functions (e.g. hyperprolactinemia is associated with oligomenorrhea) and prolactin levels are affected by stress and exercise, which influences reproductive cyclicity. In order to understand reproductive disorders or disorders due to stress, it its important to understand the nature of the connections between the various and numerous factors regulating prolactin secretion. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LACTATION
MECHANISMS
OF
SKELETAL
RECONSTITUTION
AFTER
Principal Investigator & Institution: Miller, Scott C.; Research Professor; Radiation Oncology; University of Utah Salt Lake City, Ut 84102 Timing: Fiscal Year 2002; Project Start 01-AUG-1998; Project End 31-JUL-2005 Summary: Maternal efficiency during reproduction is essential for species propagation. The mammalian skeleton provides mineral for the fetal skeleton during pregnancy and milk production during lactation. Dramatic changes occur in the maternal skeleton during the reproductive cycle and some may serve to protect skeletal integrity. The post-lactation period is particularly 'anabolic', but mechanistically not understood. To further define the maternal skeletal adaptations and mechanisms that occur during and after the reproductive cycle, the following aims are proposed. 1). To determine the cellular and tissue events in the skeleton during the transition from late pregnancy to lactation. We hypothesize that the increases in resorption in late pregnancy and sustained during lactation are the result of an increased rate of osteoclast formation, prolongation of lifespan and a decrease in apoptosis. 2) To determine the cellular and tissue events in the skeleton that occur during the transition from lactation to postweaning. The hypothesis is that increases in bone formation are associated with an
Studies
37
increased rate of osteoblast formation but decreased resorption is the result of decreased osteoclast activity, decreased formation but increased apoptosis. 3) To determine if the post-weaning increase in calcitonin (CT) levels is correlated with decreased osteoclastic functions, and establishes the "milieu" for the post-lactational recovery phase. We suspect correlation with decreases in prolactin, but increased estrogen and initiation of estrus. 4) Is there a change in the remodeling period during the reproductive cycle in mammals? This will be determined from archived materials from a species that has intracortical bone remodeling. 5) Does moderate skeletal loading improve bone mass, structure, strength and dynamics during the post-lactation 'recovery' phase? Our hypothesis is that skeletal loading will have synergistic effects on skeletal mass and structure during this period. These studies will provide new knowledge on perhaps the most dynamic and "anabolic" period in the life of the adult female skeleton and may provide new insights into treatments of diseases after reproductive capacity has ended. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MECHANISMS REGULATING UTERINE MORPHOGENESIS Principal Investigator & Institution: Spencer, Thomas E.; Assistant Professor; None; Texas A&M University Health Science Ctr College Station, Tx 778433578 Timing: Fiscal Year 2002; Project Start 06-APR-2001; Project End 31-MAR-2005 Summary: (Scanned from the applicant's abstract) Human infertility, pregnancy loss and intrauterine growth retardation represent major public health problems. A large number of reproductive age women experience these problems, which may be due to uterine dysgenesis, dysplasia and/or dysfunction. Long-term objectives are to understand the hormonal, cellular and molecular mechanisms regulating uterine morphogenesis. The proposed research specifically focuses on mechanisms regulating endometrial gland differentiation and development or adenogenesis. Adenogenesis is a critical period of uterine morphogenesis that occurs in the fetus in humans, but in the neonate after birth in ungulates and rodents. Studies in sheep and rodents indicate that uterine glands are unequivocally required for conceptus survival, growth and implantation. Thus, success of developmental mechanisms regulating uterine morphogenesis dictates the embryotrophic potential and functional capacity of the adult uterus. Our studies indicate that: neonatal ovine endometrial adenogenesis occurs during the first eight weeks after birth and is associated with increased levels of serum prolactin (PRL) and estradiol-17b (E2-17b); proliferating and morphogenetically active endometrial glands in the neonatal uterus express short and long prolactin receptors (PRL-R), insulin like growth factor one receptors (IGF1R), and high levels of estrogen receptor alpha (ER-a); and stromal cells surrounding the developing glands express IGF-I, IGF-II and ER-a. Both the IGF1R and the short and long PRL-Rs stimulate the mitogen activated protein kinase (MAPK) signaling cascade. In other systems, stimulation of the IGF1R can lead to activation of ER-a in a ligand independent manner by MAPK. Our central hypothesis is that PRL, E2-17b and IGFs regulate endometrial adenogenesis by activation of the MAPK signaling pathway and ER-a through ligand-dependent (E2-17b) and ligandindependent (PRL, IGFs) mechanisms. Using a multidisciplinary, collaborative approach, in vivo and organ culture systems will be used to test the central hypothesis using the neonatal ovine uterus as model system. Accomplishment of these research goals is expected to significantly advance our understanding of the developmental aspects of uterine biology, determinants of adult uterine function, and provide a foundation for the design of clinical therapies to prevent, identify and treat human reproductive problems, such is infertility and pregnancy loss due to endometrial gland dysgenesis, dysplasia or dysfunction.
38
Prolactin
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOLECULAR ANALYSIS OF ERYTHROPOIESIS IN VIVO Principal Investigator & Institution: Socolovsky, Merav; Whitehead Institute for Biomedical Res Biomedical Research Cambridge, Ma 02142 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2007 Summary: The receptor for erythropoietin, EpoR, is a homodimeric cytokine receptor essential for the formation of red cells. In addition, it is the principal homeostatic regulator of red cell production rate, through a wide dynamic range. The molecular mechanisms that encode quantitative features of EpoR signaling are largely unknown, but may involve the control of apoptosis in early erythroid progenitors. Dysregulation of these mechanisms may lead to oncogenic transformation. The purpose of this proposal is to identify molecular mechanisms that encode the quantitative response to EpoR signaling, and whose dysregulation predisposes to leukemia. The following approaches will be taken: 1. The receptor for prolactin, PrlR, a non-hematopoietic cytokine receptor, can rescue EpoR-/- progenitors and support their full differentiation into red cells in vitro. This and similar findings suggest that homodimeric cytokine receptors signal through a similar, 'generic' program. Components of this program will be identified using in-vitro red-cell differentiation assays. These may be relevant to other cytokine- receptor regulated systems such as mammary epithelium 2. In spite of apparent functional similarity, PrlR and EpoR share little homology in their cytoplasmic signaling domains. Gene targeting in mice will be used to generate 'knock-in' models that allow stringent testing in vivo of as yet unsuspected adaptations by these. The hypothesis that these two receptors differ in their quantitative regulation of tissue homeostasis will be tested. 3. A novel flow-cytometry assay that allows analysis and separation of erythroid precursor populations at specific maturation stages from freshly explanted hematopoietic tissue is currently being developed by the applicant. Together with expression microarrays and other approaches, this will be used to identify EpoR gene targets and cellular functions that modulate erythropoietic rate. This approach was recently validated by looking at mice mutant for the EpoR-activated transcription factor Stat 5. This identify the anti-apoptotic Stat5-bcl-xL pathway in early erythroblasts as a determinant of erythropoietic rate. 4. Retroviral expression cloning will be used to identify new erythroid anti-apoptotic genes. Components of the apoptotic machinery will be assessed as candidate modulators of erythropoietic rate and/or leukemogenic transformation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MOLECULAR BASIS OF SNELL DWARF AND LITTLE LONGEVITY Principal Investigator & Institution: Papaconstantinou, John; Professor; Human Biol Chem and Genetics; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2002; Project Start 01-APR-1999; Project End 31-MAR-2004 Summary: Experimental models of yeast, nematodes, fruit flies, and rodents indicate that aging and longevity are, in part, under genetic control. The nematode C. elegans, has provided genetic and biochemical evidence that identifies candidate genes that govern longevity. This involves attenuation of the daf-2, age-1 and daf-16 genes whose homologies to the mammalian-insulin receptor (InR) family and signaling pathway suggest that this pathway(s) may regulate metabolic characteristics that favor vertebrate longevity. The mouse dwarf mutants Snell (dw/dw), Ames (df/df) and little (lit/lit),
Studies
39
live significantly longer than their normal siblings. The nature of the dwarf mutations, i.e., growth hormone (GH), thyroid stimulating hormone (TSH) and prolactin (Prl) deficiencies may result in physiological characteristics similar to those of the long-lived C. elegans mutants. Since these mice are the only vertebrate genetic models of longevity, and since the physiological characteristics of the "anti-aging" processes of the nematode and the long-lived dwarf mutants are strikingly similar, these mice provide an excellent resource to study the molecular and genetic processes that determine longevity in vertebrates. In this research program we will determine whether the physiological characteristics of the Snell and lit dwarf mice are longevity-determining factors of vertebrate aging. Specific Aims 1 will determine whether the Snell and lit mice exhibit such characteristics of delayed senescence as a reduction-of-function phenotype due to GH, insulin and IGF-I deficiency; immunological function; and regulation of stress response genes. In Specific Aim 2 we plan to use endocrine supplementation to determine the specific role of TH and Pr1 deficiencies as longevity-determining factors; In Specific Aim 3 we will determine the role GH deficiency in longevity using conditional transgenic Snell dwarf and lit mice in which GH expression is regulatable i.e., turned on or off at will. Our long-range goal is to elucidate the molecular and genetic basis of vertebrate life span by identifying the longevity-determining factors. Achieving these aims will identify pathways involving longevity and lay down foundations for understanding the mechanism by which these pathways act. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MOUSE MODELS OF BREAST DEVELOPMENT AND NEOPLASIA Principal Investigator & Institution: Weinberg, Robert A.; Member/ Professor; Whitehead Institute for Biomedical Res Biomedical Research Cambridge, Ma 02142 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2003 Summary: (Applicant's Description) An understanding of the molecular mechanisms leading to human breast cancer development will come from insights into how the breast tissue develops normally. Such insights can be most easily obtained in the mouse breast, the development of which is governed by biochemical regulators very similar to those that operate to program human breast morphogenesis. Breast development is governed by bi-directional communication between the mammary epithelium and surrounding stroma. The present research examines three signalling pathways that appear to be essential for normal breast development and appear to be disrupted during cancer pathogenesis. First, estrogen acting through its receptor in normal mammary epithelial cells (MECs) does not appear to be mitogenic but has acquired such powers in many human breast carcinoma cells. The proposed research examines the possibility that these powers result from the inappropriate expression of a co-activator of the receptor that is not normally expressed in MECs. A second aspect of breast signalling involves the progesterone receptor, which is responsible for sidebranching of mammary ducts. The present research examines the possibility that this receptor, when activator by progesterone, causes expression of hepatocyte growth factor in nearby stroma; this factor then acts on MECs to induce ductal sidebranching. A third line of research examines the possibility that prolactin, acting through its receptor in MECs, is able to induce the production of the neuregulin growth factor in nearby stromal tissue; once released, the neuregulin causes MEC proliferation leading to the formation of alveoli. The latter pathway is often subverted in human mammary carcinoma cells that express the HER2 receptor of neuregulin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
40
•
Prolactin
Project Title: MULTIDISCIPLINARY PROGRAM IN FEMALE REPRODUCTION Principal Investigator & Institution: Albrecht, Eugene D.; Professor; Obstetrics and Gynecology; University of Maryland Balt Prof School Baltimore, Md 21201 Timing: Fiscal Year 2002; Project Start 01-APR-1998; Project End 31-MAR-2004 Summary: The objective of the Specialized Cooperative Centers Program in Reproduction Research (SCCPRR) at the University of Maryland Medical Center is to conduct innovative basic and clinical research in the reproductive sciences and to apply the knowledge gained from these studies to improve understanding of the etiology and treatment of infertility in women. A multidisciplinary experimental approach will be taken in this program to study function of the pituitary-ovarian- uterine axis as related to the central theme on cellular remodeling. In Project I (Karen A. Gregerson, PI), the physiological importance of an inwardly-rectifying, dopamine-activated pituitary K+ channel to prolactin secretion and fertility will be determined in transgenic mice in which the function of this novel membrane channel is interrupted by dominant-negative mutation. In Project II (Gerald J. Pepe, PI), the regulatory role of estrogen on fetal ovarian follicular and oocyte development and the impact on fertility will be assessed in baboons in which placental estrogen synthesis is suppressed in utero by administration of a novel aromatase inhibitor. In Project III (Robert D. Koos, PI), the physiological role of members of the fibroblast growth factor family, bFGF and keratinocyte growth factor, on ovarian and uterine function and fertility will be studied in transgenic mice in which the truncated, dominant-negative FGF receptors are spatially and temporally overexpressed. A combined clinical-basic research study is proposed in Project IV (Eugene D. Albrecht, PI), in which the roles of estrogen and progesterone, acting via vascular endothelial growth/ permeability factor and bFGF, on endometrial angiogenesis and fertility will be investigated in vivo in baboons and in vitro in the human endometrium. Each of the research projects will draw heavily upon the Cell Immunocytochemistry/In Situ Hybridization Core (Gloria E. Hoffman, PI) for the cellular localization of regulatory peptides and steroid hormone receptors. Integration of the scientific effort in this SCCPRR will be achieved through the thematic focus on cellular remodeling, common technological molecular approaches, and an established tradition of collaborative research. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: N-3 FATTY ACID & BINDING PROTEIN MRG ON MAMMARY TUMOR Principal Investigator & Institution: Shi, Yuenian E.; Long Island Jewish Medical Center 270-05 76Th Ave New Hyde Park, Ny 11040 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): There is an increasing public interest in chemoprevention by natural agents such as n-3 polyunsaturated fatty acids (PUFAs) DHA and EPA and the pregnancy-induced differentiation against breast cancer incidence. The mechanisms underlying these preventive effects are currently unknown. Little is known about the regional and developmental expression of locally acting factors in the mammary epithelium that interact with n-3 PUFA and exert differentiating effect during pregnancy. Within this content, a novel mammary derived growth inhibitor and a fatty acid binding protein (FABP) has recently been identified, characterized, and named Mammary derived growth inhibitor Related Gene (MRG). As a new member in the family of FABP, MRG has the highest binding affinity to n-3 PUFA DHA. The preliminary data indicate: (1) MRG overexpression suppresses breast cancer
Studies
41
cell growth in vitro and tumorigenesis in vivo. (2) MRG induces differentiation of mammary epithelium and its expression is associated with human mammary gland differentiation. (3) MRG synergistically interacts with DHA in growth inhibition. The present application is to test the hypotheses that (a) MRG is a mediator for intracellular accumulation of n-3 PUFAs in mammary epithelial cells and mediates tumor suppressing effect of n-3 PUFAs on mammary tumors. In this regard, one of mechanisms for pregnancy-induced prevention may be mediated in part by PUFA composition change in mammary gland which favors the ratio of n-3 PUFAs to n-6 PUFAs following pregnancy and lactation; (b) MRG is mediator of the differentiating effects of pregnancy on breast epithelium and overexpression of MRG in young nulliparous mice can induce differentiation and protect the development of mammary tumors. We propose a series of studies of both in vitro and in MMTV/MRG transgenic mice to evaluate the role of MRG on mammary differentiation and tumorigenesis and its interaction with n-3 PUFA on mammary tumorigenesis. These studies will help to identify MRG as mediator for differentiation for mammary gland and for interaction with n-3 PUPA on inhibition of mammary tumorigenesis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROENDOCRINE ABNORMALITIES INDUCED BY SLEEP DEPRIVATIO Principal Investigator & Institution: Everson, Carol A.; Associate Professor; Neurology; Medical College of Wisconsin Po Box26509 Milwaukee, Wi 532260509 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 31-MAY-2004 Summary: (adapted from applicant's abstract): Sleep is a vital biological process necessary to maintain cognitive ability and physical health. Profound sleep disturbance/deprivation in humans is nearly always associated with disease, and sleep deprivation in patients is considered a high risk factor for mortality. In animal models of sleep deprivation, morbidity is associated with septicemia subsequent to a constellation of neuroendocrine changes, most notably hypothyroxinemia. Preliminary data have shown that neuroendocrine abnormalities extend to deficiencies in growth hormone (GH) and prolactin (PRL), and have the potential to explain most of the pathology induced by sleep deprivation. There is strong evidence that the neuroendocrine changes are centrally mediated. The following three specific aims are intended to test the main hypothesis that sleep deprivation results in hypothalamic dysfunction: Aim 1: To determine whether centrally-mediated hypothyroxinemia is due to deficient proTRH expression and TRH secretion in sleep-deprived animals. Proposed studies will determine whether TRH mRNA expression in the paraventricular nucleus and TRH content in the median eminence are suppressed and unresponsive to low T4, indicating impaired thyroid hormone regulation at the level of the hypothalamus. The pathway of T3 feedback to PVN neurons will be examined to determine the degree of up-regulation in response to low T4. Potential TRH responsiveness of thyrotrophs will be assessed by evaluating TRH receptor mRNA expression in the pituitary. Aim 2: To identify regulatory mechanisms responsible for reduced growth hormone and prolactin levels in sleep-deprived rats. Proposed studies will examine the regulation of PRL and GH in individual rats during the course of sleep deprivation by studying stimulatory and inhibitory mechanisms and response that could be responsible for the deficiency at the hypothalamic and pituitary levels. Aim 3: To delineate effects of sleep deprivation on thyroid hormone processing in the brain. Low thyroid hormone concentrations in sleepdeprived rats imply decreased T4 availability for import to the brain and ensuing centrally-mediated dysfunction common to the clinical hypothyroid state. Proposed
42
Prolactin
studies will examine the content and regulation of iodothyronines in the sleep deprived brain. These studies will delineate the abnormalities in brain endocrine regulation resulting from sleep deprivation and determine the mechanisms responsible for peripheral endocrine changes that underlie its associated systemic pathologies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEUROENDOCRINE EFFECTS OF OPIATES AND COCAINE Principal Investigator & Institution: Kreek, Mary J.; Professor and Head; Rockefeller University New York, Ny 100216399 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2007 Summary: (provided by applicant): Heroin, cocaine, and alcohol addictions, alone and in combination, along with their medical complications, including hepatitis B and C, AIDS, and psychiatric comorbidity, remain the major medical problems confronting our nation and much of the world. Effective treatments must be based on a fundamental understanding of the biological basis of each addictive disease, including the effects of exposure to drugs of abuse. This Project will continue to explore the atypical stress responsivity of the hypothalamic-pituitary-adrenal (HPA) axis seen in specific addictive diseases. Contributions of opioid and dopaminergic pathophysiological mechanisms will also be investigated. The specific hypotheses are: 1) that chronic cocaine addiction causes alterations in stress-responsive HPA axis function; 2) that alterations in HPA axis function caused by cocaine may be further modulated by alcohol abuse and/or opiate dependence; 3) that the relationship between cocaine addiction and alterations in HPA axis function is controlled in part by the endogenous opioid system; 4) that the regulation and release of corticotropin releasing factor (CRF) and proopiomelanocortin (POMC; and its peptide fragments including ACTH and beta-endorphin) are, in part, under the control of the endogenous opioid system and that changes in the sensitivity of the CRF-R1 receptor in the anterior pituitary are central to the atypical stress responsivity seen in different stages of addiction; 5) that psychological states which are believed to be both stress-related and important in the development and maintenance of addictions, may occur through alterations in HPA axis function and the endogenous opioid system; and 6) that the observed alterations in the physiology of the endogenous opioid system and its interactions with the stress-responsive HPA axis in addictive diseases may, in part, be influenced by specific single nucleotide and other polymorphisms in genes of the endogenous opioid system. The hypotheses will be explored using standard and novel paradigms of HPA disinhibition (by metyrapone and dexamethasone) and stimulation (by ACTH and CRF) testing alone and in combination. The role of the endogenous opioid system in affecting the HPA axis will be studied with opioid antagonists alone and in combination with HPA axis testing. This work, to be performed in patients with specific addictions and normal volunteers, will complement rodent and non-human primate studies conducted in our Center. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NEUROENDOCRINE HORMONES TO PROMOTE IMMUNE RECONSTITUTION Principal Investigator & Institution: Murphy, William Joseph.; Professor; Microbiology and Immunology; University of Nevada Reno 204 Ross Hall Mailstop 325 Reno, Nv 89557 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2008
Studies
43
Summary: (provided by applicant): Immune deficiency following bone marrow transplantation or in AIDS leaves a patient highly susceptible to life threatening opportunistic infections. Recovery of the immune system, particularly T cell function, is often delayed for up to several years, especially in aged individuals. Thus far, while cytokines have been given clinically to accelerate myeloid recovery, very few agents have been demonstrated to promote multi-lineage immune cell recovery and fewer yet promote thymopoiesis and T cell recovery. Neuroendocrine hormones such as growth hormone (GH) and prolactin (PRL) have been demonstrated to exert pleiotropic effects on the immune system. We have previously demonstrated that GH and PRL promote T cell function and restore thymopoiesis in neuroendocrine hormone-deficient dwarf mice. This proposal will now evaluate the effects of GH and PRL on immune recovery in several BMT models, comparing the effects in both young (less than 10 weeks) and aged (greater than18 months) mice. Use of these mice will allow for the assessment on the role of age on the outcome following BMT. Toward this goal, we have developed 5 specific aims: Specific Aim 1 will assess the effects of GH and PRL on immune recovery after syngeneic BMT in young and aged mice. Particular emphasis will be given to effects on the thymus and T cell recovery. Specific Aim 2 will use a thymic organ culture model to determine the mechanism underlying the effects of hormones on the thymus. Specific Aim 3 will evaluate the effects of GH and PRL in allogeneic BMT models using T cell depleted BMC to ascertain effects on host rejection mechanisms and subsequent engraftment. Specific Aim 4 will examine the effects of GH and PRL on allogeneic BMT models in which graft-versus-host disease (GVHD) occurs to determine whether GVHD is worsened after hormone treatment. Finally, Specific Aim 5 will use nonmyeloablative BMT models to determine the effects of GH and PRL conditioning on thymic recovery and engraftment of donor-derived cells. All of the Specific Aims will use young and aged mice to ascertain if age significantly impacts hormone responsiveness. Thus far, even though immune reconstitution in the aged remains a significant and growing concern, very few preclinical studies have addressed the role of age and potential use of neuroendocrine hormones to circumvent the hampered immune recovery associated with age. This proposal will thus address both basic science (role of hormones in immune development) and clinically useful (role of age in BMT procedures and use of hormones to promote recovery) issues. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NEW APPROACHES TO EVALUATION AND TREATMENT OF ACROMEGALY Principal Investigator & Institution: Freda, Pamela U.; Medicine; Columbia University Health Sciences New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 31-DEC-2003 Summary: Acromegaly, a disorder of chronic, growth hormone excess, is associated with significant morbidity and mortality. Prevention of the long-term complications of acromegaly depends on both an accurate biochemical assessment of disease status and an understanding of the goals of therapy. The studies planned for the final two years of my K08 (DK02561) continue to examine new approaches to the evaluation and treatment of acromegaly utilizing a large cohort of patients with acromegaly and will focus on integrating the molecular, biochemical and clinical aspects of my initial studies. Studies will continue a careful biochemical assessment of this cohort with modern, sensitive techniques in order to further define the new criteria for cure suggested by our work to date. Studies will focus on a longitudinal follow up of this cohort examining detailed biochemical parameters and determining if certain patients are at risk for disease
44
Prolactin
recurrence. Studies will now include a new direction, the assessment of a clinical marker of GH status, body composition analysis, and a correlation of this analysis with the biochemical measures. I will continue to analyze tumor specimens from this larger cohort for the presence of activating mutations in the alpha subunit of Gs and will determine if these mutations define a clinical phenotype and/or biochemical response to medical therapy. The studies in this proposal are a first step toward achieving a multifaceted understanding of the optimal biochemical and clinical goals for disease control of acromegaly and toward integrating the information from molecular analysis of these tumors into our treatment approach. The R03will proved vital added support in the final two years of my K08. The R03 funds will enable me to continue to employ a clinical research assistant whose help with my studies will allow me to devote the needed effort to broadening my clinical research projects and to developing my skills in clinical and basic research methods as well as new projects for future funding. My current environment continues to be ideally suited for achieving my goals. My collaboration with Dr. Kalmon Post, providing me with access to large numbers of both patients and pituitary tumor specimens, continues to be effective. I continue to receive instruction in the molecular techniques from Drs. Sharon Wardlaw and Streamson Chua. My new collaboration with Dr. Steven Heymsfield on the body composition studies will add an important new aspect to my studies. My sponsor, Dr. Wardlaw, continues to be committed to providing me with the guidance I need to pursue my research plans and to facilitate my transition to independent investigator. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ONTOGENY OF HEPATIC ION TRANSPORT Principal Investigator & Institution: Suchy, Frederick J.; Professor of Pediatrics; Pediatrics; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2002; Project Start 01-SEP-1985; Project End 31-MAR-2003 Summary: This is a renewal application to further define the ontogeny of hepatic ion transport as well as define the mechanisms by which transporters are modified under conditions of cholestasis. The overall objective of this competing renewal application is further defined by the mechanisms underlying the expression of basolateral and canalicular transporters for bile acids and other organic anions during development and cholestatic liver disease. Since transcriptional activation of the liver Na+ /bile acid cotransporter gene (Ntcp) is largely responsible for the abrupt expression of transport activity in the perinatal period, the investigators propose that a change in chromating structure, reflected in an increase in DNASE I hypersensitivity and a decrease in gene methylation precedes the onset of transcription during development. Transgenic mice expressing various portions of the 5' untranslated region linked to the luciferase reporter gene will be used to define sequences that direct tissue- and developmental stagespecific expression of Ntcp. Transgenic animals will be used to show that the rapid postnatal increase in Ntcp transcription could in part be mediated by prolactin. To demonstrate the importance of the Na+/bile acid cotransporter to hepatobiliary function, the Ntcp gene will be rendered nonfunctional in mice by targeted disruption. The phenotypes of the mice with null mutations will be defined including whether liver disease (cholestasis) is induced and how the mutation alters hepatobiliary function and enterohepatic cycling of bile acids. The signaling mediating the targeting of the liver and ileal Na+/bile acid cotransporters to the plasma membrane will be determined through transfection and analysis of native transporters, truncated mutants lacking cytoplasmic tails, and chimeric transporters comprised of portions of the liver and ileal transporters.
Studies
45
Finally, the development of the canalicular multi specific organic anion transporter (cMOAT/Mrp1) will be defined including a correlation of transport activity in canalicular membrane vesicles with levels of Mrp2 mRNA and protein. The investigators will determine the mechanisms underlying the effects of bile acids and the inflammatory cytokines TNF-alpha and IL-beta on expression of Ntcp and Mrp2 through transfection of chimeric promoter/reporter gene constructs into primary hepatocytes. DNA foot printing and gel mobility shift assays will determine the importance of known or novel cis-acting elements and trans-activating factors in regulating gene expression. These studies should provide insights into the biology and pathobiology of hepatic anion transporters and help explain the susceptibility of the infant to develop cholestatic liver disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PARACRINE INTERACTIONS IN PROLACTIN SECRETION Principal Investigator & Institution: Shah, Girish V.; Basic Pharmaceutical Sciences; University of Louisiana at Monroe 700 University Ave Monroe, La 71209 Timing: Fiscal Year 1999; Project Start 01-MAY-1992; Project End 31-AUG-2004 Summary: Well-defined distribution of various pituitary cells types in the anterior pituitary (AP) gland suggest that Cell-to-Cell interactions play an important role in the development, function and proliferation of AP cells. Previous studies from this laboratory have shown that calcitonin- like immunoreactive peptide (pit-CT) is synthesized and secreted by cultured AP cells. It may affect lactotrope function because synthetic sCT is a potent inhibitor of PRL secretion and PRL gene transcription. Our recent studies have used immunohistological, cell culture and molecular approaches to demonstrate that putative pit-CT mRNA and pit-CT IR peptide is selectively expressed by gonadotropes and RC4B cells (tumor cells of gonadotropelineage), and not by alphaT-3, GH3 or AT20 cells. Temporally, pit-CT gene expression is initiated subsequent to, and not prior to, the expression of LH Beta-subunits because pit-CT mRNA could not be detected in alphaT-3 cells or fetal AP gland (embryonic day 19), but could be detected in the AP gland of day 20 fetal age. The studies in adult AP glands have shown that pitCT IR gonadotropes were surrounded by cup-shaped lactotropes, suggesting a role for pit-CT in juxtacrine inhibition of lactotrope function. Physiological significance of pit-CT action was demonstrated by the findings that passive immunization of pit- CT with antisCT serum caused a dramatic increase in PRL secretion under in vitro and in vivo conditions. Pit-CT IR content of the AP gland varied significantly in various physiological conditions. Three days of E2 treatment caused a nine-fold decline in putative pit-CT mRNA abundance and also caused four-fold decrease in pit-CT IR concentrations. In contrast, ovariectomy induced a three-fold increase in pit-CT IR content. Thus, pit-CT is a novel, physiologically relevant, gonadotrope-derived inhibitor of lactotrope function. Since we have obtained a putative pit- CT cDNA clone and the expression of putative pit-CT mRNA parallels the expression of pit-CT IR, an objective of the present proposal is to identify the precise role for pit-CT in maturation, function and proliferation of lactotropes during development and adulthood. Specific Aim of the proposal will develop RC4B-lactotrope co-culture model to test the role of endogenous pit-CT in lactotrope function and proliferation. Specific Aim 2 will study the consequence of gonadotrope-depletion or pit-CT overexpression on lactotrope function. Specific Aim 3 and 4 will further characterize the actions of gonadal steroids and other paracrine and neuroendocrine factors on pit-CT expression. These studies will provide new and significant findings towards the role of gonadotrope- lactotrope interactions in
46
Prolactin
pituitary function. These results will make important contributions in understanding physiology of normal reproduction and pathophysiology of aging. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PEGYLATED PROLACTIN RECEPTOR ANTAGONISTS AS CANCER DRUGS Principal Investigator & Institution: Sherman, Merry R.; Professor; Mountain View Pharmaceuticals, Inc. 3475 Edison Way, Ste S Menlo Park, Ca 94025 Timing: Fiscal Year 2002; Project Start 30-JUL-2002; Project End 30-SEP-2003 Summary: (provided by applicant): Effective management of human cancers of the breast and other prolactin-responsive tissues (e.g., prostate) is the long-term goal of this research. The first phase of this study involves the design, synthesis and in vitro testing of polymer conjugates of a novel mutein of human prolactin (hPRL) that appears to be more selective as an antagonist than those previously tested. This antagonist (PRLA), developed and provided by Charles L. Brooks, contains a deletion that interferes with the positive cooperative interactions between the two receptor-binding sites on hPRL. PRLA binds to the receptor, but inhibits the intramolecular signal transduction pathway involving phosphorylation of Janus kinase (JAK) and signal transducer and activator of transcription (STAT) proteins. Polymer conjugates of PRLA will be synthesized containing 1-3 strands of linear or branched poly(ethylene glycols) (PEGs) of various molecular weights (10-60 kDa), linked by various chemistries. The optimal conjugates will have long half-lives in the circulation, high affinity for hPRL receptors, minimal agonist activity and minimal immunogenicity. Conjugates will be tested on human breast cancer cells in culture and grown as xenografs in immunocompromised mice. Tumor growth or shrinkage will be monitored non-invasively, using tumors derived from cells transfected to contain luciferase, in collaboration with Robert S. Negrin. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PET IMAGING OF THE 5HT TRANSPORTER IN ALCOHOLISM Principal Investigator & Institution: Szabo, Zsolt; Associate Professor; Radiology and Radiological Sci; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2002; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: Impaired serotonin (5-HT) function has been implicated as a possible factor in the biological vulnerability for alcoholism, but most studies of the 5-HT system have been performed in animals or, if performed in humans, they involved only indirect measurements to assess the 5-HT system in the brain. The status of the 5-HT neurons in the brain of living alcohol dependent individuals remains unknown. To investigate the 5-HT system of the brain, quantitative PET studies of the brain 5-HT transporter (5-HTT; an established marker of serotonin neuron integrity) are proposed using [11C]McN5652 as radioligand for four groups of human subjects: family history negative (FHN) controls, family history positive (FHP) controls, FHN recovering alcoholics, and FHP recovering alcoholics. The hypothesis to be tested is that radioligand binding to the 5HT transporter is significantly reduced as a function of both alcoholism and family history of alcoholism. Serotonin function will also be measured by quantification of plasma prolactin and cortisol increase in response to fluoxetine. The genetic aspect of 5HT impairment will be investigated by measuring the frequency of specific polymorphisms of the 5-HTT gene. The hypothesis is that FHP alcoholics and FHP controls will have a higher frequency of the s-variant allele, the allele which has been associated with reduced 5-HTT expression/function in in vitro studies. The frequency of
Studies
47
the s- variant allele is predicted to be higher in subjects with reduced 5-HTT densities (as determined by PET) and with reduced hormonal responses to fluoxetine. The results of this project will lead to better understanding of the role of serotonin in the biological vulnerability for alcoholism and may lead to improved approaches to prevent and treat alcoholism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHYSIOLOGY OF THE PROLACTIN RELEASING PEPTIDES Principal Investigator & Institution: Samson, Willis K.; Professor; Pharmacological & Physiol Scis; St. Louis University St. Louis, Mo 63110 Timing: Fiscal Year 2002; Project Start 01-JUN-2001; Project End 31-MAY-2004 Summary: (applicant's abstract): The focus of this proposal is to determine the roles the recently described prolactin releasing peptides (PrRPs) may play in stress-induced elevations of prolactin secretion (neuroendocrine actions in pituitary gland and neuromodulatory actions in brain) and autonomic function (neuromodulator actions in brain). We hypothesize that the PrRPs produced in brain and pituitary gland are required for the normal neuroendocrine and cardiovascular responses to stress. Specifically we hypothesize that PrRPs, either produced locally in pituitary gland or delivered to the gland via either the portal or peripheral circulations, play a role in the secretion of prolactin from the gland during stress. Furthermore, we hypothesize that the elevation in sympathetic tone during stress depends upon the actions of brainderived PrRPs and that removal of those peptides will compromise the animal's cardiovascular response to stress. We will address the following Specific Aims (Questions): 1) Will physical or anticipatory stress elevate circulating plasma levels of PrRP, tissue levels of the peptides (brain, pituitary, adrenal), or expression of the gene (mRNA levels) in brain, pituitary gland or adrenal medulla? 2) Are the PrRPs effective releasing factors in the setting of dopamine withdrawal (which occurs in stress)? 3) Will central administration of PrRP stimulate prolactin secretion in conscious animals? 4) Can the site of action of PrRP in brain be identified by site-specific injections? 5) Will compromise of endogenous PrRP alter the neuroendocrine and cardiovascular responses to stress? The studies described here are designed to further characterize the pharmacology and physiology of the PrRPs, which have been demonstrated to act in the pituitary as neuroendocrine factors and in brain as modulators of autonomic outflow. The ultimate goal is to determine their importance in the maintenance of normal endocrine and cardiovascular function, in particular during stress. These studies will also begin to examine a potentially novel confluence of endocrine and autonomic responses to stress and thereby provide insight into the coordinated responses of multiple organ systems to stress. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: PITUITARY SPECIFIC ONCOGENE SIGNALING MECHANISMS Principal Investigator & Institution: Gutierrez-Hartmann, Arthur; Professor, Director, Mstp; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2003; Project Start 01-JUN-1994; Project End 31-MAY-2007 Summary: (provided by applicant): The cytoplasmic components and nuclear effectors mediating growth factor/Ras-induced gene expression are common to all cell types. Thus, defining the precise molecular mechanisms by which ubiquitous components of growth factor/Ras signaling pathways result in cell-specific responses remains a central
48
Prolactin
problem in biology today. Previously, we discovered an elegant and precise tri-paritite molecular code, involving the proto-oncoprotein c-Ets-1, the POUhomeodomain protein Pit-l, and a composite DNA element containing an Ets binding site (EBS) adjacent to a Pit-1 site (FPIV). Pit-l, Ets-1 and this composite site were shown to be required not only for the Ras response of the rat (r) prolactin (PRL) promoter, but also to reconstitute lactotroph-specific rPRL promoter activity. This was the first and remains the only example of a tissue-specific Ras response element (RRE). During the past funding cycle, we used NMR and GST pull-down methods to map the Ets-1/Pit-1 interaction surfaces to exact residues on the Pit-1 POUhomeodomain and to the Ets-1 RIII TAD. We reported that Ets-1 preferentially binds to the EBS in the RRE, whereas GABP preferentially binds to the BTE/EBS centered at -95. Finally, using dominant-negative and siRNA approaches, we verified that Ets factors, in particular GABP, are critical for basal and growth factor-induced rPRL promoter activity. These studies revealed that Ets-1 and GABP are critical for lactotroph-specific expression of the endogenous rPRL gene. While our previous studies have mostly used reporter gene assays, the broad mandate of this proposal is to use molecular, biochemical and transgenic approaches to dissect the physiological role of select Ets factors and Ets factor binding sites in goveming basal and Ras-regulated lactotroph-specific expression of the endogenous rPRL gene in GH4 cells and in mice. Unifying Hypothesis: We hypothesize that basal and Ras-regulated expression of the lactotroph-specific rPRL gene is governed by specific Ets factors, some acting in concert with Pit-l, whose binding to Ets binding sites on the proximal rPRL promoter is regulated by the physiological state of the cell. Specific Aims: (1) To identify Ets factor occupancy on the endogenous, proximal rPRL promoter in GH4 rat pituitary cells q oncogenic Ras. (2) To identify the oncogenie Ras-dependent protein components of Ets-1/Pit-1 transcription factor complexes. (3) To determine the functional role of basal and oncogenic Ras-regulated transcription co-regulatory molecules (4) To elucidate the physiological role of rPRL Ets binding sites and the Ets factor GABP in PRL gene expression in transgenic mice. Information gained from these studies will provide critical insights into the mechanisms by which combinatorial Ets/Pit-1 protein interactions specify cell-restricted PRL gene expression, and also provide a novel insights into the mechanisms by which Ras/MAPK regulates gene expression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREGNANCY HOOKWORMS
INDUCED
REACTIVATION
OF
ARRESTED
Principal Investigator & Institution: Arasu, Prema; Molecular Biomedical Sciences; North Carolina State University Raleigh 2230 Stinson Drive Raleigh, Nc 27695 Timing: Fiscal Year 2002; Project Start 01-JAN-1999; Project End 31-DEC-2003 Summary: Developmental arrest within a host allows many parasitic nematodes to evade adverse external conditions and action of chemotherapeutic agents, but to reactivate at opportune periods. Our long range goal is to elucidate the molecular mechanisms that trigger reactivation of arrested parasites and to identify strategies of preventing neonatally- transmitted infections as well as self-reinfections (e.g. Strongyloides in immunodeficient individuals). This study is focused on pregnancyinduced reactivation and transmammary transmission of arrested Ancylostoma larvae because hookworms infect about 1.2 billion people, and in young children, the protein loss and anemia can contribute to physical and cognitive deficiencies. We have previously shown that larval reactivation cannot be attributed to a state of generalized immunosuppression as is associated with pregnancy; rather, hormonally- induced cytokine changes appear to be critical. Using an in vitro reactivation assay, we find that
Studies
49
TGF-beta stimulates larval feeding at levels comparable to that of serum stimulation. Further, the stimulatory effect of serum can be significantly neutralized with antibodies to TGF-beta. Earlier studies have shown that exogenous estrogen and prolactin stimulate a resurgence of larvae in the milk of latently-infected, lactating dogs, and more recent work indicates that these hormones specifically upregulate the levels of TGFbeta2 during late pregnancy and lactation. In addition, TGF-beta. signaling is clearly crucial to reactivation of arrested larvae of the soil nematode, Caenorhabditis elegans. The objective of this proposal is to use the mouse/A. caninum model to test the hypothesis that host-derived TGF-beta particularly the beta2 isoform which is upregulated by estrogen and prolactin, triggers the reactivation and transmammary transmission of developmentally-arrested larvae during late pregnancy and lactation. We propose to test our hypothesis with 3 specific aims: 1. Characterize the A. caninum homologues of the TGF-beta receptor and ligand to evaluate binding of mammalian TGF-beta to the parasite receptor. 2. Use the in vivo model of infection to determine TGF-beta levels, and larval status and burden in skeletal muscle versus mammary tissue during different phases of pregnancy and lactation, and determine whether larval reactivation is stimulated by estrogen and prolactin. 3. Use in vitro co-cultures of tissue larvae with muscle versus mammary cells to distinguish the differential effects of estrogen, prolactin and staged pregnancy sera on larval reactivation, and determine if neutralizing antibodies to TGF-beta inhibit reactivation. These studies will provide important results for the development of therapeutic strategies to eradicate latent parasitic infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROLACTIN AND ESTROGENS AS MITOGENS IN PROSTATE CANCER Principal Investigator & Institution: Ben-Jonathan, Nira; Professor; Cell Biol, Neurobiol/Anatomy; University of Cincinnati 2624 Clifton Ave Cincinnati, Oh 45221 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2004 Summary: (Provided by the applicant) Prolactin (PRL) and prolactin receptor (PRLR) are members of cytokine super family. Overproduction of PRL by prostate cells results in prostatic hyperplasia in mice. Elevated serum PRL levels induced by estrogens, positive regulators of PRL, or by drugs result in rodent prostatic hyperplasia and enhanced rodent prostatic tumor growth. In rodents, hyperprolactinemia and prostatic hyperplasia are also induced by bisphenol A (BPA), an environmental estrogen. Together, this provides evidence that PRL plays a critical role in rodent prostatic hyperplasia and carcinogenesis. However, our knowledge on the role of PRL in human prostatic growth is limited and the mitogenic potential of PRL in the progression of human prostate cancer remains unexplored. Our preliminary data document expression of PRL and PRLR in different prostate cancer cells, up-regulation of PRLR expression by PRL, and increased cell proliferation in response to PRL. In addition, we show a rapid phosphorylation of ERK1/2 in response to PRL, estradiol (E2) as well as BPA. Accordingly, our hypothesis is "Human prostate cancer cells produce PRL and form a functional autocrine-paracrine regulatory loop of PRL and the PRLR. The autocrineparacrine effects of PRL/PRLR as well as the combined actions of PRL and estrogens contribute to the progression of prostate cancer. Both PRL and estrogens recruit components of the MAP kinase signaling cascade." To test our hypothesis we will use DU 145 human prostate cancer cells as a model. The following specific aims will investigate the direct as well as combined effects of PRL, E2 and BPA. Specific Aim 1: To determine: a) local production of biologically-active PRL and its effects on cell
50
Prolactin
proliferation; b) the effects of exogenous PRL, E2 and BPA on PRLR and estrogen receptor (ER)-beta expression; c) the effects of exogenous PRL, E2, and BPA on cell proliferation; d) the binding parameters of PRLR in the cells; e) the ability of tamoxifen to inhibit PRL effects via PRLR. Specific Aim 2: To examine: a) PRL induced activation of STATs and their nuclear translocation; b) activation of ERK1/2 by various treatments and their nuclear translocation; c) the enzymatic activities of Raf, MEK and MAP kinases; d) the role of the MAP kinase cascade in mediating the mitogenic responses to PRL, E2, and BPA. The results of this study should provide information on the role of local PRL and the combined actions of PRL and estrogens on prostate cancer cell proliferation. The findings on BPA may reveal the potential risk associated with human exposure to environmental estrogens. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROLACTIN AS A LACRIMAL GLAND IMMUNOREGULATOR Principal Investigator & Institution: Schechter, Joel E.; Cell & Neurobiology; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, Ca 90033 Timing: Fiscal Year 2003; Project Start 01-APR-1994; Project End 31-DEC-2006 Summary: (provided by applicant): Dry eye is one of the most frequently encountered problems in ophthalmology, with highest incidence in women, especially postmenopausally where atrophy and decreased tear formation are associated with chronic inflammation. It also occurs in Sjogren's syndrome, an autoimmune disease characterized by lymphocytic infiltration and loss of lacrimal acinar cells. The hormonal milieu is a critical factor in maintenance of normal lacrimal function, and androgens and prolactin (PRL) both play important roles. We have demonstrated that lacrimal fluid production in rabbits is decreased during pregnancy, and that pregnant women experience increased symptoms of dry eye, worsening with multiple pregnancies. Our studies in rabbits demonstrate dramatic changes in the concentration and distribution of PRL and growth factors within the lacrimal gland (LG) during pregnancy and lactation, increasingly being concentrated within ductal epithelial cells. These changes are accompanied by the appearance of "reactive acinar cells," which are immunopositive for MHC Class II protein and which may also be passive sources of autoantigenic stimulation, and by a marked redistribution of T and B lymphocytes from their normal periductal location to interacinar sites. We propose a new paradigm for physiological regulation of LG function, i.e., an "acinar-ductal loop." In this system, ductal epithelial cells monitor the contents of the acinar effluent, absorb and transport materials from the duct lumen to periductal immune cells, and in so doing function in transmitting immunoregulatory signals (PRL, growth factors, cytokines) that may enhance periductal immune cell activation and responses to autoantigens. We propose to approach this integrated physiological system from perspectives of endocrinology and cellular physiology, employing rabbits, and mouse models of Sjogren's syndrome to pursue the following specific aims: (1) Test the hypothesis that lacrimal acinar cells and lacrimal ductal epithelial cells represent a physiological loop, in which ductal epithelial cells monitor acinar fluid contents, absorb and transport materials from within the duct lumen, and function in local immunoregulation. (2) Test the hypothesis that artificially altering the hormonal milieu of non-pregnant rabbits will elicit responses in the LG which are identical to those observed during pregnancy and lactation. (3) Use in vitro methods to characterize the effects of pregnancy, and growth factors whose expression is increased during pregnancy, on secretory function and intracellular autoantigen traffic in lacrimal acinar cells. (4) Test the hypothesis that increased PRL, charactersitic of pregnancy and lactation, enhances activation of lymphocytes in the LG. (5) Test the
Studies
51
hypothesis that pregnancy accelerates and exacerbates the progress of Sjogren's-like infiltration of the LG in mouse models of Sjogren's syndrome. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROLACTIN TRANSDUCTION
INDUCED
PHOSPHOPROTEIN
SIGNAL
Principal Investigator & Institution: Rui, Hallgeir; Associate Professor; Oncology; Georgetown University Washington, Dc 20057 Timing: Fiscal Year 2002; Project Start 01-SEP-1998; Project End 31-JUL-2005 Summary: (provided by applicant): Breast cancer is a leading cause of death among women. Malignant breast tumors that are not cured by initial surgery typically respond poorly to traditional chemotherapy and further antiestrogen therapy. New therapeutic strategies that will inhibit growth and suppress progression of breast cancer cells need to be identified. This goal might be achieved through targeting of signaling pathways used by the most prominent peptide hormones that regulate breast cancer growth and differentiation. Based on novel preliminary data that extend the work supported by this grant, we provide compelling rationale for investigating the growth-regulatory role of the prolactin-activated Jak2 tyrosine kinase/Stat5 transcription factor pathway in normal and malignant human breast epithelial cells. Importantly, we have discovered loss of Stat5 activation during progression from normal to primary cancer and to metastatic disease. We have also discovered a novel prolatin-activated Jak1-Stat3 signaling pathway that is Jak2-independent, and appears to require the interleukin-6 signal transducer, gp130. We will use specialized molecular tools and technologies to test the following two central hypotheses: a) Prolactin inhibits growth of normal and malignant human breast epithelial cells through activation of the Jak2-Stat5 signaling pathway. b) Prolactin activates an alternative, breast cancer-specific Jak1-Stat3 pathway by a mechanism that requires the interleukin-6 signal transducer, gpl30. We are well qualified to successfully undertake the proposcd studies. We expect to establish the importance of the Jak2-Stat5 pathway in growth-suppression of untransformed and malignant breast epithelial cells, and to identify the mechanism by of aberrant prolactin activation of the Jak 1-Stat3 pathway in breast cancer cells. The research is significant and important because it will provide novel insight into the biological role and mechanisms of prolactin signal transduction in breast cancer. More effective therapeutic strategies for breast cancer could be a result. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PROTEIN INTERACTIONS REGULATING PITUITARY SIGNALING Principal Investigator & Institution: Duval, Dawn L.; Medicine; University of Colorado Hlth Sciences Ctr P.O. Box 6508, Grants and Contracts Aurora, Co 800450508 Timing: Fiscal Year 2002; Project Start 15-FEB-2001; Project End 31-DEC-2003 Summary: (taken from the application) Transcriptional activity is dependent not only on the binding of transcription factors to cis-acting elements, but also on the ability of those factors to recruit a complex hierarchy of proteins to stabilize the basal transcriptional machinery. Basal lactotroph specific expression of the rat prolactin (rPRL) promoter is dependent on the interaction of the proto-oncoprotein c-Ets-1, a member of the -Ets family of transcription factors, with the pituitary-specific transcription factor, Pit-1, at a composite Ets/Pit-1 DNA binding element in the rPRL promoter. While each of these factors alone is capable of activating rPRL gene transcription, the combination of these two transcription factors results in a marked synergistic response. Although the precise
52
Prolactin
mechanism for this synergy remains unknown, it is clear that physical interaction of these two factors is required. Recent studies suggest that the activity of Pit-1 and Ets-1 may be determined by the formation of co-regulatory complexes. Thus, I hypothesize that the Pit-1/Ets-1 complex mediates the synergistic response of the rPRL promoter by recruiting specific transcription regulatory proteins. The goals of this study are to map the specific amino acids of Pit-1 and Ets-1 responsible for their physical and functional interaction, and to use liquid chromatography/mass spectrometry methods to identify the protein components that are recruited to the Ets-1/Pit-1 complex. Therefore, these studies are likely to provide critical insights into the molecular mechanisms underlying combinatorial factor interactions and how they mediate synergistic responses. Finally, these studies are important to my career development, as they will allow me to gain expertise in the cutting edge field of proteomics and protein structure-function relationships, which I can then utilize to establish my career as an independent investigator. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PUBERTY AND GENDER DIFFERENCES IN PAIN RESPONSIVITY Principal Investigator & Institution: Zeltzer, Lonnie K.; Professor; Pediatrics; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2002; Project Start 22-SEP-1999; Project End 31-AUG-2004 Summary: (adapted from investigator's abstract): Female predominance in certain chronic pain syndromes begins to arise in adolescence, suggesting that age or puberty may be a marker for the emergence of gender differentiation in pain. Research shows estrogen affects pain sensitivity. However, studies have not always found higher pain responsivity in the luteal phase of menses (when estrogen levels are high) compared to the follicular phase (when estrogen is relatively low). This suggests that there are other factors which modulate the effects of estrogen on pain responses. Psychological vulnerability, as manifested in heightened physiological reactivity, sensitivity to somatic sensations, and a threat-oriented attentional focus, has been linked to increased pain responsivity. A composite of these psychological vulnerability factors may interact with estrogen levels (and thus puberty status) to produce enhanced pain responsivity in late puberty females. Experimental work to test this hypothesis is lacking; the developmental trajectory for the emergence of adult chronic pain has not been studied. A gender (male vs. female) by puberty status (early: Tanner Stages I-II vs. late: Tanner Stages III-V) by psychological vulnerability (low vs. high composite score) by task type (thermal, pressure and cold pressor pain) between-within factorial design will be used to examine the role of puberty in laboratory pain responsivity among 240 health children, ages 8-17 years. The aims of the study are to: (1) examine among health children the effects of gender, puberty and psychological vulnerability on pain responsivity as measured by subjective, behavioral, autonomic, gonadal and pituitaryadrenal responses to three types of laboratory pain tasks; (2) examine interactions between gender, puberty, and psychological vulnerability in three types of pain responses (tolerance, intensity ratings and distress ratings); and (3) determine the effects of stage of menses (luteal vs. follicular) and dysmenorrhea on pain responsivity among post-menarchal females adolescents. Puberty status will be identified by self-rating pictorial questionnaires tied to Tanner staging and confirmed by hormone assays (FSH, E2, progesterone, testosterone and DHEA-S). Physiologic (ANS) behavioral (tolerance) and subjective measures (pain intensity and distress ratings) will be recorded in response to each pain task. Two finger pricks for spot blood analyses 20 minutes apart will test for stress reactivity in two systems (cortisol, prolactin). Potential psychosocial
Studies
53
moderators of pain responsivity (e.g., concurrent negative life events, past experiences with pain, and adherence to traditional gender roles which emphasize passivity and helplessness among females) will also be assessed. This study is an initial step in understanding the role of puberty in the developmental trajectory of gender differences in pain responsivity from childhood to adulthood. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REGULATION OF SMC/RMUC4 TRANSCRIPTION BY CELL SIGNALING Principal Investigator & Institution: Perez, Aymee; Cell Biology and Anatomy; University of Miami-Medical Box 248293 Coral Gables, Fl 33124 Timing: Fiscal Year 2002; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: The long-term research objectives of this laboratory involve elucidating the roles of the glycoprotein complex ASGP-1/ASGP-2 (SMC) in mammary cancer, in other cancers and in normal tissues. Our short-term plan focuses on the transcriptional regulation of SMC expression in the mammary gland, uterus and mammary tumors. Abnormal expression of SMC/MUC4 has been reported in rat mammary adenocarcinoma and in human breast, pancreatic, lung and colon carcinomas; particularly in cells of highly invasive tumors obtained from patient body fluids. Our recent studies described novel post-transcriptional regulatory mechanisms for the expression of SMC in mammary gland, which has important implications for breast cancer and mammary development. Thus, the overall goal of our proposed studies is to understand the functions of SMC in normal epithelial development and tumor progression, focusing particularly on the mammary gland and uterus, and the mechanisms by which regulation of its expression contribute to those functions. The hypotheses being tested in this work are: 1) SMC contributes to tumor progression, 2) SMC is regulated by a combination of transcriptional and post-transcriptional mechanisms and 3) SMC contributes to epithelial development, specifically to mammary development. Specific Aims are to: I)investigate the mechanism required for lactogenic hormone induction of SMC/rMUC4 using an in vitro model system, the Rama 37 rat mammary epithelial stem cell line, 2) study the role of PEA3 transcription factor in SMC expression in 13762 ascites cell line and rat primary mammary epithelial cells, and 3) investigate the mechanism implicated in uterine rMUC4 expression through TGFbetasignaling using rat primary uterine epithelial cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: REPRODUCTIVE AND HORMONAL RISK FACTORS FOR ADENOMYOSIS Principal Investigator & Institution: Holt, Victoria L.; Professor; Fred Hutchinson Cancer Research Center Box 19024, 1100 Fairview Ave N Seattle, Wa 98109 Timing: Fiscal Year 2002; Project Start 01-MAR-2002; Project End 31-JAN-2007 Summary: Adenomyosis, also known as internal endometriosis, is the progressive invasion of endometrial glands and stroma from the uterine endometrial lining down into the myometrium, the inner muscle wall of the uterus. This condition is diagnosed in over 150,000 women in the U.S. annually, can be associated with severe pelvic and menstrual pain and excessive bleeding, and almost always requires hysterectomy for definitive treatment. Clinical observations have raised the hypothesis that multiparity and excessive estrogen may increase disease risk; however, there is little epidemiologic data to confirm or deny this hypothesis. Consequently, we propose to conduct a case-
54
Prolactin
control study to investigate the relationships between adenomyosis and reproductive and hormonally-related exposures, including polymorphisms in genes involved in steroid hormone synthesis and metabolism. The study will be conducted at Group Health Cooperative of Puget Sound (GHC), a health maintenance organization serving approximately 500,000 people in western Washington State. Cases will be 500 female GHC enrollees 18-59 years of age diagnosed with adenomyosis between March 1, 2001 and Feb. 28, 2006. Two control groups will be used: 1) 500 women undergoing hysterectomy during the study period who are found to have a condition other than adenomyosis, endometriosis, or leiomyoma, frequency matched to cases on age, and 2) 500 women randomly selected from computerized enrollment files, also frequency matched to cases on age. Data will be obtained from cases and controls by in-person interview, anthropometric measurement and collection of a blood sample for DNA analysis; and these data will be linked with the GHC computerized pharmacy database. Subjects will be interviewed regarding factors known or suspected to be associated with uterine trauma or steroid hormone levels (including reproductive, contraceptive, and menstrual histories; obesity; exercise; diet; cigarette smoking) as well as other potential risk factors for adenomyosis. Blood samples will be analyzed for two polymorphic genes coding enzymes active in estrogen metabolism (CYP17, COMT). Analyses comparing cases and controls with respect to reproductive and hormonal risk factors and their interactions with genetic polymorphisms will be conducted to address the specific aims. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: REPRODUCTIVE CONSEQUENCES OF PUBERTAL MORPHINE ABUSE Principal Investigator & Institution: Byrnes, Elizabeth M.; Environmental/Population Hlth; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2002; Project Start 27-SEP-2001; Project End 31-AUG-2004 Summary: (provided by applicant): The present proposal will study the impact of opiate abuse during puberty on future reproductive health. In both the rat and human, puberty is a period during which the reproductive cycles and daily hormonal rhythms begin to emerge. Because endogenous opioids mediate some of these changes, artificially elevated levels of opioids during this period can interfere with reproductive development. While some of the acute effects of opiates like morphine, heroin, and methadone in pubertal females have been delineated, the long-term effects of opiate abuse during the tumultuous pubertal period are unknown. Recent preliminary studies indicate that administering morphine to female rats around the time of puberty results in reproductive alterations that can be observed weeks after drug withdrawal. Specifically, while these females give birth to healthy pups, the rate of growth of their offspring is reduced. Moreover, there appears to be a decrease in the suckling-induced release of prolactin. Given the positive correlation between prolactin secretion and milk yield, a reduction in prolactin secretion could underlie reduced pup growth. Using a chronic increasing dose regimen of morphine (twice daily injections from age 30 to 50 days old), the present set of studies will examine the possible neuroendocrine alterations that may subserve both the decrease [in] suckling-induced prolactin secretion and decreased pup growth. These include examination of the level of prolactin content and message in the anterior pituitary, the sensitivity of the mu-opioid and D2 dopamine receptor subtypes to modulate prolactin secretion, and the expression of prolactin receptors in the mammary gland. In addition, the longevity of alterations in sucklinginduced prolactin secretion and reduced pup growth will be examined. The long-term objective of this proposal is to use these studies as an animal model of drug addiction in
Studies
55
adolescent females. Given the recent rise in the number of adolescent girls abusing heroin, these studies will provide information on some of the potential reproductive consequences that may arise in the future for girls addicted to opiates during this sensitive developmental period. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: S179D PROLACTIN: INHIBITION OF PROSTATE CANCER GROWTH Principal Investigator & Institution: Walker, Ameae M.; None; University of California Riverside 900 University Ave Riverside, Ca 92521 Timing: Fiscal Year 2002; Project Start 30-SEP-2001; Project End 31-AUG-2005 Summary: (Provided by the applicant) Prostate cancer is the second leading cause of cancer deaths among males in the United States. While effective treatments exist for as long as the tumors remain sensitive to androgens, there are no good therapies available once evolution to an androgen-insensitive state occurs. An evaluation of factors which contribute to the growth of these later stage tumors is crucial to the development of new therapeutic strategies. Prolactin (PRL) is one such factor. Although large quantities of PRL are produced by the pituitary, PRL also serves as an autocrine growth factor in the normal human prostate and, as we have shown, this autocrine growth loop continues to be operative in cells representative of highly metastatic, androgen-independent cancers. Using a novel PRL growth antagonist developed in our laboratory, S179D PRL, we have demonstrated that blockade of the PRL autocrine growth loop reduces both the growth of well-established tumors and tumor initiation when androgen-independent cancer cells are grown in nude mice. This PRL growth antagonist therefore has the potential to be an important new therapeutic for late stage disease. The overall aim of the proposed project is to gain a fuller understanding of the molecular and cellular mechanisms underlying S179D PRL's antagonism of prostate tumor growth so that the full potential of this therapeutic can be realized. The specific aims are 1) to determine the optimal dose of S179D PRL, 2) to establish whether S179D PRL slows or halts growth or actually reduces tumor size, 3) to determine whether resistance can develop, and 4) to determine whether any aspect of the growth inhibition involves a) the promotion of apoptosis, or b) downregulation of the growth-promoting PRL autocrine loop, or c) upregulation of the short PRL receptor. In most experiments tumor size will be monitored by the amount of a secreted transfected gene product in the urine. In this way, individual nude mice can be assessed for their response to treatment. S179D PRL will be administered by Alzet minipumps implanted subcutaneously. Molecular and cellular effects on the tumors/tumor cells will be assessed by end-labeling for apoptosis, Northern, Western and microarray analysis for gene expression and immunoprecipitation, Western and radiolabel incorporation for signaling. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SELF INJURIOUS BEHAVIOR AND PRIMATE WELL BEING Principal Investigator & Institution: Novak, Melinda A.; Professor; Psychiatry; Harvard University (Medical School) Medical School Campus Boston, Ma 02115 Timing: Fiscal Year 2002; Project Start 30-SEP-1996; Project End 31-JUL-2005 Summary: Primates, such as Old World monkeys, represent a crucial research resource, and major scientific advances in medicine, biology, and neuroscience can be attributed to their use. Despite the recent strides made in controlling colony diseases, in developing new housing regimens, and in modernizing facilities, some monkeys
56
Prolactin
develop pathological behavior. Of particular concern is the small but persistent percentage of monkeys that develop the syndrome of self-injurious behavior (SIB). The occurrence of SIB compromises the goal of promoting the physical and psychological well-being of laboratory primates as mandated by the Animal Welfare Act (Revised 1991). It also threatens the quality of the monkey research resource, particularly because monkeys with this condition differ both behaviorally and physiologically from other monkeys in the colony. Our research has shown that monkeys with SIB are more aggressive, are more likely to have experienced early social separation, and have been exposed to more stressful events than normal monkeys. Monkeys with this disorder also show altered heart rate patterns and a dysregulation of the hypothalamic-pituitaryadrenal (HPA) axis manifested by unusually low levels of plasma cortisol. This pattern of precipitating stressors and low cortisol parallels similar observations in patients with post-traumatic stress disorder (PTSD). The continuing objective of this project is to characterize the nature of SIB in rhesus monkeys, to identify the mechanisms responsible for this behavioral pathology, and to devise effective treatment regimens. Our current focus is on the HPA and serotonergic systems, both of which may be altered in monkeys with SIB. We will use various endocrine challenges to determine whether monkeys with SIB show reduced adrenocortical responsivity and heightened sensitivity of the glucocorticoid negative feedback system as is observed in PTSD patients. We will determine whether monkeys with SIB show altered stress responses to various social situations using our newly developed procedure of noninvasive collection of salivary cortisol in unrestrained adult animals. We will investigate cardiac and HPA reactions that surround spontaneous episodes of self-directed biting in an effort to determine whether biting serves as a coping strategy to reduce arousal. Other studies will examine the role of the serotonergic system in the expression of SIB by measuring hormonal responses to a fenfluramine challenge. Finally, we will evaluate the efficacy of serotonergic drugs as potential pharmacotherapeutic agents for reducing the incidence of SIB. These studies should provide important new information concerning the pathophysiology of SIB in monkeys and should lead to the development of useful treatment strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SEROTONIN FUNCTION IN PATIENTS WITH EATING DISORDERS Principal Investigator & Institution: Jimerson, David C.; Professor; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2000; Project Start 30-SEP-1991; Project End 31-JAN-2005 Summary: (Adapted from the Applicant's Abstract): The eating disorders bulimia nervosa and anorexia nervosa are serious psychiatric syndromes affecting 2 to 3 percent of young women, and significant although smaller number of young men. Women with bulimia nervosa or anorexia nervosa manifest abnormalities in regulation of serotonin, a central nervous system (CNS) neurotransmitter involved in regulation of food intake, mood and impulsive/obsessional behaviors. The goal of the current project is to evaluate whether abnormalities in serotonin regulation reflection reflect trait-related characteristics present in individuals who develop an eating disorder. Recurrent dieting is a frequent precursor to bulimia nervosa and anorexia nervosa. In healthy controls, dieting decreases blood tryptophan levels, resulting in an apparent decrease in CNS serotonin synthesis. Normally, serotonergic pathways are though to respond to dieting through augmentation of post-synaptic receptor responsiveness. It is hypothesized that in women with a neurobiological predisposition to eating disorders, CNS receptors are not able to respond adequately to compensate for diet-associated decreases in serotonin
Studies
57
synthesis. This deficiency could contribute to the onset of eating disorder symptoms. Study groups will include women who have recovered from bulimia nervosa, women who have recovered from anorexia nervosa, and healthy female controls. Based on a randomized, controlled, crossover design, subjects will participate in low-tryptophan and normal tryptophan eight-day study diets. In comparison to results in controls, the long-term remitted patient groups are anticipated to respond to a low-tryptophan diet with significantly impaired diet-induced augmentation of dexfenfluramine-stimulated prolactin response. Indirect measures of physiological/metabolic response to dietary changes, including blood leptin concentration, will be compared across study groups. These studies will provide important new information on the potential roles of dieting and serotonin in the development of eating disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SEROTONIN, DRUG USE AND MDMA INDUCED DEFICITS Principal Investigator & Institution: Moeller, Frederick G.; Associate Professor; Psychiatry and Behavioral Scis; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, Tx 77225 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2006 Summary: (provided by applicant): The neurotoxic effects of the drug methylenedioxymethamphetamine (MDMA), popularly known as "ecstasy", have been conclusively shown in animals. Human studies on the long-term effects of MDMA have been hampered by the confounding issue that other drugs are often sold as MDMA, and the fact that MDMA users tend to use other drugs of abuse. Thus, it has been questioned whether the neurobehavioral deficits seen in MDMA users are specifically due to MDMA. Taken together, these key issues justify the need to conduct more systematic, rigorous examination of neurobehavioral effects of MDMA use in humans. Likewise, the more clear evidence that MDMA causes detrimental effects on the brain and behavior, the more likely MDMA users will consider substance abuse treatment. Since the United States has recently seen a dramatic increase in the use of MDMA, primarily by young adults, the significance of the neurotoxic effects of MDMA in humans is clear. A further understanding of the long-term neurobehavioral effects of MDMA in humans will have a direct and significant effect on treatment development. This resubmission will use multi-modal neurobehavioral measures including behavioral laboratory measures of impulsivity and functional magnetic resonance imaging to answer three key questions regarding MDMA use in humans. First, what are the specific effects of MDMA use on mood, impulsivity, memory, and brain function? Second, how are these deficits related to quantity and frequency of MDMA use? Third, are these deficits related to serotonin function in MDMA users? The Specific Aims of this proposal are: Specific Aim 1: To compare neurobehavioral measures of mood, memory, impulsivity and functional magnetic resonance imaging between heavy MDMA using subjects, matched nonMDMA using drug users, and healthy controls. Specific Aim 2: To determine whether the quantity and frequency of MDMA use are related to the neurobehavioral deficits seen in heavy MDMA users. Specific Aim 3: To determine whether neurobehavioral deficits seen in heavy MDMA users are related to serotonergic function as measured by a mCPP neuroendocrine challenge in these subjects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
58
•
Prolactin
Project Title: SEX POSTMENOPAUSE
STEROIDS
&
MAMMOGRAPHIC
DENSITY
IN
THE
Principal Investigator & Institution: Greendale, Gail A.; Associate Professor; Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, Ca 90024 Timing: Fiscal Year 2004; Project Start 01-JUN-1998; Project End 31-MAR-2008 Summary: (provided by applicant): Higher mammographic density is an independent risk factor for breast cancer and the magnitude of risk associated with mammographic density is greater than that associated with almost all other known risk factors for breast cancer. This application proposes to continue work in "Sex Steroids and Mammographic Density in the Postmenopause", a study of the effects of endogenous and exogenous sex steroids on mammographic percent-density. This study is an outgrowth of the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, which randomly assigned postmenopausal women to placebo, estrogen-only, or one of three combination estrogen/progestin treatments. To date, the principal findings of the "Sex Steroids and Mammographic Density Study" are: 1) Exogenous estrogen-only treatment did not affect mean mammographic density but significant increases in mammographic density did occur in 3 groups assigned to estrogen/progestin treatments; 2) In the three estrogen/progestin groups, but not in the estrogen-only group, the degree of increase in serum estrone level on-treatment predicted the amount of increase in mammographic density; and 3) Endogenous (we-treatment) serum levels of estrone, estradiol, progesterone, and sex hormone binding globulin were positively associated with baseline mammographic density. Based on these findings, we propose to continue work in this study to gain a further understanding of variation in mammographic density, specifically: 1) What other factors are associated with baseline (pre-treatment) mammographic density? and 2) What additional factors predict increases in mammographic density during treatment? We hypothesize that hormones (in addition to those already studied), genetic polymorphisms in sex steroid biosynthetic/metabolic pathways, and genetic polymorphisms in sex steroid receptors will be related to baseline mammographic density and/or mammographic density response to treatment with hormone therapy. The proposed continuation project will last 4 years and will take place at UCLA and USC. Using stored samples, we will measure baseline and 12-month levels of prolactin and progestins. We will also extract DNA from stored samples to assess selected genetic polymorphisms. The mammographic density outcome data and all relevant covariates have already been measured during our prior work. We will quantify the relations between the hormone and genetic exposures measured in this project and mammographic density (at baseline as well as change in density between baseline and 12 months). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SLEEP AND NOCTURNAL ENDOCRINE FUNCTION IN MDMA USER Principal Investigator & Institution: Mccann, Una D.; Associate Professor of Pyschiatry; Psychiatry and Behavioral Scis; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-JUL-2007 Summary: (provided by applicant): (+/-) 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") is an increasingly popular psychoactive drug of abuse that has been shown to be a potent brain serotonin (5-HT) neurotoxin in animals. Growing evidence in
Studies
59
recreational MDMA users indicates that MDMA can also lead to 5-HT damage in humans. Recent data in non-human primates suggests that some MDMA users (i.e., those who use MDMA in a "binge" regimen) may also incur brain dopamine (DA) neurotoxicity, although clinical studies to test this possibility have not yet been conducted. Functional consequences of MDMA neurotoxicity in humans have been difficult to identify. However, several studies have demonstrated altered sleep patterns and endocrine function in individuals previously exposed to MDMA. Since 5-HT and DA are involved in the regulation of sleep and endocrine function, it is possible that altered sleep and endocrine function in MDMA users is related to MDMA-induced 5-HT and/or DA neurotoxicity. Further, since sleep and circadian rhythms influence hormonal secretion (and vice versa), abnormalities of sleep and endocrine function in MDMA users may be inter-related. The proposed studies are intended to extend previous studies of sleep and neuroendocrine function in MDMA users, and explore possible interrelations between sleep and nocturnal neuroendocrine function in MDMA users and matched controls. The specific aims of the project are: 1) To analyze sleep patterns of 2 groups of MDMA users and 2 groups of matched control subjects using standard polysomnographic and spectral power methods. One group of MDMA users will be "bingers," whereas the second group will report never having taken more than dose of MDMA dose per 12-hour period. One control group will be matched with MDMA users for non-MDMA drug use (in addition to other demographic variables) whereas the second group of controls will have no history of illicit drug abuse. 2) To characterize the nocturnal secretion patterns of prolactin, growth hormone, and cortisol, three hormones that are modulated by 5-HT and/or DA influenced by sleep; and 3) To conduct 5-HT pharmacological challenges with m-chlorophenylpiperazine (m-CPP) in male and female MDMA users during sleep, when environmental and cognitive factors that can influence endocrine secretion are minimal. Results from the proposed studies will help better define the functional consequences of MDMA exposure in humans, and could shed light on the roles of 5-HT and DA in sleep and nocturnal endocrine function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SOCS-3 IN IGF-IR SIGNALING IN MALIGNANT CELLS Principal Investigator & Institution: Dey, Bhakta R.; Orthopedics & Rehabilitation; Creighton University 2500 California Plaza Omaha, Ne 68178 Timing: Fiscal Year 2002; Project Start 23-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant) The insulin-like growth factor-I receptor (IGF-IR) plays an important role in promoting the growth of cancers by stimulating malignant cell proliferation and transformation, and inhibiting apoptosis. We identified suppressor of cytokine signaling (SOCS)-3 as an intracellular binding partner of the IGF-IR. In human colon cancer Caco-2 cells, the IGF-IR and IGF-II are expressed at high levels and SOCS-3 is significantly induced by IGF-I stimulation. SOCS-3 protein is heavily phosphorylated in serine residues and this serine phosphorylation is noticed with or without IGF-I stimulation. SOCS-3 protein localized mostly in the cytoplasm and IGF-I stimulation results in both nuclear and cytoplasmic localization. Moreover, SOCS-3 protein is ubiquitinated in mammalian cells. These results suggest that SOCS-3 protein may play regulatory roles in IGF-IR signaling. SOCS-3 has been shown to be a negative regulator of interleukin (IL-2, IL-6), growth hormone, prolactin, insulin and leptin receptor signaling pathways. The primary goal of this study is to define the function of SOCS-3 in IGF-IR signaling in malignant cells. We hypothesize that SOCS-3 may play a negative regulatory role in IGF-IR signaling in malignant cells. To test this hypothesis we formulated the following specific aims: 1) to identify which signal transduction
60
Prolactin
pathway(s) of the IGF-IR might be affected by the IGF-IR-SOCS-3 interaction, 2) to determine whether this interaction alters kinase activity or stability of the receptor, and 3) to determine the mechanisms by which IGF-IR-SOCS-3 interaction might interfere with IGF-I stimulated proliferation, invasion and inhibition of apoptosis in malignant cells. Our long-term goal is to investigate the negative regulation of the IGF-IR signaling by SOCS-3, a potentially novel mechanism for growth resistance and cancer prevention. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SPECIFIC REPRESSION OF PROLACTIN GENE EXPRESSION Principal Investigator & Institution: Day, Richard N.; Associate Professor; Internal Medicine; University of Virginia Charlottesville Box 400195 Charlottesville, Va 22904 Timing: Fiscal Year 2002; Project Start 11-JUL-1994; Project End 31-MAR-2003 Summary: (Adapted from applicant's abstract) The broad objective of this proposal will be to continue the ongoing studies to map protein protein interactions of Pit1. This study will begin to assess how cell signaling influences such interactions and, specifically, it is proposed to assess how an Ets repressor protein ERF negatively regulates prolactin gene regulation. First, the applicant proposes to identify the endogenous ERF protein and characterize its subcellular localization during critical periods within the cell cycle and in response to activation of signal transduction cascades. Second, the requirements for Pit-1 nuclear localization will be precisely identified so as to permit further protein protein analysis by FRET microscopy. Continuing on this theme, the final aim will investigate the association of Pit-1 and its protein partners with the nuclear matrix. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: STEM CELLS AND PERINATAL FACTORS FOR BREAST CANCER RISK Principal Investigator & Institution: Hsieh, Chung-Cheng; Professor of Medicine; Cancer Center; Univ of Massachusetts Med Sch Worcester Office of Research Funding Worcester, Ma 01655 Timing: Fiscal Year 2002; Project Start 15-MAR-2002; Project End 31-JAN-2006 Summary: (provided by applicant): This study proposes to examine whether hormone levels in human umbilical cord blood are associated with measurements of stem cell potential and expression of Bcl-2 family proteins indicating levels of apoptotic activity. Measurements of stem cells and Bcl-2 apoptosis will be further examined to see if they correlate with birth weight as an indicator of fetal growth. The study is based on the hypothesis that cancer risk can be influenced in part by the hormonal environment in utero and that cancer risk is proportional to the number of primitive proliferating stem cells. Umbilical cord blood from 300 donors will be obtained from singleton birth, fullterm, and low-risk deliveries at hospitals affiliated with the American Red Cross Cord Blood Program. Hormones and other growth factors including estradiol, estriol, progesterone, prolactin, sex-hormone binding globulin (SHIBG), testosterone, insulinlike growth factor-1 (IGF-1), and IGF binding protein-3 (IGFBP-3) will be assayed in cord blood samples. We will measure the total number of nucleated cells, number of cells per volume expressing CD34 protein on the cell surface as well as CD34+/CD38, CD34+/c-kit, and CD45/GlyA sub-population cells, and the number of colony-formingunit granulocytes and macrophages (CFU-GM) as laboratory parameters for primitive proliferating stem cells. Among Bcl-2 family proteins we will measure the expression of Bcl-2, Bcl-xL, Bax, and Bad to construct an overall apoptotic index. We will apply
Studies
61
regression analysis treating as outcome variables each measurement of stem cell potential and Bcl-2 apoptotic index and as predictor variables hormone levels, controlling for maternal and neonatal characteristics. Stem cell measurements and index of Bcl-2 apoptotic expressions will be further examined as predictors of birth weight. The study seeks to obtain information on parameters of perinatal cell proliferation relevant to intervening steps between intrauterine hormone exposure and subsequent cancer risk. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE INVOLVEMENT OF THE VMH IN MATERNAL BEHAVIOR IN RATS Principal Investigator & Institution: Mann, Phyllis E.; Veterinary Biomedical Sciences; Tufts University Boston Boston, Ma 02111 Timing: Fiscal Year 2002; Project Start 01-FEB-2002; Project End 31-JAN-2005 Summary: (provided by applicant): Based on new evidence from our laboratory, which has discovered an important inhibitory role of the ventromedial nucleus of the hypothalamus (VMH) in maternal behavior, the objective of this grant proposal is to elucidate the involvement of the VMH in the onset of maternal behavior. The experiments described in the present grant proposal will use behavioral, molecular, and anatomical approaches to identify the possible mechanisms of action of the VMH on the inhibition of maternal behavior. The hypothesis underlying the present proposal is that under normal physiological conditions the VMH inhibits the display of maternal behavior in virgin and late-pregnant rats by inhibiting the actions of the medial preoptic area (MPOA, an area considered to be crucially involved in the display of maternal behavior). The specific aim of the first three experiments will be to examine the role of the VMH in the regulation of maternal behavior in estradiol-primed, virgin rats. Experiment 1 will analyze the timing of neurotoxin administration into the VMH and subsequent maternal behavior stimulation. Experiment 2 will determine if infusions of the sodium channel blocker, tetrodotoxin, will stimulate short-latency maternal behavior, while experiment 3 will examine the role of GABA infusions into the VMH and subsequent maternal behavior. The second specific aim is to determine the changes in receptor gene expression of the key pregnancy hormones, estrogen, progesterone, and prolactin, in estradiol-primed, virgin rats. Experiments 4,5 and 6 will use in situ hybridization histochemistiy (ISHH) to determine the changes in estrogen, progesterone, and prolactin receptor gene expression, respectively, in the VMH and MPOA following estradiol stimulation in virgin rats. These 3 experiments will also investigate the changes in receptor gene expression in the MPOA following neurotoxic lesions to the VMH. The third specific aim is to determine, using anatomical, tracktracing methods, whether neurons in the VMH that are activated in the presence of pups project to the MPOA (experiment 7). Experiment 8 will determine the neurotransmitter involved in the regulation of the MPOA by the VMH. Together, these studies will help elucidate the role of the VMH in maternal behavior in virgin rats and identify the neural basis of parental care. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THE ROLE OF PLACENTAL LACTOGEN IN FETAL DEVELOPMENT Principal Investigator & Institution: Freemark, Michael S.; Pediatrics; Duke University Durham, Nc 27706 Timing: Fiscal Year 2003; Project Start 01-MAY-1988; Project End 31-MAY-2008
62
Prolactin
Summary: (provided by applicant): Prolactin (PRL) and placental lactogen (PL) stimulate fat deposition, weight gain, and leptin production in rodents and humans, suggesting that lactogens play roles in maternofetal lipid metabolism and obesity. The mechanisms by which lactogens promote fat storage and weight gain are unknown. We hypothesize: (a) that lactogens promote fat deposition through induction of adipogenesis, the process of differentiation of adipocytes from stromal precursors; (b) that adipogenic effects of lactogens are mediated through induction of transcription factors including PPARkhi-2; (c) that PPARkhi-2 induction is mediated through activation of Stat5; and (d) that adipogenic effects of lactogens are modulated by insulin, IGF-1, glucocorticoids, and sex steroids. To test these hypotheses we will examine effects of exogenous PRL and PL on adipogenesis in 3T3-L1 preadipocytes, primary mouse preadipocytes and embryonic fibroblasts and the effects of constitutive expression of PL in a novel 3T3-L1 cell line. To determine if lactogenic signaling is required for preadipocyte differentiation, we will compare rates of adipogenesis in preadipocytes of PRL receptor (PRLR)-deficient mice with rates of adipogenesis in cells of wild-type littermates. To characterize effects of lactogens on PPARkhi expression we will examine effects of PRL and PL on PPARkhi1 and 2 mRNA and protein levels in 3T3-L1 cells, primary preadipoyctes, mouse embryonic fibroblasts and will compare PPARkhi expression in tissues of PRLR deficient mice with that in wild-type littermates, We will examine effects of lactogens on transcriptional activation of the human and mouse PPARkhi-2 promoters expressed in 3T3-L1 cells and will compare the time course of expression of PPARkhi1I and 2 mRNAs in PRL-treated cells with that of ADD1 and c/EBPs beta, delta, and alpha. To test the hypothesis that induction of PPARkhi-2 is mediated through activation of Stat5, we will determine if lactogens induce binding of STAT 5 to consensus binding sites in the human and mPPAR c-2 promoters. We will examine the effect of mutating PPARkhi-2 Stat5 consensus sequences on lactogendependent activation of PPAR gamma2 transcription, and the effect of a dominantnegative STAT5 construct on the induction of PPARkhi mRNA and protein levels in 3T3-L1 cells. Finally, to test the hypothesis that the adipogenic effects of the lactogens are modulated by sex steroids, we will examine the effects of progesterone and estradiol on the adipogenic effects of PRL in 3T3-L 1 cells and the effects of progesterone supplementation on fat deposition and leptin production in PRLR-deficient mice. The results of our studies should provide new insist into the roles of pituitary and placental hormones in adipose development and function. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TRANSCRIPTION ENHANCER FACTOR CONTROL OF PLACENTAL GENES Principal Investigator & Institution: Jiang, Shi-Wen; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Syncytiotrophoblasts are a major placental component responsible for feto-maternal exchange and secretion of pregnancy-specific hormones. Syncytia formation is a hallmark of placental cell differentiation, accompanied by dramatic activation of the chorionic somatomammotropin (CS) gene. CS, growth hormone, and prolactin comprise a gene family required for normal growth, metabolism, and reproduction. We demonstrated that placental-specific human CS gene I expression is mediated by cooperative action of enhancers (CSEn) located downstream of each of the three CS genes. These enhancers stimulate the CS promoter in placental cells, but silence the promoter in pituitary cells. Members of the transcription enhancer
Studies
63
factor (TEF) family bind to several GT-IIC and Sphl/Sphll elements in CSEn and mediate the CS enhancer/silencer functions. We isolated two differential splicing isoforms TEF-1beta and TEF-1gamma, and found that their limited sequence divergence is associated with stronger CSEn binding and trans-repression function than TEF-la. We cloned a new TEF family member, TEF-5, that trans-activates CSEn in placental cells. We are now addressing TEF actions on endogenous hCS gene expression and placental cell differentiation using primary cultures of human placental trophoblasts. We discovered that fusogenic membrane glycoprotein (FMG)-mediated fusion of choriocarcinoma cells (BeWo) results in activation of CSEn, providing another possible physiologic model that will facilitate the study of TEF regulation on placental cell function. Using these cell models and the newly developed TEF antibodies, we will define the function of individual TEF members by hCS/TEF expression correlation, TEF antisense experiments, and chromatin immunoprecipitation assays (Aim 1). Our preliminary studies demonstrate several fundamental insights with direct bearing on the mechanism of TEF action: 1) TEF control of GT-IIC enhancer is subject to PKC phosphorylation regulation; 2) TEF molecules bind cooperatively to direct repeats of GT-IIC sequences separated by 3 nucleotides, suggesting that TEF homo- and hetero-dimerization may be involved in their action; 3) two TEF-5 differentially spliced cDNA clones containing gross structural alterations are present in placenta and may play distinct roles in CSEr regulation. We will perform mechanistic studies on how PKC phosphorylation (Aim 2) and homo- and hetero-dimerization (Aim 3) regulate TEF DNA binding and transcriptional activities in cellular environments. We will determine TEF-5 isoform expression levels in placenta and examine their roles in CSEn function (Aim 4). The proposal addresses specific hypotheses that will enhance our understanding of TEFmediated placental gene expression and trophoblast differentiation that are important for human fetal development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATMENT OF EARLY ONSET SCHIZOPRENIA SPECTRUM (TEOSS) Principal Investigator & Institution: Frazier, Jean A.; Director; Mc Lean Hospital (Belmont, Ma) Belmont, Ma 02478 Timing: Fiscal Year 2002; Project Start 19-SEP-2001; Project End 31-AUG-2006 Summary: (Adapted from the Applicant?s Abstract): Objectives: This is one of four identical revised applications of a collaborative R01 proposal being conducted at the University of Washington, Seattle, WA, University of North Carolina (UNC), Chapel Hill, NC, Harvard Medical School, Boston, MA and Case Western University, Cleveland, Ohio. The study will examine the long-term effectiveness of three different antipsychotic medications in the treatment of early onset schizophrenia and schizoaffective disorder: risperidone (RIS), olanzapine (OLA), the molindone (MOL) over a one year period. Specific Aims: 1) To determine the efficacy of MOL, RIS, and OLA in reducing psychotic symptoms in youth with schizophrenia and related disorders; 2) To determine the ability to sustain treatment over one year with each of these agents; 3) To examine the effects of treatment on adaptive and neurocognitive functioning; and 4) To examine the safety and tolerability of these agents in the pediatric population, particularly potential effects on neuropyramidal symptoms and weight gain. Research Design: 168 youths (ages 8-19 years) with schizophrenia, schizophreniform disorder or schizoaffective disorder and active psychotic symptoms will be recruited across four sites. Subjects will be randomly assigned to double-blind treatment with one of the three study medications. Standard dosage schedules will be
64
Prolactin
followed, with modifications allowed dependent on the clinical status of subjects. Antipsychotic agents will be cross-tapered over the first week of the study to prevent exacerbation of psychotic symptoms. Symptom ratings and neurocognitive testing will be performed at baseline and repeated at specific intervals. The acute phase of treatment will last 8 weeks. Subjects with clinically significant improvement and without intolerable side effects, will continue maintenance therapy for an additional 44 weeks. Tolerance of the study medications will be systematically monitored with assessments for extrapyramidal side effects and weight gain. Revision of treatment algorithms, reliability testing and data analysis will be coordinated between the four sites. Randomization, preparation of study medications, and overall management of the database will be centralized at UNC. Revisions: To address reviewers concerns, the revised proposal has added a fourth site (Harvard), revised the data management and analysis plan, and adjusted some of the primary outcome measures. Significance: There are very few controlled studies to inform clinical practice for the treatment of youth with psychotic disorders. This study will provide information about the comparative effectiveness of the most commonly used and representative antipsychotic drugs in youth with schizophrenia spectrum disorders. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “prolactin” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for prolactin in the PubMed Central database: •
A bacterial cell that synthesizes a protein containing the antigenic determinants of rat prolactin. by Erwin CR, Maurer RA, Donelson JE.; 1980 Jun 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=324100
•
A BgIII RFLP at the human prolactin gene locus on chromosome 6 (PRL). by Myal Y, DiMattia GE, Gregory CA, Friesen HG, Hamerton JL, Shiu RP.; 1991 Mar 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=333824
•
A novel transcriptional enhancer is involved in the prolactin- and extracellular matrix-dependent regulation of beta-casein gene expression. by Schmidhauser C, Casperson GF, Myers CA, Sanzo KT, Bolten S, Bissell MJ.; 1992 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=275624
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
65
•
A Single Phosphotyrosine Residue of the Prolactin Receptor is Responsible for Activation of Gene Transcription. by Lebrun J, Ali S, Goffin V, Ullrich A, Kelly PA.; 1995 Apr 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42096
•
Absolute requirement of glucocorticoid for expression of the casein gene in the presence of prolactin. by Ganguly R, Ganguly N, Mehta NM, Banerjee MR.; 1980 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=350201
•
Activation of JAK2 Tyrosine Kinase by Prolactin Receptors in Nb2 Cells and Mouse Mammary Gland Explants. by Campbell GS, Argetsinger LS, Ihle JN, Kelly PA, Rillema JA, Carter-Su C.; 1994 Jun 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43968
•
Activation of Mitogen-Activated Protein Kinases by Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Capillary Endothelial Cells is Inhibited by the Antiangiogenic Factor 16-kDa N-Terminal Fragment of Prolactin. by D'Angelo G, Struman I, Martial J, Weiner RI.; 1995 Jul 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41520
•
Activation of the prolactin receptor gene by promoter insertion in a Moloney murine leukemia virus-induced rat thymoma. by Barker CS, Bear SE, Keler T, Copeland NG, Gilbert DJ, Jenkins NA, Yeung RS, Tsichlis PN.; 1992 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=240173
•
Adenosine acts by A1 receptors to stimulate release of prolactin from anteriorpituitaries in vitro. by Yu WH, Kimura M, Walczewska A, Porter JC, McCann SM.; 1998 Jun 23; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22760
•
Analysis of prolactin-modulated gene expression profiles during the Nb2 cell cycle using differential screening techniques. by Bole-Feysot C, Perret E, Roustan P, Bouchard B, Kelly PA.; 2000; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15026
•
cDNA Cloning of Somatolactin, a Pituitary Protein Related to Growth Hormone and Prolactin. by Ono M, Takayama Y, Rand-Weaver M, Sakata S, Yasunaga T, Noso Y, Kawauchi H.; 1990 Jun 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54103
•
Central Prolactin Infusions Stimulate Maternal Behavior in Steroid-Treated, Nulliparous Female Rats. by Bridges RS, Numan M, Ronsheim PM, Mann PE, Lupini CE.; 1990 Oct 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54880
•
Characterization of BCE-1, a Transcriptional Enhancer Regulated by Prolactin and Extracellular Matrix and Modulated by the State of Histone Acetylation. by Myers CA, Schmidhauser C, Mellentin-Michelotti J, Fragoso G, Roskelley CD, Casperson G, Mossi R, Pujuguet P, Hager G, Bissell MJ.; 1998 Apr; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=121460
66
Prolactin
•
Cloning and Expression of Stat5 and an Additional Homologue (Stat5b) Involved in Prolactin Signal Transduction in Mouse Mammary Tissue. by Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L.; 1995 Sep 12; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41061
•
Cloning and nucleotide sequence of an ovine prolactin cDNA. by Adams TE, Baker L, Brandon MR.; 1989 Jan 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=331561
•
Comparison of long and short forms of the prolactin receptor on prolactin-induced milk protein gene transcription. by Lesueur L, Edery M, Ali S, Paly J, Kelly PA, Djiane J.; 1991 Feb 1; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=50906
•
Conformational Similarity of Ovine Prolactin and Bovine Growth Hormone. by Aloj SM, Edelhoch H.; 1970 Jul; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=283125
•
Construction and analysis of recombinant DNAs containing a structural gene for rat prolactin. by Gubbins EJ, Maurer RA, Hartley JL, Donelson JE.; 1979 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=327742
•
Construction and characterization of a cDNA clone containing a portion of the bovine prolactin sequence. by Nilson JH, Thomason AR, Horowitz S, Sasavage NL, Blenis J, Albers R, Salser W, Rottman FM.; 1980 Apr 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=324017
•
Context effects on N6-adenosine methylation sites in prolactin mRNA. by Narayan P, Ludwiczak RL, Goodwin EC, Rottman FM.; 1994 Feb 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=307810
•
Cortisol rapidly reduces prolactin release and cAMP and 45Ca2+ accumulation in the cichlid fish pituitary in vitro. by Borski RJ, Helms LM, Richman NH 3rd, Grau EG.; 1991 Apr 1; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=51318
•
d(TG)n.d(CA)n sequences upstream of the rat prolactin gene form Z-DNA and inhibit gene transcription. by Naylor LH, Clark EM.; 1990 Mar 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=330531
•
d24-hour changes in circulating prolactin, follicle-stimulating hormone, luteinizing hormone and testosterone in male rats subjected to social isolation. by Esquifino AI, Chacon F, Jimenez V, Reyes Toso CF, Cardinali DP.; 2004; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=373458
Studies
67
•
Detection of two chromatin proteins which bind specifically to the 5'-flanking region of the rat prolactin gene. by White BA, Preston GM, Lufkin TC, Bancroft C.; 1985 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=369108
•
Diagnosis and management of hyperprolactinemia. by Serri O, Chik CL, Ur E, Ezzat S.; 2003 Sep 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=191295
•
Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth. by Chun TY, Gregg D, Sarkar DK, Gorski J.; 1998 Mar 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=19333
•
DNA recognition element required for PUF-I mediated cell-type-specific transcription of the rat prolactin gene. by Sharp ZD, Helsel S, Cao ZD, Barron EA, Sanchez Y.; 1989 Apr 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=317652
•
Dual functions of a cis-acting element within the rat prolactin gene promoter. by Barron EA, Cao Z, Schneider BG, Kraig E, Carrillo AJ, Sharp ZD.; 1989 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=362659
•
Effects of deletion of the prolactin receptor on ovarian gene expression. by Grosdemouge I, Bachelot A, Lucas A, Baran N, Kelly PA, Binart N.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151786
•
Evidence for a physiological role of hypothalamic gastrin-releasing peptide to suppress growth hormone and prolactin release in the rat. by Kentroti S, Dees WL, McCann SM.; 1988 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=279675
•
Expression Cloning of a cDNA Encoding a Fish Prolactin Receptor. by Sandra O, Sohm F, Luze AD, Prunet P, Edery M, Kelly PA.; 1995 Jun 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=41637
•
Expression of the Xenopus laevis Prolactin and Thyrotropin Genes During Metamorphosis. by Buckbinder L, Brown DD.; 1993 May 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=46397
•
Galanin regulates prolactin release and lactotroph proliferation. by Wynick D, Small CJ, Bacon A, Holmes FE, Norman M, Ormandy CJ, Kilic E, Kerr NC, Ghatei M, Talamantes F, Bloom SR, Pachnis V.; 1998 Oct 13; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=22889
•
Genomic organization of rat prolactin and growth hormone genes. by Chien YH, Thompson EB.; 1980 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=349888
68
Prolactin
•
Identification and Functional Activity of Prolactin Receptors in Thymic Epithelial Cells. by Dardenne M, Kelly PA, Bach J, Savino W.; 1991 Nov 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52786
•
Identification and sequence analysis of a second form of prolactin receptor by molecular cloning of complementary DNA from rabbit mammary gland. by Edery M, Jolicoeur C, Levi-Meyrueis C, Dusanter-Fourt I, Petridou B, Boutin JM, Lesueur L, Kelly PA, Djiane J.; 1989 Mar; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=286858
•
Identification of a distal regulatory element in the 5' flanking region of the bovine prolactin gene. by Wolf JB, David VA, Deutch AH.; 1990 Aug 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=331977
•
Identification of an estrogen-responsive element from the 5'-flanking region of the rat prolactin gene. by Maurer RA, Notides AC.; 1987 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=368106
•
Identification of Prolactin and Growth Hormone Binding Proteins in Rabbit Milk. by Postel-Vinay M, Belair L, Kayser C, Kelly PA, Djiane J.; 1991 Aug 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=52153
•
Increased level of prolactin gene sequences in bromodeoxyuridine treated GH cells. by Biswas DK, Hanes SD.; 1982 Jul 10; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=320773
•
Induction of prolactin-deficient variants of GH3 rat pituitary tumor cells by ethyl methanesulfonate: reversion by 5-azacytidine, a DNA methylation inhibitor. by Ivarie RD, Morris JA.; 1982 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=346329
•
Inhibition of Gonadotropin Hormone-Releasing Hormone Release by Prolactin from GT1 Neuronal Cell Lines Through Prolactin Receptors. by Milenkovic L, D'Angelo G, Kelly PA, Weiner RI.; 1994 Feb 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=43133
•
Interaction of basal positive and negative transcription elements controls repression of the proximal rat prolactin promoter in nonpituitary cells. by Jackson SM, Keech CA, Williamson DJ, Gutierrez-Hartmann A.; 1992 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=364465
•
Interferon-regulatory factor 1 is an immediate-early gene under transcriptional regulation by prolactin in Nb2 T cells. by Yu-Lee LY, Hrachovy JA, Stevens AM, Schwarz LA.; 1990 Jun; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=360673
Studies
69
•
Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad /estrogen receptor crosstalk. by Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST, Low MJ, Holsboer F, Stalla GK, Arzt E.; 2003 Feb 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=298721
•
Isolation and characterization of two peptides with prolactin release-inhibiting activity from porcine hypothalami. by Schally AV, Guoth JG, Redding TW, Groot K, Rodriguez H, Szonyi E, Stults J, Nikolics K.; 1991 May 1; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=51487
•
Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. by Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, Asa SL, Low MJ.; 2002 Oct 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151153
•
Low-calorie diet prevents the development of mammary tumors in C3H mice and reduces circulating prolactin level, murine mammary tumor virus expression, and proliferation of mammary alveolar cells. by Sarkar NH, Fernandes G, Telang NT, Kourides IA, Good RA.; 1982 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=347427
•
Mechanism of induction of prolactin synthesis in GH cells. by Biswas DK, Hanes SD, Brennessel BA.; 1982 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=345662
•
Membrane modification differentially affects the binding of the lactogenic hormones human growth hormone and ovine prolactin. by Bhattacharya A, Vonderhaar BK.; 1981 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=348835
•
Modulations of prolactin and growth hormone gene expression and chromatin structure in cultured rat pituitary cells. by Levy-Wilson B.; 1983 Feb 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=325755
•
Molecular cloning of a prolactin-related mRNA expressed in bovine placenta. by Schuler LA, Hurley WL.; 1987 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=298920
•
More about hyperprolactinemia. by Kovacs CS.; 2004 Jan 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=315510
•
More about hyperprolactinemia. by Parmar MS.; 2004 Jan 20; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=315509
•
N6-methyladenosine residues in an intron-specific region of prolactin pre-mRNA. by Carroll SM, Narayan P, Rottman FM.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=361031
70
Prolactin
•
Neonatal administration of prolactin antiserum alters the developmental pattern of Tand B-lymphocytes in the thymus and spleen of BALB/c female mice. by Russell DH, Mills KT, Talamantes FJ, Bern HA.; 1988 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=282195
•
Nerve Growth Factor in the Anterior Pituitary: Localization in Mammotroph Cells and Cosecretion with Prolactin by a Dopamine-Regulated Mechanism. by Missale C, Boroni F, Sigala S, Buriani A, Fabris M, Leon A, Toso RD, Spano P.; 1996 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39519
•
Nerve Growth Factor Suppresses the Transforming Phenotype of Human Prolactinomas. by Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Toso RD, Balsari A, Spano P.; 1993 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=47267
•
Nucleotide sequence of carp prolactin cDNA. by Chao SC, Pan FM, Chang WC.; 1988 Oct 11; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=338723
•
Nucleotide sequence of porcine preprolactin cDNA. by Schulz-Aellen MF, Schmid E, Movva RN.; 1989 Apr 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=317735
•
Nucleotide sequence of turkey prolactin. by Karatzas CN, Zadworny D, Kuhnlein U.; 1990 May 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=330859
•
Opposing actions of intact and N-terminal fragments of the human prolactin /growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis. by Struman I, Bentzien F, Lee H, Mainfroid V, D'Angelo G, Goffin V, Weiner RI, Martial JA.; 1999 Feb 16; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=15448
•
Ovine prolactin: equilibrium characteristics of the recombinant molecule formed by noncovalent interaction of two fibrinolysin fragments by fluorescence polarization. by Jibson MD, Li CH, Glaser CB.; 1981 May; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=319451
•
Pituitary Ets-1 and GABP bind to the growth factor regulatory sites of the rat prolactin promoter. by Schweppe RE, Gutierrez-Hartmann A.; 2001 Mar 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=29733
•
Pituitary-specific chromatin structure of the rat prolactin distal enhancer element. by Willis SD, Seyfred MA.; 1996 Mar 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=145752
Studies
71
•
Prolactin Activates the Interferon-Regulated p91 Transcription Factor and the Jak2 Kinase by Tyrosine Phosphorylation. by David M, Petricoin EF III, Igarashi K, Feldman GM, Finbloom DS, Larner AC.; 1994 Jul 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44361
•
Prolactin and glucocorticoid hormones synergistically induce expression of transfected rat beta-casein gene promoter constructs in a mammary epithelial cell line. by Doppler W, Groner B, Ball RK.; 1989 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=286412
•
Prolactin Effects on the Dietary Regulation of Mouse Mammary Tumor Virus Proviral DNA Expression. by Hamada N, Engelman RW, Tomita Y, Chen R, Iwai H, Good RA, Day NK.; 1990 Sep 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54611
•
Prolactin Increases CD4/CD8 Cell Ratio in Thymus-Grafted Congenitally Athymic Nude Mice. by Gaufo GO, Diamond MC.; 1996 Apr 30; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=39505
•
Prolactin induces release of a factor from membranes capable of stimulating [beta]casein gene transcription in isolated mammary cell nuclei. by Teyssot B, Houdebine LM, Djiane J.; 1981 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=349123
•
Prolactin inhibits epidermal growth factor (EGF)-stimulated signaling events in mouse mammary epithelial cells by altering EGF receptor function. by Fenton SE, Sheffield LG.; 1993 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=300991
•
Prolactin is not a juvenile hormone in Xenopus laevis metamorphosis. by Huang H, Brown DD.; 2000 Jan 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=26639
•
Prolactin modulates the naive B cell repertoire. by Peeva E, Michael D, Cleary J, Rice J, Chen X, Diamond B.; 2003 Jan 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=151869
•
Prolactin Synthesized and Secreted by Human Peripheral Blood Mononuclear Cells: An Autocrine Growth Factor for Lymphoproliferation. by Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, Kooijman R, Kutz L, Kelley KW, Malarkey WB.; 1992 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=49781
•
Prolactin upstream factor I mediates cell-specific transcription. by Cao ZD, Barron EA, Sharp ZD.; 1988 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=365646
72
Prolactin
•
Prolactin-deficient variants of GH3 rat pituitary tumor cells: linked expression of prolactin and another hormonally responsive protein in GH3 cells. by Ivarie RD, Morris JA, Martial JA.; 1982 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=369771
•
Prolactin-Immunoglobulin G Complexes from Human Serum Act as Costimulatory Ligands Causing Proliferation of Malignant B Lymphocytes. by Walker AM, Montgomery DW, Saraiya S, Ho TW, Garewal HS, Wilson J, Lorand L.; 1995 Apr 11; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42149
•
Prolactin-like activity of anti-prolactin receptor antibodies on casein and DNA synthesis in the mammary gland. by Djiane J, Houdebine LM, Kelly PA.; 1981 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=349284
•
Prostaglandin I2 modifies both prolactin binding capacity and fluidity of mouse liver membranes. by Dave JR, Knazek RA.; 1980 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=350333
•
Purification of a prolactin receptor. by Liscia DS, Vonderhaar BK.; 1982 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=347024
•
Radioimmunoreactivity and receptor-binding activity of the recombined molecule obtained by complementation of two fibrinolysin fragments of ovine prolactin. by Wong TM, Cheng CH, Li CH.; 1981 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=318995
•
Rapid activation of protein kinase C in isolated rat liver nuclei by prolactin, a known hepatic mitogen. by Buckley AR, Crowe PD, Russell DH.; 1988 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=282517
•
Rapid glucocorticoid inhibition of vasoactive intestinal peptide-induced cyclic AMP accumulation and prolactin release in rat pituitary cells in culture. by Rotsztejn WH, Dussaillant M, Nobou F, Rosselin G.; 1981 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=349313
•
Receptor to Nucleus Signaling by Prolactin and Interleukin 2 Via Activation of Latent DNA-Binding Factors. by Gilmour KC, Reich NC.; 1994 Jul 19; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=44295
•
Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormonereleasing hormone and somatostatin. by Kadar T, Redding TW, Ben-David M, Schally AV.; 1988 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=279662
Studies
73
•
Reconstitution of cell-type-specific transcription of the rat prolactin gene in vitro. by Cao ZD, Barron EA, Carillo AJ, Sharp ZD.; 1987 Oct; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=367990
•
Regulation of Interleukin 2-Driven T-Lymphocyte Proliferation by Prolactin. by Clevenger CV, Russel DH, Appasamy PM, Prystowsky MB.; 1990 Aug 15; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=54554
•
Regulatory elements controlling pituitary-specific expression of the human prolactin gene. by Peers B, Voz ML, Monget P, Mathy-Hartert M, Berwaer M, Belayew A, Martial JA.; 1990 Sep; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=361059
•
Role of Nitric Oxide in Control of Prolactin Release by the Adenohypophysis. by Duvilanski BH, Zambruno C, Seilicovich A, Pisera D, Lasaga M, DIaz MdC, Belova N, Rettori V, McCann SM.; 1995 Jan 3; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=42839
•
Selective transcription and DNase I protection of the rat prolactin gene by GH3 pituitary cell-free extracts. by Gutierrez-Hartmann A, Siddiqui S, Loukin S.; 1987 Aug; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=298824
•
Site-specific methylation of the rat prolactin and growth hormone promoters correlates with gene expression. by Ngo V, Gourdji D, Laverriere JN.; 1996 Jul; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=231318
•
Somatotropic actions of the homologous growth hormone and prolactins in the euryhaline teleost, the tilapia, Oreochromis mossambicus. by Shepherd BS, Sakamoto T, Nishioka RS, Richman NH III, Mori I, Madsen SS, Chen TT, Hirano T, Bern HA, Grau EG.; 1997 Mar 4; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=20044
•
Src Family Kinases Are Required for Prolactin Induction of Cell Proliferation. by Vara JA, Caceres MA, Silva A, Martin-Perez J.; 2001 Jul 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=55670
•
Stoichiometric Structure-Function Analysis of the Prolactin Receptor Signaling Domain by Receptor Chimeras. by Chang WP, Ye Y, Clevenger CV.; 1998 Feb; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=108801
•
Stress-induced release of prolactin: blockade by dexamethasone and naloxone may indicate beta-endorphin mediation. by Rossier J, French E, Rivier C, Shibasaki T, Guillemin R, Bloom FE.; 1980 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=348336
•
TaqI and RsaI RFLP's at the prolactin inducible protein (PIP) locus on chromosome 7. by Myal Y, Gregory CA, Karpan C, Hamerton JL, Shiu RP.; 1989 Jul 25; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=318240
74
Prolactin
•
The effect of anandamide on prolactin secretion is modulated by estrogen. by Scorticati C, Mohn C, De Laurentiis A, Vissio P, Fernandez Solari J, Seilicovich A, McCann SM, Rettori V.; 2003 Feb 18; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=149971
•
The intranuclear prolactin /cyclophilin B complex as a transcriptional inducer. by Rycyzyn MA, Clevenger CV.; 2002 May 14; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=124481
•
The Prolactin Gene is Expressed in the Hypothalamic-Neurohypophyseal System and the Protein is Processed Into a 14-kDa Fragment with Activity Like 16-kDa Prolactin. by Clapp C, Torner L, Gutierrez-Ospina G, Alcantara E, Lopez-Gomez FJ, Nagano M, Kelly PA, Mejia S, Morales MA, de la Escalera GM.; 1994 Oct 25; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=45024
•
The rat prolactin gene contains at least six poly(dT-dG).poly(dC-dA) repeats. by McFarlane D, Farrance I, Hall I, Morris J, Ivarie R.; 1986 Oct 10; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=311799
•
The Role of Endogenous Atrial Natriuretic Peptide in Resting and Stress-Induced Release of Corticotropin, Prolactin, Growth Hormone, and Thyroid-Stimulating Hormone. by Franci CR, Anselmo-Franci JA, McCann SM.; 1992 Dec 1; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&rendertype=abstr act&artid=50556
•
The signaling domain of the erythropoietin receptor rescues prolactin receptormutant mammary epithelium. by Brisken C, Socolovsky M, Lodish HF, Weinberg R.; 2002 Oct 29; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=137868
•
Thyrotropin-releasing hormone exerts rapid nuclear effects to increase production of the primary prolactin mRNA transcript. by Potter E, Nicolaisen AK, Ong ES, Evans RM, Rosenfeld MG.; 1981 Nov; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=349109
•
Transcriptional and posttranscriptional regulation of the rat prolactin gene by calcium. by Preston GM, Billis WM, White BA.; 1990 Feb; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=360809
•
Use of antiserum to neurotensin reveals a physiological role for the peptide in rat prolactin release. by Vijayan E, Carraway R, Leeman SE, McCann SM.; 1988 Dec; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=282882
•
Variation in the polyadenylylation site of bovine prolactin mRNA. by Sasavage NL, Smith M, Gillam S, Woychik RP, Rottman FM.; 1982 Jan; http://www.pubmedcentral.gov/picrender.fcgi?tool=pmcentrez&action=stream&blobt ype=pdf&artid=345698
Studies
75
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with prolactin, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “prolactin” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for prolactin (hyperlinks lead to article summaries): •
A case of macroprolactinoma with subclinical growth hormone production. Author(s): Kageyama K, Nigawara T, Kamata Y, Takahashi T, Anzai J, Suzuki S, Osamura YR, Suda T. Source: Endocrine Journal. 2002 February; 49(1): 41-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12008749
•
A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Author(s): Lissoni P, Bucovec R, Malugani F, Ardizzoia A, Villa S, Gardani GS, Vaghi M, Tancini G. Source: Anticancer Res. 2002 March-April; 22(2B): 1131-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12168912
•
A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. Author(s): Acquati S, Pizzocaro A, Tomei G, Giovanelli M, Libe R, Faglia G, Ambrosi B. Source: Journal of Neurosurgical Sciences. 2001 June; 45(2): 65-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11533529
•
A double-blind placebo-controlled study of buspirone-stimulated prolactin release in non-ulcer dyspepsia--are central serotoninergic responses enhanced? Author(s): Dinan TG, Mahmud N, Rathore O, Thakore J, Scott LV, Carr E, Naesdal J, O'Morain CA, Keeling PW. Source: Alimentary Pharmacology & Therapeutics. 2001 October; 15(10): 1613-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11564001
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
76
Prolactin
•
A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. Author(s): Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2001 July; 145(1): 35-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11415850
•
A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice. Author(s): Xu X, Kreye E, Kuo CB, Walker AM. Source: Cancer Research. 2001 August 15; 61(16): 6098-104. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11507059
•
A preliminary study of buspirone stimulated prolactin release in generalised social phobia: evidence for enhanced serotonergic responsivity? Author(s): Condren RM, Dinan TG, Thakore JH. Source: European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 2002 August; 12(4): 349-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12126875
•
A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia. Author(s): Condren RM, Sharifi N, Thakore JH. Source: Psychiatry Research. 2002 August 5; 111(1): 87-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12140123
•
A rare cause of hyperprolactinemia: persistent trigeminal artery with stalk-section effect. Author(s): Ekinci G, Baltacioglu F, Kilic T, Cimsit C, Akpinar I, Pamir N, Erzen C. Source: European Radiology. 2001; 11(4): 648-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11354761
•
A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin. Author(s): De Marinis L, Zuppi P, Valle D, Mancini A, Bianchi A, Lauriola L, Pasquini P, Anile C, Maira G, Giustina A. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2002 March; 34(3): 137-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11972303
Studies
77
•
A serum prolactin-binding protein: implications for growth hormone. Author(s): Dannies PS. Source: Trends in Endocrinology and Metabolism: Tem. 2001 December; 12(10): 427-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11701331
•
A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Author(s): Vigano D, Lissoni P, Rovelli F, Roselli MG, Malugani F, Gavazzeni C, Conti A, Maestroni G. Source: Neuroendocrinol Lett. 2001 April; 22(2): 137-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11335890
•
A woman with isolated prolactin deficiency. Author(s): Douchi T, Nakae M, Yamamoto S, Iwamoto I, Oki T, Nagata Y. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2001 April; 80(4): 368-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11264615
•
Absence of orgasm-induced prolactin secretion in a healthy multi-orgasmic male subject. Author(s): Haake P, Exton MS, Haverkamp J, Kramer M, Leygraf N, Hartmann U, Schedlowski M, Krueger TH. Source: International Journal of Impotence Research : Official Journal of the International Society for Impotence Research. 2002 April; 14(2): 133-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11979330
•
ACTH, cortisol and prolactin in active rheumatoid arthritis. Author(s): Zoli A, Lizzio MM, Ferlisi EM, Massafra V, Mirone L, Barini A, Scuderi F, Bartolozzi F, Magaro M. Source: Clinical Rheumatology. 2002 August; 21(4): 289-93. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12189455
•
Activation and association of the Tec tyrosine kinase with the human prolactin receptor: mapping of a Tec/Vav1-receptor binding site. Author(s): Kline JB, Moore DJ, Clevenger CV. Source: Molecular Endocrinology (Baltimore, Md.). 2001 May; 15(5): 832-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11328862
•
Aggregation of human wild-type and H27A-prolactin in cells and in solution: roles of Zn(2+), Cu(2+), and pH. Author(s): Sankoorikal BJ, Zhu YL, Hodsdon ME, Lolis E, Dannies PS. Source: Endocrinology. 2002 April; 143(4): 1302-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11897686
78
Prolactin
•
An Ets motif in the proximal decidual prolactin promoter is essential for basal gene expression. Author(s): Brar AK, Kessler CA, Handwerger S. Source: Journal of Molecular Endocrinology. 2002 August; 29(1): 99-112. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12200232
•
An unusual form of big, big (macro) prolactin in a pregnant patient. Author(s): Diver MJ, Ewins DL, Worth RC, Bowles S, Ahlquist JA, Fahie-Wilson MN. Source: Clinical Chemistry. 2001 February; 47(2): 346-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11159789
•
Analysis of anti-prolactin autoantibodies in systemic lupus erythematosus. Author(s): Blanco-Favela F, Chavez-Rueda K, Leanos-Miranda A. Source: Lupus. 2001; 10(10): 757-61. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11721703
•
Androgen suppression and clinical improvement with dopamine agonists in hyperandrogenic-hyperprolactinemic women. Author(s): Hagag P, Hertzianu I, Ben-Shlomo A, Weiss M. Source: J Reprod Med. 2001 July; 46(7): 678-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11499189
•
Anti-prolactin autoantibodies in paediatric systemic lupus erythematosus patients. Author(s): Blanco-Favela F, Quintal MaG, Chavez-Rueda AK, Leanos-Miranda A, Berron-Peres R, Baca-Ruiz V, Lavalle-Montalvo C. Source: Lupus. 2001; 10(11): 803-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11789490
•
Antiprolactin autoantibodies in systemic lupus erythematosus: frequency and correlation with prolactinemia and disease activity. Author(s): Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA, Blanco-Favela F. Source: The Journal of Rheumatology. 2001 July; 28(7): 1546-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11469460
•
Antipsychotic drugs and obesity: is prolactin involved? Author(s): Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias MA, Hernandez L. Source: Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie. 2001 November; 46(9): 829-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11761634
Studies
79
•
Antipsychotic induced hyperprolactinaemia: a series of illustrative case reports. Author(s): Haddad PM, Helleweil JS, Wieck A. Source: Journal of Psychopharmacology (Oxford, England). 2001 December; 15(4): 293-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11769824
•
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Author(s): Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI. Source: Psychiatry Research. 2002 August 5; 111(1): 11-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12140115
•
Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Author(s): Compton MT, Miller AH. Source: Psychopharmacology Bulletin. 2002 Winter; 36(1): 143-64. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12397853
•
Antipsychotics: impact on prolactin levels. Author(s): Goodnick PJ, Rodriguez L, Santana O. Source: Expert Opinion on Pharmacotherapy. 2002 October; 3(10): 1381-91. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12387684
•
Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy. Author(s): Veldman RG, Frolich M, Pincus SM, Veldhuis JD, Roelfsema F. Source: The Journal of Clinical Endocrinology and Metabolism. 2000 November; 85(11): 4039-46. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11095430
•
Association between high serum prolactin levels and concomitant infections in HIVinfected patients. Author(s): Montero A, Bottasso OA, Luraghi MR, Giovannoni AG, Sen L. Source: Human Immunology. 2001 February; 62(2): 191-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11182231
•
Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin. Author(s): Kondo T, Ishida M, Tokinaga N, Mihara K, Yasui-Furukori N, Ono S, Kaneko S. Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2002 February; 26(2): 287-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11817505
80
Prolactin
•
Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations. Author(s): Vesely DL, San Miguel GI, Hassan I, Schocken DD. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2002 May; 34(5): 245-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12063637
•
Augmentation of prolactin secretion by estrogen in hypogonadal women. Author(s): Yen SS, Ehara Y, Siler TM. Source: The Journal of Clinical Investigation. 1974 February; 53(2): 652-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11344580
•
Autoimmune hypothyroidism coexisting with a pituitary adenoma secreting thyroidstimulating hormone, prolactin and alpha-subunit. Author(s): Idiculla JM, Beckett G, Statham PF, Ironside JW, Atkin SL, Patrick AW. Source: Annals of Clinical Biochemistry. 2001 September; 38(Pt 5): 566-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11587139
•
Autonomic failure mimicing dopamine agonist induced vertigo in a patient with macroprolactinoma. Author(s): Seiler L, Braune S, Borm K, Magerkurth C, Talazko J, Peters T, Reincke M. Source: Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association. 2002 October; 110(7): 3649. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12397537
•
Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia. Author(s): Veldman RG, Frolich M, Pincus SM, Veldhuis JD, Roelfsema F. Source: The Journal of Clinical Endocrinology and Metabolism. 2001 April; 86(4): 1562-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11297584
•
Beta-human chorionic gonadotropin and prolactin assays in cervicovaginal secretions as a predictor of preterm delivery. Author(s): Guvenal T, Kantas E, Erselcan T, Culhaoglu Y, Cetin A. Source: International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics. 2001 December; 75(3): 229-34. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11728482
Studies
81
•
Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Author(s): Leanos-Miranda A, Chavez-Rueda KA, Blanco-Favela F. Source: Arthritis and Rheumatism. 2001 April; 44(4): 866-75. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11315926
•
Biphasic action of prolactin in the regulation of murine Leydig tumor cell functions. Author(s): Manna PR, El-Hefnawy T, Kero J, Huhtaniemi IT. Source: Endocrinology. 2001 January; 142(1): 308-18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11145594
•
Bone mineral density and prolactin associations in patients with chronic schizophrenia. Author(s): Abraham G, Halbreich U, Friedman RH, Josiassen RC. Source: Schizophrenia Research. 2003 January 1; 59(1): 17-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12413637
•
Bromocriptine and the expression of c-myc and c-fos in human prolactinomas. Author(s): Burdman JA, Guerra LN, Calabrese MT, Basso A. Source: Neurological Research. 2001 October; 23(7): 721-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11680511
•
Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome. Author(s): Papaleo E, Doldi N, De Santis L, Marelli G, Marsiglio E, Rofena S, Ferrari A. Source: Human Reproduction (Oxford, England). 2001 November; 16(11): 2263-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11679501
•
Changes in prolactin and testosterone levels induced by acute physical exertion in young female athletes. Author(s): Kochanska-Dziurowicz A, Gawel-Szostek V, Gabrys T, Kmita D. Source: Fiziol Cheloveka. 2001 May-June; 27(3): 100-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11548414
•
Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domain. Author(s): Kline JB, Rycyzyn MA, Clevenger CV. Source: Molecular Endocrinology (Baltimore, Md.). 2002 October; 16(10): 2310-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12351696
82
Prolactin
•
Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Author(s): Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR. Source: Arthritis and Rheumatism. 2001 October; 44(10): 2358-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11665977
•
Chemokines, prolactin and parasite interactions. Author(s): Pearson RD. Source: Trends in Parasitology. 2002 September; 18(9): 386. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12377252
•
Ciliary neurotrophic factor, a gp130 cytokine, regulates preovulatory surges of luteinizing hormone and prolactin in the rat. Author(s): Watanobe H, Habu S. Source: Neuroendocrinology. 2001 November; 74(5): 281-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11694760
•
Circulating anti-prolactin auto-antibodies must be considered in the differential diagnosis of hyperprolactinaemia in adolescents. Author(s): Vanbesien J, Schiettecatte J, Anckaert E, Smitz J, Velkeniers B, De Schepper J. Source: European Journal of Pediatrics. 2002 July; 161(7): 373-6. Epub 2002 June 04. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12111188
•
Clinical features and medical treatment of male prolactinomas. Author(s): Asano S, Ueki K, Suzuki I, Kirino T. Source: Acta Neurochirurgica. 2001; 143(5): 465-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11482696
•
Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas. Author(s): Ma W, Ikeda H, Yoshimoto T. Source: Cancer. 2002 July 15; 95(2): 258-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12124824
•
Coitus-induced orgasm stimulates prolactin secretion in healthy subjects. Author(s): Exton MS, Kruger TH, Koch M, Paulson E, Knapp W, Hartmann U, Schedlowski M. Source: Psychoneuroendocrinology. 2001 April; 26(3): 287-94. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11166491
Studies
83
•
Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects. Author(s): Pretorius JL, Phillips M, Langley RW, Szabadi E, Bradshaw CM. Source: British Journal of Clinical Pharmacology. 2001 September; 52(3): 322-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11560566
•
Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Author(s): Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S, Otani K. Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2002 April; 26(3): 575-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11999910
•
Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Author(s): Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S. Source: Psychopharmacology. 2002 June; 162(1): 63-6. Epub 2002 April 17. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12107619
•
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Author(s): Sabuncu T, Arikan E, Tasan E, Hatemi H. Source: Intern Med. 2001 September; 40(9): 857-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11579944
•
Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial. Author(s): Hergovich N, Singer E, Agneter E, Eichler HG, Graselli U, Simhandl C, Jilma B. Source: Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 2001 May; 24(5): 590-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11282259
•
Complex 5' genomic structure of the human prolactin receptor: multiple alternative exons 1 and promoter utilization. Author(s): Hu ZZ, Zhuang L, Meng J, Tsai-Morris CH, Dufau ML. Source: Endocrinology. 2002 June; 143(6): 2139-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12021177
84
Prolactin
•
Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall. Case report. Author(s): Cattaneo FA, Fahie-Wilson MN. Source: Journal of Neurosurgery. 2001 August; 95(2): 334-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11780906
•
Control of unremitting rheumatoid arthritis by the prolactin antagonist cabergoline. Author(s): Erb N, Pace AV, Delamere JP, Kitas GD. Source: Rheumatology (Oxford, England). 2001 February; 40(2): 237-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11257171
•
Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Author(s): Matera L, Mori M. Source: Annals of the New York Academy of Sciences. 2000; 917: 505-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11268378
•
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Author(s): Alfaro CL, Wudarsky M, Nicolson R, Gochman P, Sporn A, Lenane M, Rapoport JL. Source: Journal of Child and Adolescent Psychopharmacology. 2002 Summer; 12(2): 8391. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12188977
•
Current management of prolactinomas. Author(s): Nomikos P, Buchfelder M, Fahlbusch R. Source: Journal of Neuro-Oncology. 2001 September; 54(2): 139-50. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11761431
•
Cyclosporine A-induced mammary hyperplasia and hyperprolactinemia in New Zealand White rabbits. Author(s): Petraitiene R, Petraitis V, Bacher J, Das SR, Parlow AF, Walsh TJ. Source: Comp Med. 2001 October; 51(5): 430-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11924803
•
Cytokine-like effects of prolactin in human mononuclear and polymorphonuclear leukocytes. Author(s): Dogusan Z, Hooghe R, Verdood P, Hooghe-Peters EL. Source: Journal of Neuroimmunology. 2001 November 1; 120(1-2): 58-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11694320
Studies
85
•
Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Author(s): Parra A, Ramirez-Peredo J, Larrea F, Cabrera V, Coutino B, Torres I, Angeles A, Perez-Romano B, Ruiz-Arguelles G, Ruiz-Arguelles A. Source: Clinical Endocrinology. 2001 June; 54(6): 731-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11422107
•
Decreased nocturnal levels of prolactin and growth hormone in women with fibromyalgia. Author(s): Landis CA, Lentz MJ, Rothermel J, Riffle SC, Chapman D, Buchwald D, Shaver JL. Source: The Journal of Clinical Endocrinology and Metabolism. 2001 April; 86(4): 1672-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11297602
•
Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women. Author(s): Ratchanon S, Taneepanichskul S. Source: Obstetrics and Gynecology. 2000 December; 96(6): 926-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11084179
•
Detection of macroprolactin causing hyperprolactinemia in commercial assays for prolactin. Author(s): Fahie-Wilson MN. Source: Clinical Chemistry. 2000 December; 46(12): 2022-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11106347
•
Detection of macroprolactinemia with the polyethylene glycol precipitation test in systemic lupus erythematosus patients with hyperprolactinemia. Author(s): Leanos-Miranda A, Pascoe-Lira D, Chavez-Rueda KA, Blanco-Favela F. Source: Lupus. 2001; 10(5): 340-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11403264
•
Determination of endometrial prolactin in vivo as a marker for endometrial development in spontaneous ovulatory cycles and in vitro fertilization cycles. Author(s): Dekker JJ, Martens F, Schoemaker J. Source: Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology. 2001 June; 15(3): 210-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11447733
86
Prolactin
•
Disorders of prolactin secretion. Author(s): Molitch ME. Source: Endocrinology and Metabolism Clinics of North America. 2001 September; 30(3): 585-610. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11571932
•
Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas? Author(s): Yermus R, Ezzat S. Source: Clinical Endocrinology. 2002 April; 56(4): 562. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11966752
•
Dopamine as a prolactin (PRL) inhibitor. Author(s): Ben-Jonathan N, Hnasko R. Source: Endocrine Reviews. 2001 December; 22(6): 724-63. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11739329
•
Dopamine receptor agonists for treating prolactinomas. Author(s): Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Source: Expert Opinion on Investigational Drugs. 2002 June; 11(6): 787-800. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12036422
•
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Author(s): Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, Casanueva F, Popovic V. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2002 July; 147(1): 77-84. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12088923
•
Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Author(s): Melkersson KI, Hulting AL, Rane AJ. Source: British Journal of Clinical Pharmacology. 2001 April; 51(4): 317-24. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11318766
•
Ectopic production of prolactin by colorectal adenocarcinoma. Author(s): Bhatavdekar JM, Patel DD, Chikhlikar PR, Shah NG, Vora HH, Ghosh N, Trivedi TI. Source: Diseases of the Colon and Rectum. 2001 January; 44(1): 119-27. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11805572
Studies
87
•
Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. Author(s): Lissoni P, Malugani F, Casu M, Bukovec R, Egardi R, Bordin V, Fumagalli E, Mengo S, Gardani G. Source: Neuroendocrinol Lett. 2002 February; 23(1): 61-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11880864
•
Effect of branch chain amino acids supplemented with tryptophan on tyrosine availability and plasma prolactin. Author(s): Scarna A, Gijsman HJ, Harmer CJ, Goodwin GM, Cowen PJ. Source: Psychopharmacology. 2002 January; 159(2): 222-3. Epub 2001 November 23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11862353
•
Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Author(s): Matera L, Mori M, Galetto A. Source: Lupus. 2001; 10(10): 728-34. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11721699
•
Effect of risperidone dose on serum prolactin level. Author(s): Daniels GH, Hayden DL, Goff DC, Kearns AE. Source: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2001 May-June; 7(3): 224. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11421571
•
Effect of seizures and antiepileptic drugs on prolactin secretions. Author(s): Wang MF. Source: Di Yi June Yi Da Xue Xue Bao. 2002 August; 22(8): 742-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12376268
•
Effect of the CYP2D6 genotype on prolactin concentration in schizophrenic patients treated with haloperidol. Author(s): Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Tokinaga N, Inoue Y, Otani K, Kaneko S. Source: Schizophrenia Research. 2001 October 1; 52(1-2): 139-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11595402
•
Effect of transitory hyperprolactinemia on in vitro fertilization of human oocytes. Author(s): Mendes MC, Ferriani RA, Sala MM, Moura MD, Carrara HH, de Sa MF. Source: J Reprod Med. 2001 May; 46(5): 444-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11396370
88
Prolactin
•
Effects of acute alcohol intoxication on pituitary-gonadal axis hormones, pituitaryadrenal axis hormones, beta-endorphin and prolactin in human adults of both sexes. Author(s): Frias J, Torres JM, Miranda MT, Ruiz E, Ortega E. Source: Alcohol and Alcoholism (Oxford, Oxfordshire). 2002 March-April; 37(2): 169-73. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11912073
•
Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Author(s): Lasco A, Cannavo S, Gaudio A, Morabito N, Basile G, Nicita-Mauro V, Frisina N. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2002 October; 147(4): 461-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12370106
•
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Author(s): Esel E, Basturk M, Saffet Gonul A, Kula M, Tayfun Turan M, Yabanoglu I, Sofuoglu S. Source: Psychoneuroendocrinology. 2001 August; 26(6): 641-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11403983
•
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Author(s): Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA. Source: The Journal of Clinical Psychiatry. 2002 May; 63(5): 408-13. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12019665
•
Effects of prolactin on hematopoiesis. Author(s): Welniak LA, Richards SM, Murphy WJ. Source: Lupus. 2001; 10(10): 700-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11721696
•
Effects of prolactin on HLA-DR and CD40 expressions by human thyrocytes. Author(s): Li J, Teng W, Shan Z. Source: Chinese Medical Journal. 2001 November; 114(11): 1151-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11729509
•
Effects of prolactin on intracellular calcium concentration and cell proliferation in human glioma cells. Author(s): Ducret T, Boudina S, Sorin B, Vacher AM, Gourdou I, Liguoro D, Guerin J, Bresson-Bepoldin L, Vacher P. Source: Glia. 2002 May; 38(3): 200-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11968058
Studies
89
•
Effects of prolactin on signal transduction and gene expression: possible relevance for systemic lupus erythematosus. Author(s): Hooghe R, Dogusan Z, Martens N, Velkeniers B, Hooghe-Peters EL. Source: Lupus. 2001; 10(10): 719-27. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11721698
•
Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Author(s): Sagud M, Pivac N, Muck-Seler D, Jakovljevic M, Mihaljevic-Peles A, Korsic M. Source: Neuropsychobiology. 2002; 45(3): 139-43. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11979064
•
Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Author(s): Basturk M, Karaaslan F, Esel E, Sofuoglu S, Tutus A, Yabanoglu I. Source: Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2001 February; 25(2): 315-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11294478
•
Effects of stress on serum prolactin levels in patients with systemic lupus erythematosus. Author(s): Dostal C, Marek J, Moszkorzova L, Lacinova Z, Musilova L, Zvarova J. Source: Annals of the New York Academy of Sciences. 2002 June; 966: 247-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12114279
•
Effects of the gp130 cytokines ciliary neurotropic factor (CNTF) and interleukin-11 on pituitary cells: CNTF receptors on human pituitary adenomas and stimulation of prolactin and GH secretion in normal rat anterior pituitary aggregate cultures. Author(s): Perez Castro C, Carbia Nagashima A, Paez Pereda M, Goldberg V, Chervin A, Carrizo G, Molina H, Renner U, Stalla GK, Arzt E. Source: The Journal of Endocrinology. 2001 June; 169(3): 539-47. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11375124
•
Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Author(s): Lissoni P, Vaghi M, Ardizzoia A, Fumagalli E, Tancini G, Gardani G, Conti A, Maestroni GJ. Source: Neuroendocrinol Lett. 2001; 22(1): 27-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11335876
90
Prolactin
•
Elevated bioactive prolactin levels in systemic lupus erythematosus--association with disease activity. Author(s): Pacilio M, Migliaresi S, Meli R, Ambrosone L, Bigliardo B, Di Carlo R. Source: The Journal of Rheumatology. 2001 October; 28(10): 2216-21. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11669159
•
Elevated levels of serum prolactin in patients with advanced multiple myeloma. Author(s): Gado K, Rimanoczi E, Hasitz A, Gigler G, Toth BE, Nagy GM, Paloczi K, Domjan G. Source: Neuroimmunomodulation. 2001; 9(4): 231-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11847486
•
Elevated prolactin to cortisol ratio and polyclonal autoimmune activation in Hashimoto's thyroiditis. Author(s): Legakis I, Petroyianni V, Saramantis A, Tolis G. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2001 October; 33(10): 585-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11607877
•
Elevation of prolactin levels by atypical antipsychotics. Author(s): Turrone P, Kapur S, Seeman MV, Flint AJ. Source: The American Journal of Psychiatry. 2002 January; 159(1): 133-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11772702
•
Elk-1, C/EBPalpha, and Pit-1 confer an insulin-responsive phenotype on prolactin promoter expression in Chinese hamster ovary cells and define the factors required for insulin-increased transcription. Author(s): Jacob KK, Stanley FM. Source: The Journal of Biological Chemistry. 2001 July 6; 276(27): 24931-6. Epub 2001 May 04. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11340077
•
Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Author(s): Jacobi AM, Rohde W, Ventz M, Riemekasten G, Burmester GR, Hiepe F. Source: Lupus. 2001; 10(8): 554-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11530997
•
Estrogen, prolactin, and autoimmunity: actions and interactions. Author(s): McMurray RW. Source: International Immunopharmacology. 2001 June; 1(6): 995-1008. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11407318
Studies
91
•
Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients. Author(s): Gado K, Nagy G, Hasitz A, Toth BE, Rimanoczi E, Domjan G. Source: Neuroimmunomodulation. 2001; 9(2): 95-102. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11549891
•
Exercise increases prolactin-receptor expression on human lymphocytes. Author(s): Dohi K, Kraemer WJ, Mastro AM. Source: Journal of Applied Physiology (Bethesda, Md. : 1985). 2003 February; 94(2): 51824. Epub 2002 October 11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12391112
•
Expression and one-step purification of intracellular human prolactin in insect cells. Author(s): Strokovskaya L, Bartoszewicz Z, Szolajska E, Kikhno I, Solomko A, Michalik J. Source: Protein Expression and Purification. 2001 July; 22(2): 242-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11437600
•
Expression of dominant-negative STAT5 inhibits growth hormone- and prolactininduced proliferation of insulin-producing cells. Author(s): Galsgaard ED, Friedrichsen BN, Nielsen JH, Moldrup A. Source: Diabetes. 2001 February; 50 Suppl 1: S40-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11272198
•
Expression of ovarian prolactin receptor in relation to hormonal changes during induction of ovulation in the rat. Author(s): Kinoshita H, Yasui T, Ushigoe K, Irahara M, Tanaka M, Nakashima K, Aono T. Source: Gynecologic and Obstetric Investigation. 2001; 52(2): 132-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11586043
•
Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. Author(s): Gill S, Peston D, Vonderhaar BK, Shousha S. Source: Journal of Clinical Pathology. 2001 December; 54(12): 956-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11729217
92
Prolactin
•
Expression of prolactin-releasing peptide and its receptor in the human adrenal glands and tumor tissues of adrenocortical tumors, pheochromocytomas and neuroblastomas. Author(s): Takahashi K, Totsune K, Murakami O, Sone M, Noshiro T, Hayashi Y, Sasano H, Shibahara S. Source: Peptides. 2002 June; 23(6): 1135-40. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12126742
•
Expression of prolactin-releasing peptide and its receptor in the human decidua. Author(s): Reis FM, Vigano P, Arnaboldi E, Spritzer PM, Petraglia F, Di Blasio AM. Source: Molecular Human Reproduction. 2002 April; 8(4): 356-62. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11912284
•
Expression of prolactin-releasing peptide in human placenta and decidua. Author(s): Yasui Y, Yamaguchi M, Jikihara H, Yamamoto T, Kanzaki T, Murata Y. Source: Endocrine Journal. 2001 June; 48(3): 397-401. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11523913
•
False hyperprolactinemia corrected by the use of heterophilic antibody-blocking agent. Author(s): Sapin R, Simon C. Source: Clinical Chemistry. 2001 December; 47(12): 2184-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11719493
•
Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. Author(s): Yu S, Zheng L, Asa SL, Ezzat S. Source: American Journal of Physiology. Endocrinology and Metabolism. 2002 September; 283(3): E490-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12169442
•
Free prolactin determinations in hyperprolactinemic men with suspicion of macroprolactinemia. Author(s): Sapin R, Gasser F, Grucker D. Source: Clinica Chimica Acta; International Journal of Clinical Chemistry. 2002 February; 316(1-2): 33-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11750272
Studies
93
•
Frequency of macroprolactinemia due to autoantibodies against prolactin in pregnant women. Author(s): Pascoe-Lira D, Duran-Reyes G, Contreras-Hernandez I, Manuel-Apolinar L, Blanco-Favela F, Leanos-Miranda A. Source: The Journal of Clinical Endocrinology and Metabolism. 2001 February; 86(2): 924-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11158068
•
From prolactin cell to prolactinoma. Author(s): Velkeniers B. Source: Verh K Acad Geneeskd Belg. 2001; 63(6): 561-73; Discussion 574-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11813510
•
Galactorrhoea, hyperprolactinaemia, and protease inhibitors. Author(s): Montero A, Bottasso OA, Luraghi MR, Giovannoni AG, Sen L. Source: Lancet. 2001 February 10; 357(9254): 473-4; Author Reply 475. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11273087
•
Gamma knife radiosurgery as a primary treatment for prolactinomas. Author(s): Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW. Source: Journal of Neurosurgery. 2000 December; 93 Suppl 3: 10-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11143223
•
Gamma knife radiosurgery for prolactinomas. Author(s): Landolt AM, Lomax N. Source: Journal of Neurosurgery. 2000 December; 93 Suppl 3: 14-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11143231
•
Gender-related differences in prolactin secretion in pituitary prolactinomas. Author(s): Nishioka H, Haraoka J, Akada K, Azuma S. Source: Neuroradiology. 2002 May; 44(5): 407-10. Epub 2002 April 04. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12012125
•
Giant prolactinomas presenting as skull base tumors. Author(s): Minniti G, Jaffrain-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R, Cantore G. Source: Surgical Neurology. 2002 February; 57(2): 99-103; Discussion 103-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11904200
94
Prolactin
•
Giant prolactinomas: clinical management and long-term follow up. Author(s): Shrivastava RK, Arginteanu MS, King WA, Post KD. Source: Journal of Neurosurgery. 2002 August; 97(2): 299-306. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12186457
•
Growth hormone and prolactin expression in the immune system. Author(s): Kooijman R, Gerlo S, Coppens A, Hooghe-Peters EL. Source: Annals of the New York Academy of Sciences. 2000; 917: 534-40. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11268381
•
Growth hormone and prolactin secretion after metoclopramide administration (DA2 receptor blockade) in fertile women. Author(s): Cunha-Filho JS, Gross JL, Vettori D, Dias EC, Passos EP. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2001 September; 33(9): 536-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11561213
•
Growth hormone- and prolactin-induced proliferation of insulinoma cells, INS-1, depends on activation of STAT5 (signal transducer and activator of transcription 5). Author(s): Friedrichsen BN, Galsgaard ED, Nielsen JH, Moldrup A. Source: Molecular Endocrinology (Baltimore, Md.). 2001 January; 15(1): 136-48. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11145745
•
Growth potential of female prolactinomas. Author(s): Nishioka H, Ito H, Haraoka J, Hirano A. Source: Surgical Neurology. 2001 April; 55(4): 213-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11358591
•
Human skin expresses growth hormone but not the prolactin gene. Author(s): Slominski A, Malarkey WB, Wortsman J, Asa SL, Carlson A. Source: The Journal of Laboratory and Clinical Medicine. 2000 December; 136(6): 476-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11128749
•
Hyperprolactinaemia and its clinical significance. Author(s): Rajasoorya C. Source: Singapore Med J. 2001 September; 42(9): 398-401. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11811604
Studies
95
•
Hyperprolactinaemia and prolactine binding in benign intracranial tumours. Author(s): Ciccarelli E, Razzore P, Gaia D, Todaro C, Longo A, Forni M, Ghe C, Camanni F, Muccioli G, Faccani G, Lanotte MM. Source: Journal of Neurosurgical Sciences. 2001 June; 45(2): 70-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11533530
•
Hyperprolactinaemia caused by antipsychotic drugs. Author(s): Wieck A, Haddad P. Source: Bmj (Clinical Research Ed.). 2002 February 2; 324(7332): 250-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11823343
•
Hyperprolactinaemia during prolonged exercise in the heat: evidence for a centrally mediated component of fatigue in trained cyclists. Author(s): Pitsiladis YP, Strachan AT, Davidson I, Maughan RJ. Source: Experimental Physiology. 2002 March; 87(2): 215-26. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11856966
•
Hyperprolactinaemia in patients with heart failure: clinical and immunogenetic correlations. Author(s): Limas CJ, Kroupis C, Haidaroglou A, Cokkinos DV. Source: European Journal of Clinical Investigation. 2002 February; 32(2): 74-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11895452
•
Hyperprolactinemia and luteal insufficiency in infertile patients with mild and minimal endometriosis. Author(s): Cunha-Filho JS, Gross JL, Lemos NA, Brandelli A, Castillos M, Passos EP. Source: Hormone and Metabolic Research. Hormon- Und Stoffwechselforschung. Hormones Et Metabolisme. 2001 April; 33(4): 216-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11383925
•
Hyperprolactinemia complicating juvenile granulosa cell tumor of the ovary. Author(s): Santala M, Suvanto-Luukkonen E, Kyllonen A, Ruokonen A, Puistola U. Source: Gynecologic Oncology. 2001 August; 82(2): 389-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11531301
•
Hyperprolactinemia does not influence hypothalamic-pituitary-adrenocortical function during hypoglycemia in women. Author(s): Imrich R, Rovensky J, Cervenakova Z, Ksinantova L, Kvetnansky R, Koska J. Source: Int J Tissue React. 2002; 24(2): 73-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12182236
96
Prolactin
•
Identification and characterization of the prolactin-binding protein in human serum and milk. Author(s): Kline JB, Clevenger CV. Source: The Journal of Biological Chemistry. 2001 July 6; 276(27): 24760-6. Epub 2001 May 03. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11337493
•
Identification of a decidua-specific enhancer on the human prolactin gene with two critical activator protein 1 (AP-1) binding sites. Author(s): Watanabe K, Kessler CA, Bachurski CJ, Kanda Y, Richardson BD, Stanek J, Handwerger S, Brar AK. Source: Molecular Endocrinology (Baltimore, Md.). 2001 April; 15(4): 638-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11266514
•
Impact of cortisol on buspirone stimulated prolactin release: a double-blind placebocontrolled study. Author(s): Dinan TG, Scott LV, Thakore J, Naesdal J, Keeling PW. Source: Psychoneuroendocrinology. 2001 October; 26(7): 751-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11500255
•
Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Author(s): Maccario M, Veldhuis JD, Broglio F, Vito LD, Arvat E, Deghenghi R, Ghigo E. Source: European Journal of Endocrinology / European Federation of Endocrine Societies. 2002 March; 146(3): 310-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11888836
•
Implication of alpha4 phosphoprotein and the rapamycin-sensitive mammalian target-of-rapamycin pathway in prolactin receptor signalling. Author(s): Boudreau RT, Sangster SM, Johnson LM, Dauphinee S, Li AW, Too CK. Source: The Journal of Endocrinology. 2002 June; 173(3): 493-506. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12065239
•
In polymyalgia rheumatica serum prolactin is positively correlated with the number of typical symptoms but not with typical inflammatory markers. Author(s): Straub RH, Georgi J, Helmke K, Vaith P, Lang B. Source: Rheumatology (Oxford, England). 2002 April; 41(4): 423-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11961173
Studies
97
•
In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells. Author(s): Ramamoorthy P, Sticca R, Wagner TE, Chen WY. Source: International Journal of Oncology. 2001 January; 18(1): 25-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11115535
•
In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Author(s): Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A. Source: Clinical Endocrinology. 2001 April; 54(4): 469-77. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11318782
•
In vivo studies of the anti-tumor effects of a human prolactin antagonist, hPRLG129R. Author(s): Chen NY, Holle L, Li W, Peirce SK, Beck MT, Chen WY. Source: International Journal of Oncology. 2002 April; 20(4): 813-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11894130
•
Increase of serum prolactin during combined high-dose estrogen and progestin treatment in girls with constitutional tall stature. Author(s): Houdijk EC, Delemarre-van de Waal HA. Source: Acta Paediatrica (Oslo, Norway : 1992). 2000 December; 89(12): 1504-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11195249
•
Increased demand for steroid therapy in hyperprolactinemic patients with rheumatoid arthritis. Author(s): Rovensky J, Bakosova J, Payer J, Lukac J, Raffayova H, Vigas M. Source: Int J Tissue React. 2001; 23(4): 145-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11771778
•
Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Author(s): Kapur S, Roy P, Daskalakis J, Remington G, Zipursky R. Source: The American Journal of Psychiatry. 2001 February; 158(2): 311-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11156818
•
Induction of preprotachykinin-I and neurokinin-1 by adrenocorticotropin and prolactin. Implication for neuroendocrine-immune-hematopoietic axis. Author(s): Maloof PB, Joshi DD, Qian J, Gascon P, Singh D, Rameshwar P. Source: Journal of Neuroimmunology. 2001 January 1; 112(1-2): 188-96. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11108948
98
Prolactin
•
Influence of midluteal serum prolactin on outcome of pregnancy after IVF-ET: a preliminary study. Author(s): Ozaki T, Takahashi K, Kurioka H, Miyazaki K. Source: Journal of Assisted Reproduction and Genetics. 2001 July; 18(7): 387-90. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11499323
•
Inhibition of protein phosphatase PP1 in GH3B6, but not in GH3 cells, activates the MEK/ERK/c-fos pathway and the human prolactin promoter, involving the coactivator CPB/p300. Author(s): Manfroid I, Martial JA, Muller M. Source: Molecular Endocrinology (Baltimore, Md.). 2001 April; 15(4): 625-37. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11266513
•
Interferon-gamma modulates prolactin and tissue factor expression in differentiating human endometrial stromal cells. Author(s): Christian M, Marangos P, Mak I, McVey J, Barker F, White J, Brosens JJ. Source: Endocrinology. 2001 July; 142(7): 3142-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11416037
•
Isolated adrenocorticotropic hormone deficiency, thyroid autoimmunity, and transient hyperprolactinemia. Author(s): Gurlek A, Nar A, Gedik O. Source: Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2001 March-April; 7(2): 1025. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11421554
•
Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. Author(s): Hu ZZ, Meng J, Dufau ML. Source: The Journal of Biological Chemistry. 2001 November 2; 276(44): 41086-94. Epub 2001 August 22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11518703
•
Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. Author(s): Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK, Sheridan B, Atkinson AB. Source: The Journal of Clinical Endocrinology and Metabolism. 2001 June; 86(6): 2743-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11397880
Studies
99
•
Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. Author(s): Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI, Cardinali DP. Source: Journal of Pineal Research. 2001 January; 30(1): 34-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11168905
•
Latent prolactinoma on MRI-selective venous sampling and trans-sphenoidal microsurgical treatment. Author(s): Nakagawa H, Iwatsuki K, Yamada M, Hagiwara Y, Moriuchi S, Kadota T. Source: Neurological Re